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Summary 
 
The entire epidermis of patients with vitiligo exhibits accumulation of up to 10-3M 
concentrations of hydrogen peroxide (H2O2) (Schallreuter, Moore et al. 1999). Over 
the last decade our group and others have focused on the effect of H2O2-mediated 
oxidative stress on the function of many proteins and peptides due to oxidation of 
target amino acid residues in their structure including L-methionine, L-tryptophan, 
L-cysteine and seleno cysteine (Rokos, Beazley et al. 2002; Gillbro, Marles et al. 
2004; Hasse, Kothari et al. 2005; Schallreuter, Chavan et al. 2005; Spencer, Chavan 
et al. 2005; Chavan, Gillbro et al. 2006; Elwary, Chavan et al. 2006; Gibbons, Wood 
et al. 2006; Schallreuter, Bahadoran et al. 2008; Shalbaf, Gibbons et al. 2008; Wood, 
Decker et al. 2009). Moreover, it was shown that patients with vitiligo possess up 
regulated wild type functioning p53 protein in their skin (Schallreuter, Behrens-
Williams et al. 2003). The reason behind this up regulation has remained unclear 
(Schallreuter, Behrens-Williams et al. 2003).  
Therefore the aim of this thesis was to get a better understanding of these puzzling 
data. Along this project different techniques have been used including Western blot, 
dot blot, immuno precipitation, immuno fluorescence, EMSA and computer 
modelling. 
In this thesis we confirmed the previous result on up regulation of p53 in vitiligo and 
we showed that p90MDM2, the master regulator for p53 protein is not different in 
patients and healthy controls. Therefore we decided to test for expression of p76MDM2 
which mediates the inhibition of p90MDM2-p53 binding. Our results show for the first 
time the presence and over expression of p76MDM2 protein in vitiligo compared to 
 3 
healthy individuals. This result could provide an explanation, why up regulated p53 
is not degraded in this disease. 
Since epidermal H2O2 accumulation has been extensively documented in vitiligo, we 
wanted to know whether other ROS could also contribute to the overall oxidative 
stress in this scenario. Therefore we turned our interest to nitric oxide (NO) and its 
possible effects on p53 protein. In order to elucidate this role in more detail, the 
expression levels of epidermal nitric oxide synthesase (iNOS) and the oxidation 
product of NO and O2
- i.e peroxynitrite (ONOO-) were investigated. Our data 
revealed over expression of iNOS and nitrated tyrosine residues, the foot print for 
ONOO-. Moreover, we show for the first time the presence of abundant nitration of 
p53 protein in vitiligo. In addition using purified p53 from E. coli strain (BL21/DE3) 
and mutant p53 protein from HT-29 cells (colon cancer cells), we show that nitration 
takes place in a dose and time dependent manner. On this basis we investigated the 
effect of both H2O2 and ONOO
- on p53-DNA binding capacity employing EMSA, 
since this is the most acceptable technique to follow the binding between proteins 
and DNA. Our results revealed that ONOO- abrogated p53-DNA binding capacity at 
concentrations >300 µM, meanwhile oxidation of p53 protein with H2O2 at the same 
concentrations does not affect binding capacity. Importantly, a much higher p53-
DNA binding capacity was observed after exposure to both ONOO- and H2O2.  
Taken together, p53 is regulated by both ROS (H2O2) and RNS (ONOO
-). 
Next we identified the presence of phosphorylated and acetylated p53 in vitiligo. 
Phosphorylation of ser 9 and ser 15 residues of the protein are associated with over 
expressed ATM protein kinase, while acetylation of lys 373, 382 residues correlates 
with increased PCAF expression. We show that up regulated p53 is associated with 
over expressed p21 (cyclin dependent kinase inhibitor 1) and induced PCNA 
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expression.  Hence, we can conclude that p53 in patients with vitiligo is up regulated, 
activated and functional.  
Finally we show up regulated BCL-2 supporting the long voiced absence of 
increased apoptosis in vitiligo. Given that patients with vitiligo have no increased 
risk for solar induced skin cancer and increased photo damage (Calanchini-Postizzi 
and Frenk 1987; Westerhof and Schallreuter 1997; Schallreuter, Tobin et al. 2002), 
despite the presence of increased DNA damage as evidenced by increased 8-oxoG 
levels in the skin and in the plasma, our findings suggest that both p53 and PCNA 
provide a powerful machinery to mediate DNA repair via hOgg1, APE1 and DNA 
polymerase β (Shalbaf 2009). On this basis it is tempting to conclude that DNA-
repair is the overriding mechanism to combat oxidative stress in this disease.  
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1.0 INTRODUCTION 
 
 
1.1 p53 tumour suppressor gene 
 
 
The p53 tumour suppressor has been one of the most studied genes in the last 28 
years, because of its major role in cancer prevention. It has been reported that the 
malfunction of p53 pathway is a common hallmark for human tumours (Vogelstein, 
Lane et al. 2000; Vousden and Lane 2007). Therefore it was reviewed that the 
somatic mutation of p53 gene is one of the most universal mechanism by which the 
function of p53 protein is affected in cancer progression (Petitjean, Mathe et al. 
2007). Moreover, the p53 mutations are divided into tumour associated mutations 
which are present in somatic cells as a result of DNA damage and this mutation 
appears in the DNA-binding domain of p53. Germline mutations are detected in 
people with Li-Fraumeni syndrome giving a high risk for developing lots of tumours 
such as sarcoma, breast and brain cancer. However, the germline mutation causes 
silent mutations (Whibley, Pharoah et al. 2009). Importantly p53 has been recognised 
to be mutated and/or deleted in approximately 50% of human cancers (Hollstein, 
Sidransky et al. 1991). P53 has been also named the guardian of the genome (Lane 
1992). 
The p53 gene is located on the short arm of chromosome 17 (Oren 1985) at 17p13.1, 
a region which is frequently deleted in human cancers. The protein was first 
identified as a 53 kDa protein that co-immunoprecipitated with the SV40 large T 
antigen in SV40 transformed cell lines (Lane and Crawford 1979; Agoff, Hou et al. 
1993). Moreover, p53 was also easily detected in cancer cells by using antibodies 
specific for the protein. Subsequently, the p53 gene was demonstrated to be an 
oncogene, because of its ability to increase plating efficiency of primary cultures 
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after transfection (Jenkins, Rudge et al. 1984) and after co-transfection with an 
activated H-ras oncogene in transformed primary rat embryo fibroblasts (Finlay, 
Hinds et al. 1988). However, it was later discovered that the p53 gene is actually a 
tumour suppressor gene, since introduction of wild type p53 gene stopped the 
formation of tumours (Finlay, Hinds et al. 1988) and blocked the ability of an 
oncogene, such as H-ras, to promote cancer. Further evidence for the p53 gene to be 
a human tumour suppressor gene was provided (Chen, Chen et al. 1990). It was 
reported that the transfection of a wild type p53 gene into human oesteosarcoma cells 
lacking endogenous p53 gene stopped neoplastic growth by reducing both cell 
growth and cell division. These data also suggested that the wild type p53 gene was 
dominant over the mutant p53 gene in the short-term. 
In normal cells p53 is present at a very low concentration at approximately 1000 
molecules/cell, and is therefore undetectable by antibodies, using standard 
immunocytochemistry or immunohistochemistry. In some cancer cells p53 protein is, 
however, readily detected because its half - life is extended from ~20 mins (WT p53) 
to ~18hrs (mutant p53 protein). P53 protein expression is regulated at the post-
translational level which is consistent with mutant p53 being a tumour antigen 
(Momand, Zambetti et al. 1992; Haupt, Maya et al. 1997; Kubbutat, Jones et al. 
1997). P53 is also the founding member of a small family of proteins which includes 
two other members, p63 and p73. These two genes p63 and p73 (Arrowsmith 1999; 
Levrero, De Laurenzi et al. 1999; Levrero, De Laurenzi et al. 2000) are able to 
produce proteins (p63 and p73) which appear similar in structure and function but 
not identical to p53 protein (Kaghad, Bonnet et al. 1997; Yang, Kaghad et al. 1998). 
Both p63 and p73 proteins have the ability to bind to p53 response elements, activate 
p53 mediated gene expression and they are capable to promote apoptosis. But in 
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contrast to p53, both p63 and p73 are rarely mutated in cancer. They are playing a 
vital role in normal development (Mills, Zheng et al. 1999; Yang, Walker et al. 
2000). The overall sequence homology and domain structures, for these three 
proteins, is shown in Figure 1. 
 
 
Figure 1 
Structure of the p53 family 
All three proteins (p53, p63 and p73) share common domains but they have different lengths 
for the NRD region (negative regulatory domain). Adapted from Pelengaris and Khan 2006. 
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1.2 Structure of p53 protein 
 
P53 acts as a DNA-damage-inducible transcription factor, inducing cell cycle arrest, 
DNA repair and programmed cell death (Hollstein, Sidransky et al. 1991; He, 
Brinton et al. 1993; Lane 1993; Oren 1994; Prokocimer and Rotter 1994; Fukasawa, 
Choi et al. 1996; Ko and Prives 1996). 
The structure of p53 contains 393 amino acids with an apparent molecular weight of 
53kDa (Lane and Crawford 1979). P53 is activated in response to many cellular 
stresses, including DNA damage, ionizing radiation, viral infection, and hypoxia. 
P53 becomes stable and is present in high levels when activated by cellular stress 
(Kastan, Zhan et al. 1992; Lu and Lane 1993). Stabilization of p53 is associated with 
DNA binding activity and transcriptional activation of a number of other genes 
which mediate cell cycle arrest or apoptosis (Kastan, Zhan et al. 1992). In many 
human cancers, p53 is mutated or loses its function as a tumour suppressor gene 
(Hollstein, Sidransky et al. 1991). The loss of p53 function leads to a failure in cell 
cycle arrest, and repairing DNA damage, yielding cells with aberrant DNA which in 
turn gives rise to tumour growth, (reviewed in Lane 1992). P53 acts as a transcription 
factor, and contains the typical domain found in these proteins. There are five major 
domains which are very important for p53 function. These include: 1. the N-terminal 
transcriptional activation domain, aa 1-42 (Unger, Juven-Gershon et al. 1999), 2. a 
proline rich region aa 63-97 containing five repeats of the SH3 binding motif PxxP 
(Walker and Levine 1996), 3. the central sequence-specific DNA binding domain aa 
102-292 (Bargonetti, Manfredi et al. 1993; Halazonetis, Davis et al. 1993; Pavletich, 
Chambers et al. 1993; Wang, Reed et al. 1993), 4. The C-terminal which includes an 
oligomerization or tetramerization domain aa 323-356 and 5. a regulatory domain aa 
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360-393 (Wang, Reed et al. 1993; Bakalkin, Yakovleva et al. 1994; Bayle, Elenbaas 
et al. 1995; Lee, Elenbaas et al. 1995; Reed, Woelker et al. 1995). Key parts of two 
of these domains are represented in five highly conserved regions in vertebrate 
species, these regions are, Ι aa 13-23, Π aa 117-142, III aa 171-181, IV aa 234-250aa, 
V aa 270-286 (Soussi, Caron de Fromentel et al. 1990; Soussi and May 1996), 
(Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
p53 containing the three dimensional structure of the DNA-binding domain complexed 
to DNA and the tetramerization domain 
ß-strands are shown as arrows and α-helices as coils. The five conserved regions are shown 
in Roman numbers. The frequency of p53 mutations (hot spots) are indicated by a histogram 
along the top of p53 structure. Adapted from Arrowsmith and Morin 1996 
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1.2.1 The N-terminal domain of p53 
This region is characterised by containing acidic amino acid residues. The N-
terminal domain is a transcriptional activation domain, consisting of aa 1-42, which 
can enhance transcription by containing the binding sites for TATA box binding 
protein (TBP) and TATA box binding protein-associated factors (TFIID) (Lu and 
Levine 1995; Thut, Chen et al. 1995). Both TBP and TFIID are positive factors for 
gene expression. It was reported that the N-terminal domain also binds to the 
transcription factor TFIID (Dutta, Ruppert et al. 1993; He, Brinton et al. 1993; Li and 
Botchan 1993). This region is also bound by proteins that negatively regulate the 
transcriptional activity of p53 (Momand, Zambetti et al. 1992; Yew and Berk 1992; 
Oliner, Pietenpol et al. 1993; Picksley, Vojtesek et al. 1994) namely the cellular 
protein mdm2, and the Ad E1B viral protein. All of these proteins bind p53 at amino 
acids sequence 13-23, playing an important role in transcription. This importance is 
underlined by the fact that mdm2 is the master regulator of p53 function, and 
negatively regulates its expression (Lin, Chen et al. 1994; Picksley, Vojtesek et al. 
1994). Key residues in this region have been identified to be amino acids F19, L22 and 
W23 (Lin, Chen et al. 1994; Picksley, Vojtesek et al. 1994). Beyond the 
transactivation domain (63-97) there is a hydrophobic proline rich region, aa 63-97, 
consisting of five copes of the sequence (PxxP). This region interacts with proteins 
having an -SH3- domain (Src tyrosine kinase) and it has a role in the non-
transcriptional activation of the intrinsic apoptotic pathway (Sakamuro, Sabbatini et 
al. 1997; Venot, Maratrat et al. 1998). 
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1.2.2 DNA binding domain of p53  
 
The central domain of p53 contains the sequence specific for DNA binding. It is 
located between amino acids 102-292 (Hupp, Meek et al. 1992). This region is 
defined by its resistance to the protease thermolysin (Pavletich, Chambers et al. 1993). 
The DNA binding region of p53 has the ability to interact with specific DNA 
sequences in those genes which are regulated by p53. They are so called p53 response 
elements (RE). Cho et al revealed by X-ray crystallography that the DNA binding 
domain contains two large anti-parallel β sheets, each one having four and five β 
strands, forming a scaffold for 3 loops, L1, L2 and L3, which interact directly with the 
DNA duplex (Cho, Gorina et al. 1994). The interaction with DNA is as follows: loop 
L1 interacts with the major groove and the second loop L2 with the minor groove. The 
third loop L3 connects to L1 and co-ordinates a central Zn+2 atom. Because of the 
importance of the DNA binding domain, most point mutations occur within this 
region and are located within codons 126-307 of the p53 gene. Hot spots at aa 175, 
245, 248, 294, 273 and 282 play a role in the structural integrity of this domain for 
DNA contact sites (Figure 3). It was demonstrated that p53 acts as a tetramer and 
mediates transcription by binding to a specific sequence (response element) located in 
the regulated region of the mediated genes (Raycroft, Wu et al. 1990; el-Deiry, 
Tokino et al. 1993; Cho, Gorina et al. 1994). These response elements consist of two 
halves, each half includes two copies of the sequence Pu Pu Pu C (A/T) (T/A) G py py 
py and this sequence is arranged by head to head and separated by 0-13 nucleotides 
(el-Deiry, Kern et al. 1992; Funk, Pak et al. 1992; Levine 1997). It was discovered 
that p53 response elements are present in many genes such as p21, gadd45, mdm2 and 
bax (Ko and Prives 1996). 
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Figure 3 
Locations for mutations of p53 in human cancer  
Mutations are found along the entire sequence but there are high frequencies in the DNA-
binding domain. Adapted from Pelengaris and Khan 2006. 
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1.2.3 Structure of the C-terminal domain 
The C-terminal domain (aa 292-393) is protease-sensitive. The C-terminal domain 
contains a flexible linker (aa 300-318), a region responsible for oligomerization or 
tetramerization (amino acids 323-356) and a regulatory domain (amino acids 363-
393) (Hupp, Meek et al. 1992). The amino acid residues 323-356 are responsible for 
the tetramerization or oligomerization of p53 (Kraiss, Quaiser et al. 1988). The C-
terminal region regulates the sub-cellular localization of p53 according to three 
nuclear localization signals (NLS). Therefore, a mutation in NLS1 (amino acids 316-
325) causes p53 to locate in the cytoplasm, while in NLS2 (amino acids 369-375) 
and in NLS3 (amino acids 379-384) leads to location in both cytoplasm and nucleus 
(Shaulsky, Goldfinger et al. 1991). The binding of monoclonal antibody PAb421 
(which recognises a C-terminal epitope) of p53 can activate the DNA binding 
activity of p53 (Hupp, Meek et al. 1992). It was revealed that PAb421 antibody has 
the ability to restore the DNA binding activity of mutant p53 in vitro and in vivo 
(Dornan and Hupp 2001). Also the phosphorylation at residue Ser378 by casein 
kinase II inactivates the regulatory domain of p53 and the deletion of the C-terminal 
activates p53 DNA binding (Hupp, Meek et al. 1992). 
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1.3 Activation of p53 
 
1.3.1 Phosphorylation of p53  
Phosphorylation of proteins has been demonstrated to affect nuclear import or export 
of many proteins including SV40 large T antigen (Rihs and Peters 1989; Jans, 
Ackermann et al. 1991), cycline B1 (Yang, Bardes et al. 1998) and MAPKAP kinase 
2 (Engel, Kotlyarov et al. 1998). Phosphorylation is important for p53 stabilization to 
perform its usual function as a transcription factor, (Giaccia and Kastan 1998; 
Appella and Anderson 2001). In this context it was shown that this process is 
induced by many stress factors including DNA damage affecting mainly 30 amino 
acids residues at both the amino terminus and the carboxyl terminus (Ito, Lai et al. 
2001). It is known that in normal cells p53 is regulated by mdm2 in response to the 
genotoxic stress, such as DNA damage. P53 is hyperphosphorylated at multiple sites 
within or near the mdm2 binding domain (Giaccia and Kastan 1998; Chehab, 
Malikzay et al. 1999). The phosphorylation of p53 is related to cellular stresses, 
activating the expression of ATM and ATR (family of protein kinases) which 
mediate the phosphorylation of Ser 15 and Ser 37 on p53 (Canman, Lim et al. 1998; 
Tibbetts, Brumbaugh et al. 1999). It was shown by several groups (Shieh, Ikeda et al. 
1997; Unger, Juven-Gershon et al. 1999; Hirao, Kong et al. 2000; Shieh, Ahn et al. 
2000) that DNA damage causes the activation of CHK2 kinase promoting 
phosphorylation of p53 at ser 20 and ser 15 which in turn leads to its stabilization 
preventing mdm2 from binding to p53. Moreover, phosphorylation at ser15 of p53 
mediates its binding to p300/CBP (histone acetyltransferase), where 
dephosphorylation leads to a defect in the activity of p53 (Lambert, Kashanchi et al. 
1998; Dumaz and Meek 1999). Here it is noteworthy that DNA damage induces 
phosphorylation of p53 at a number of serine residues (i.e 6, 9, 15, 20, 33, 37 and 
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392). Recent studies have shown that the phosphorylation of ser 46 of p53 promotes 
the transactivation of proapoptotic genes (Shmueli and Oren 2007). For instance the 
mutation in ser 46 decrease the ability of p53 to activate proapoptotic genes such as 
Noxa and PUMA (Oda, Arakawa et al. 2000; Feng, Hollstein et al. 2006). DNA 
damage also mediates dephosphorylation of ser 376 leading to activation of the 14-3-
3 protein, a large family of protein (28-33 kDa) causing cell cycle arrest 
(Knippschild, Milne et al. 1997; Shieh, Ikeda et al. 1997; Siliciano, Canman et al. 
1997; Waterman, Stavridi et al. 1998). Phosphorylation of p53 at ser 392 mediates 
p53 tetramer formation. P53 is phosphorylated at ser37 by DNA-PK (DNA-protein 
kinase) (Shieh, Ikeda et al. 1997). All phosphorylation sites are shown in Figure 4. 
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1.3.2 Acetylation of p53  
Acetylation is one of the posttranslational modifications for many proteins. 
Acetylation occurs for 85% of eukaryotic proteins (Polevoda and Sherman 2000). 
p300/CBP or PCAF a histoneacetyltransferase (HAT) acetylates lysine residues (i.e 
lys-370, lys-371, lys-372,373, lys-381, lys-382) of p53 at its C-terminal leading to 
activation of p53-DNA binding activity (Kouzarides 2000; Sterner and Berger 2000). 
Histone acetyltransferase (HAT) mediates the transcription of p53 (Brooks and Gu 
2003). Both the covalent linkage of the acetyl group to lysine and the enzymatic 
reaction of acetylation were first identified on histones and its importance in 
transcriptional regulation was understood (Jenuwein and Allis 2001; Berger 2007). 
However, p53 was the first nonhistone protein to be activated by acetylation (Gu and 
Roeder 1997; Luo, Su et al. 2000). As a result of increasing cellular stress, the 
acetylation levels for p53 are significantly enhanced (Luo, Su et al. 2000; Barlev, Liu 
et al. 2001; Ito, Lai et al. 2001; Luo, Nikolaev et al. 2001; Vaziri, Dessain et al. 
2001; Knights, Catania et al. 2006; Li, Piluso et al. 2007; Kim, Chen et al. 2008; 
Zhao, Kruse et al. 2008). With other words acetylation of p53 is a result of exposing 
the cell to cellular stress (Sakaguchi, Watanabe et al. 1998; Liu, Jin et al. 1999; 
Pearson, Carbone et al. 2000; Gottifredi and Prives 2001; Ito, Shinkai et al. 2001). In 
addition it was demonstrated by various groups (Sakaguchi, Sakamoto et al. 1997; 
Liu, Jin et al. 1999; Ito, Lai et al. 2001) that p53 can be acetylated by p300/CBP 
associated factor at lys-320. Acetylation of p53 is regulated by phosphorylation, 
which increases the interaction between p300/CBP and p53 (Lambert, Kashanchi et 
al. 1998; Dumaz and Meek 1999; Dornan and Hupp 2001). In vivo acetylation of 
K164 was demonstrated in p53 protein by PCAF and this acetylation was added to 
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the mode of action required to activate p53 (Tang, Zhao et al. 2008). All amino acids 
residues affected by acetylation are represented in Figure 4. 
 
 
 
Figure 4 
DNA damage mediates post-translational modification for p53 
P53 is shown by a bar with 393 amino acids. P53 regions are transactivation domain (TA), 
DNA binding domain (DBD), nuclear localization (NLS), tetramerization domain (TET), 
and regulatory domain (REG). The phosphorylation (CP) and acetylation (AC) positions are 
represented by ovals and squares respectively. The numbers refer to the amino acids. 
Adapted from the review of Appella and Anderson 2001. 
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1.4 Functions of p53 protein 
 
P53 acts as a transcription factor for many genes responsible for cell cycle arrest 
DNA repair and apoptosis (Bates and Vousden 1996). It was demonstrated that the 
p53 gene is not essential for normal development and cell growth because the cells 
lacking the p53 gene develop normally, although they are prone to cancer 
(Donehower, Harvey et al. 1992). It was reported that some mutant p53 can block the 
tumour suppression function of the wild type p53 in a dominant negative manner 
leading to inhibition of p53 binding to DNA (Miller, Aslo et al. 1990). Li-Fraumeni 
syndrome is a genetic syndrome, leading to initiation of cancer at the age of 30 and 
these families suffer from oesteosarcoma, breast cancer and brain tumours. Li-
Fraumeni syndrome is frequently associated with a germ line mutation in the p53 
gene (Malkin, Li et al. 1990; Srivastava, Zou et al. 1990). It was demonstrated that 
such germ line mutations of the p53 gene are missense or nonsense mutations 
(Frebourg, Barbier et al. 1995). There are two entities of Li-Fraumeni syndrome, the 
classical Li-Fraumeni (LFS) and the Li-Fraumeni-like syndrome (LFL). It was 
shown that in 70% of LFS cases and in 40% of LFL cases there is a germ line 
mutation in the p53 gene (Tennant, French et al. 1995; Bachinski, Olufemi et al. 
2005). Nullizygous p53(-/-) mice, exhibit a defect in DNA repair and apoptosis 
resulting in the progression of tumours for 30 % of homozygotes at the age of 4.5 
months and death after 10 months of age (Perry, Piette et al. 1993). The tumours that 
developed in such animals were principally, lymphomas and sarcomas. P53 (+/-) mice 
were extensively affected with urinary bladder tumourgenesis when compared with 
p53 (+/+) (Ozaki, Sukata et al. 1998). P53 knockout mice are accompanied with 
increasing malignant progression of cancers (Kemp, Donehower et al. 1993), and 
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they were easily affected with genotoxic carcinogens (Malkin, Li et al. 1990; 
Tennant, French et al. 1995). It was demonstrated that there are some differences 
between Li-Fraumeni families and p53 (+/-) mice according to p53 germ line 
mutations, where in the Li-Fraumeni families point mutations cause missense and 
nonsense mutations leading to truncated proteins, while in p53 (+/-) mice there are 
deletions that lead to the absence of p53 protein. Also from tumour incidence, the Li-
Fraumeni families show that 50% of the individuals develop cancer around the age of 
30, while in p53 (+/-) mice, cancers developed by the age of 18 months in 50% of the 
individuals (depending on lifespan of the mouse) (Harvey, McArthur et al. 1993; 
Donehower, Harvey et al. 1995). 
Figure 5 summarises the current understanding of activation and function of p53. 
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Figure 5 
Activation and function of p53  
Step 1: Cells are subject to many types of stresses most of the time. Step 2: Signal mediator 
proteins upregulate p53 by phosphorylation or suppressing ubiquitylation by MDM2. Step 3: 
Both processes increase the half-life of p53 which quickly leads to higher levels of p53. Step 
4: Moreover p53 can be modified by acetyltransferases (CBP, p300, PCAF) and 
methyltransferases (SET9) that accumulate p53 protein and increase its DNA binding. Step 
5: The deacetylase HDAC2 can inhibit p53 binding to DNA by deacetylation. Step 6: The 
p53 tetramer binds to a p53 response element (RE) to promote transcription of its gene. Step 
7: P53 also needs cofactors such as histone acetyltransferases (HATs) and TATA-binding 
protein-associated factors (TAFs). Step 8: In this example, p53 mediates transactivation of 
its target genes. Step 9: P53 protein mediates various genes which produce proteins involved 
in various functions. Step 10: The previously activated proteins can perform DNA repair, 
cell-cycle arrest, senescence and apoptosis. ATM, ataxia telangiectasia mutated; BAX, 
BCL2-associated X protein; BBC3, BCL2-binding component-3; BIRC5, survivin; 
CDKN1A, cyclin-dependent kinase inhibitor-1A; CHK2, checkpoint kinase-2; DDB2, 
damage-specific DNA-binding protein-2; DDIT4, DNA-damage-inducible transcript-4; FAS, 
TNF receptor subfamily, member 6; GADD45 , growth arrest and DNA-damage inducible  
; p14ARF; SFN, stratifin; TP53I3, tumour protein p53-inducible protein-3; TRIM22, 
tripartite motif containing-22. Adapted from Riley, Sontag et al. 2008. 
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1.4.1 p53 promotes cell cycle arrest 
As a result of DNA damage, p53 is undergoning activation by 
ATM/ATR/CHK1/CHK2 and turning on the transcription of p21 (el-Deiry, Tokino et 
al. 1993; Kastan and Lim 2000; Bartek and Lukas 2003). Once p21 is activated, it 
binds to cyclin and cdk complex: cyclin D1-Cdk4, cyclin E-Cdk2, cyclin A-Cdk2 
and cylin A-Cdc2 and causes cell cycle arrest at G1 phase. Moreover, it was 
demonstrated that p53 induces the cell cycle arrest at G2/M phase as well (Cross, 
Sanchez et al. 1995). Inhibition for cell cycle progression leads to stage of mitosis 
and it is induced after DNA damage or unrepaired damage originating from earlier S 
or G1 phase (Nyberg, Michelson et al. 2002; Xu, Kim et al. 2002). This role of p53 
at G2 phase was confirmed when mitotic spindle inhibitors, such as noodazole was 
added to cells with wild type p53 protein. Surprisingly, the cell cycle was arrested at 
G2 phase while in case of absence of wild type p53 there was a progression of cell 
cycle and the DNA synthesis was reinitiated (Cross, Sanchez et al. 1995). The 
inhibition of cell cycle at G2 phase relies on the transcriptional proteins mediated by 
p53 such as p21, GADD45α (growth arrest and DNA-damage inducible 45 alpha) 
and 14-3-3 sigma protein (Taylor and Stark 2001; Nyberg, Michelson et al. 2002). 
From the previous results it is clear that p53 causes cell cycle arrest to keep the cell 
safe from accumulating any damage that happened to DNA. It was shown that p53 
has the ability to stop the cell cycle at G0 phase by binding to Gas1 gene (a 
membrane protein) and its function, once being activated, keeps cells in G0 phase for 
providing more protection to the cell (Del Sal, Ruaro et al. 1995). The scenario of the 
cell cycle is demonstrated in Figure 6. 
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Figure 6 
p53 mediates cell cycle arrest 
One of the steps required for cell cycle arrest is DNA damage including double strand breaks 
(DSBs). Accordingly, some mediators (53BP1, BRCA1) activate ATM protein kinase. 
CHK1 and CHK2 mediate phosphorylation of p53 and inhibit CDC25s respectively. Once 
p53 is phosphorylated, it transactivates p21 which in turn inhibits CDKs (cyclin dependent 
kinases) with either delayed sustained or rapid transient speed depending on the degree of 
DNA damage. Adapted from Kastan and Bartek 2004. 
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1.4.2 Up-regulation of apoptosis by p53  
As said before the tumour suppressor p53 protein plays an important part of the cell 
response due to DNA damage, either by inducing DNA repair or apoptosis. P53 
inhibits the bcl-2 gene which induces anti-apoptotic activity (White 1996). It was 
shown by many studies that p53 can mediate apoptosis by transactivation of series of 
pro-apoptotic proteins from the BCL2 family, including BAX, BID, PUMA and 
Noxa (Vousden and Lu 2002). These transactivated proteins induce mitochondrial 
membrane permeabilization (MMP) follwed by release of apoptotic factors from the 
mitochondrial intermembrane space. BAX protein has the ability to promote 
apoptosis due to the release of cytochrome c from mitochondria, which in turn 
activates the caspase cascade (Miyashita and Reed 1995). It was reported that p53 up 
regulates the protein ASK (activator of S-phase kinase) which mediates the 
activation of BAX and its interaction with mitochondria (Zhivotovsky and Kroemer 
2004). P53 represses BCL2 (anti-apoptotic protein) which is expressed in 
mitochondria and inhibits membrane permeabilization (White 1996). It was shown 
that p53 due to DNA damage can stimulate the production of histone H1.2 promoting 
the induction of MMP (Konishi, Shimizu et al. 2003). It was observed that normal 
thymocytes undergo apoptosis after DNA damage, where the thymocytes from p53(-/-
) mice do not undergo apoptosis when subjected to the same stimulus (Miyashita and 
Reed 1995). Moreover, p53 can also initiate apoptosis in a transcription independent 
way (Chipuk, Maurer et al. 2003). This mechanism is mediated by protein-protein 
interaction. P53 has the ability to bind to BCL2 and BCL-XL which inhibits the 
function of both (Marchenko, Zaika et al. 2000; Mihara, Erster et al. 2003). 
Interestingly, apoptosis can be activated independently of p53. This can be achieved 
by involving p73, which acts as a p53-related transcription factor (Melino, 
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Bernassola et al. 2004). Apoptosis can be induced by NUR77 (also known as NGF1β 
or TR3) that can translocate to mitochondria and induce MMP after interacting with 
BCL2 (Lin, Kolluri et al. 2004). Therefore there might be a mechanism by caspase2 
which can be activated in the nucleus by PIDDosome, a molecular complex that 
contains PIDD protein (p53-inducible death domain containing protein) and RAIDD, 
an adaptor protein containing a death domain (Tinel and Tschopp 2004). The 
pathway which represents p53 dependent and independent signals for apoptosis is 
shown in Figure 7. 
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P53-dependent P53-independent
 
Figure 7 
P53 dependent and independent apoptotic pathways 
P53-mediated apoptosis might require the transcriptional activation of several genes that 
function at mitochondrial proteins (NOXA or PUMA) to induce apoptosis. P53 protein can 
promote a transcription-independent action, by direct interaction with BCL2 family, leading 
in turn to loss of anti-apoptotic activity of BCL2 or BCL-XL while activating pro-apoptotic 
proteins i.e. BAX and BAK (dashed arrows). Moreover, damaged nuclei can release histone 
H1.2 in a p53-dependent way which works on mitochondria. Alternatively, DNA damage 
can mediate apoptosis in a p53-independent manner that involves caspase-2, NUR77 and 
p73. Taken together, it is clear that both p53-dependent and p53-independent apoptosis are 
present because the activation of the mitochondrial pathway is crucial for programmed cell 
death. ATM, ataxia telangiectasia mutated; ATR, ATM- and Rad3-related; RAD17; histone 
H2AX; and CHK2, checkpoint kinase-2. Adapted from Zhivotovsky and Kroemer 2004. 
 
 
Apoptosis can be induced by both an extrinsic and an intrinsic pathway (Fesik 2005). 
The extrinsic pathway (cell death signals) includes death receptors, for example FasL 
(Fas ligand) binding to Fas receptors. The Fas receptors bind to the DEAD domain 
(DD) resulting in FADD (Fas receptors dead domain) which in turn activates caspase 
8 and the apoptotic pathway (Nagata 1997). It was demonstrated that the intrinsic 
pathway results from the interaction of cytochrome c with apoptotic protease-
activating factor 1 (APAF1) and then binds to dATP forming a complex leading in 
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turn to activate caspase 9 which then activates the death response (Budihardjo, Oliver 
et al. 1999). Moreover, it was shown that p53 transports the FAS (death receptor 
protein) to the cell surface, consequently, apoptosis can be mediated (Bennett, 
Macdonald et al. 1998) (Figure 8). The decision taken by the cell, for either growth 
arrest or apoptosis, is controlled by several factors including the cell type, the degree 
of DNA damage, survival factors and also environmental conditions (Chen, Chen et 
al. 1996) . 
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Figure 8 
The intrinsic and extrinsic apoptotic pathways  
The intrinsic death pathway starts with the release of cytochrome c from mitochondria in 
response to various stresses leading to the release of PUMA which, in turn, inhibits the pro-
survival family members, BCL2 and BCL-XL preventing binding to the pro-apoptotic 
protein, BAX. Since BAX mediates alteration of mitochondrial membrane permeability, 
cytochrome c is released. Cytochrome c promotes the formation of the apoptotic-protease-
activating factor-1 (APAF1) and caspase-9-containing 'apoptosome' that initiates the caspase 
cascade, which in turn leads to cell death. The extrinsic pathway is activated by the 
interaction of secreted ligands, Fas ligand (FasL) to death receptors. Both of adaptor protein 
Fas-associated death-domain protein (FADD) and pro-caspase-8, are complexed within the 
death-inducing signalling complex, DISC. Cleavage and activation of caspase-8 in the 
complex promote the effector-caspase cascade, finally leading to cell death. Caspases are 
suppressed by inhibitor of apoptosis (IAP) proteins, which can bind to and block the active 
site on the caspase. IAPs are degraded by the activity of pro-apoptotic proteins like second 
mitochondria-derived activator of caspase (SMAC)/Diablo and its functional homologues in 
flies, which include Grim, Reaper and Hid. Adapted from Hipfner and Cohen 2004. 
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1.4.3 DNA repair function of p53  
DNA repair mechanisms rely on many factors such as, DNA damage levels, the 
ability of cells for repairing and the time allowed for repairing (Gudkov and 
Komarova 2003). As said before, p53 is a multifunctional protein. It mediates the 
transcription processes for proteins involved in cell cycle arrest as well as DNA 
repair and apoptosis (Lane 1992; Prives, Bargonetti et al. 1994; Wang, Gibson et al. 
1995). Using DNA-binding assays, it was shown that the affinity of p53 for 
mismatched and bulged DNA is equal to the human mismatch repair (MMR) 
complex, MSH2-MSH6, under the same binding conditions (Lee, Elenbaas et al. 
1995).  
In eukaryotes there are five main processes for DNA-repair, nuclear excision repair 
(NER), base excision repair (BER), MMR, non-homologous end-joining (NHEJ) and 
homologous recombination (HR) (Friedberg 2001; Tang and Chu 2002; Dianov, 
Sleeth et al. 2003; Lieber, Ma et al. 2003; Sancar, Lindsey-Boltz et al. 2004; 
Hoeijmakers 2007). Interestingly as shown in Figure 9, p53 promotes the DNA-
repair process by both dependent and independent transactivation. This may explain, 
why p53 is acting as molecular node between the upstream signalling cascade and 
downstream DNA repair (Vogelstein, Lane et al. 2000).  
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Figure 9 
Functions of p53 in DNA repair 
There are many causes for DNA damage such as ionizing radiation, UV, replication errors 
and HU. These events lead to the activation of ATM, ATR, CHK1 and CHK2 which in turn 
phosphorylate p53 protein at different amino acids in the sequence of p53. This activated p53 
mediates many functions either through transactivation dependent or transactivation 
independent. The mediated process by p53 depends on the level of DNA damage and cell 
type. ATM, ataxia telangiectasia mutated; ATR-ATRIP, ataxia telangiectasia-and-RAD3-
related-ATR-interacting protein complex; MRE11, mitotic-recombination-11; NBS1, 
Nijmegen breakage syndrome-1; BRCA1, breast cancer-susceptibility protein-1; H2AX, 
histone-2A family, member X; 53BD1, p53-binding protein-1; MDC1, mediator of DNA-
damage checkpoint protein-1; SMC1, structural maintenance of chromosomes-1; RPA, 
replicating protein A; BLM, bloom syndrome protein; NER, nuclear excision repair; BER, 
base excision repair; MMR, mismatch repair; NHEJ, non-homologous end-joining; HR, 
homologous recombination; HU, hydroxyurea; UV, ultraviolet light. Adapted from Sengupta 
and Harris 2005. 
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It was shown that the loss of p53 in human cells leads to reduction in the repair 
process for damaged DNA (Smith, Chen et al. 1995; Wang, Yeh et al. 1995; Ford and 
Hanawalt 1997). Moreover, it was shown that p53 affects NER in vivo by regulating 
the transcription of proteins that are involved in this process including p48DDB2 and 
XPC (Hwang, Ford et al. 1999; Adimoolam and Ford 2002). In this context it was 
demonstrated that p53 stimulates BER by interacting directly with APE1/REF1 and 
DNA polymerase β (Zhou, Ahn et al. 2001; Achanta and Huang 2004) (Figure 10). 
 
 
 
 
 
 
Figure 10 
p53 and its role in base excision repair 
P53 stimulates BER through binding with APE1/REF1, 8-oxoguanine (8-oxoG) and DNA 
polymerase-β. In the presence of ROS and γ-irradiation p53 transactivates 3-MEAde DNA 
glycosylase or OGG1 respectively. Adapted from Sengupta and Harris 2005.  
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MMR was shown also to be affected and regulated by p53 protein, where p53 is 
acting as a transactivator by binding to many response elements located in the 
promoter region of human MSH2 (Scherer, Maier et al. 2000). Surprisingly, in vitro 
p53-DNA-binding was enhanced by MSH2-MSH6 complex showing that MMR 
proteins and p53 protein work synergistically in cells (Subramanian and Griffith 
2002). It was demonstrated that p53 binds to cellular proteins mediating DNA repair 
(e.g. replicating protein antigen, (RPA), xeroderma pigmentosum group B DNA 
helicase (XPB), xeroderma pigmentosum group D DNA helicase (XPD), P62, 
topoisomerase 1, and Cockayne’s group B (CSB) (Dutta, Ruppert et al. 1993; Gobert, 
Bracco et al. 1996; Leveillard, Andera et al. 1996). Furthermore it was demonstrated 
that in the case of DNA damage by cellular stress (eg, UV light, X-rays, oxygen 
radicals (ROS)), p53 was expressed and mediates the expression of p21 which can 
cause cell cycle arrest at the G1 phase (Kuerbitz, Plunkett et al. 1992; el-Deiry, 
Tokino et al. 1993) and G2 phase (Hartwell 1992) to sustain the replication of DNA. 
Moreover, it was documented that if p53 failed to induce DNA repair during cell 
cycle arrest, it still has the ability to mediate apoptosis and inhibit the replication of 
the damaged DNA (Yonish-Rouach, Resnitzky et al. 1991; Hartwell and Kastan 
1994). However, p53 can also mediate DNA repair by expressing p21 and GADD45. 
These two proteins can bind to PCNA which mediates DNA repair and replication 
(Flores-Rozas, Kelman et al. 1994). It was shown  that GADD45 is a nuclear protein 
during cell cycle arrest after DNA damage and it activates PCNA function for DNA 
repair (Waga, Hannon et al. 1994). PCNA is capable of interacting with various 
proteins involved in DNA replication, repair, and translation and DNA synthesis 
supportting its role in regulating cellular DNA replication and repair processes 
(Warbrick 2000; Maga and Hubscher 2003; Prosperi 2006). Moreover, PCNA can 
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perform its role in DNA replication and repair through direct interacting with DNA 
polymerases inducing their processivity (Warbrick 2000; Maga and Hubscher 2003; 
Majka and Burgers 2004; Johnson and O'Donnell 2005; Prosperi 2006). PCNA can 
bind and stimulate AP endonuclease (e.g human APE2) (Tsuchimoto, Sakai et al. 
2001). Interestingly, PCNA is required for early events of MMR (Umar, Buermeyer et 
al. 1996; Lee and Alani 2006) where it interacts directly with MSH6 and MSH3. P21 
binds to PCNA and inhibits its function in DNA replication (Cahilly-Snyder, Yang-
Feng et al. 1987; Flores-Rozas, Kelman et al. 1994). This inhibition mechanism was 
proceeded through displacement of DNA polymerases and other proteins that are 
involved in DNA replication (Gulbis, Kelman et al. 1996; Waga and Stillman 1998; 
Warbrick 2000; Cazzalini, Perucca et al. 2003; Perucca, Cazzalini et al. 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
1.5 The interaction between p53 and mdm2 
 
1.5.1 A hint on mdm2 
The mdm2 (murine double minute) gene was detected in a spontaneously 
tumourigenic murine Balb/c 3T3 fibroblast cell line (3T3DM) in the molecular 
biology lab of Donna and co-workers (Cahilly-Snyder, Yang-Feng et al. 1987). It 
was shown that mdm2 gene is localized on double minute chromosomes (Oliner, 
Kinzler et al. 1992). The full length human mdm2 protein contains 491 amino acids 
while the mouse mdm2 protein is 489 amino acids. This protein contains zinc 
fingers, an acidic domain and a putative nuclear localization signal (Fakharzadeh, 
Trusko et al. 1991; Oliner, Kinzler et al. 1992; Boddy, Freemont et al. 1994). The 
mdm2 gene generates many mdm2 protein products. Some of these isoforms still 
have the ability to bind to p53 and others do not. The most frequent isoforms is 
p85/90MDM2 which contains the entire structure for the main mdm2, p74/76MDM2 and 
p54/57MDM2 (Olson, Marechal et al. 1993; Haines, Landers et al. 1994; Gudas, 
Nguyen et al. 1995). It is noteworthy that the p74/76MDM2 isoform can not bind to 
p53 protein because it lacks the N-terminal domain of the full length protein (Olson, 
Marechal et al. 1993; Haines, Landers et al. 1994). Moreover, it was shown that 
p74/76MDM2 can antagonise the ability of p85/90MDM2 to target p53 protein 
degradation (Perry, Mendrysa et al. 2000). By contrast the p54/57MDM2 isoform can 
bind to p53 protein but it lacks the C-terminal domain (Olson, Marechal et al. 1993) 
(Figure 11).  
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Figure 11 
General structure of mdm2  
(A) Different binding sites for p53, pRb and p14ARF with mdm2 protein at the top. Nuclear 
localization (NLS), export (NES) and signals (NrLS) are indicated by the hatched boxes. 
Zinc fingers are represented by black boxes. The full length protein contains a C-terminal 
and an acidic domain. The reactivity of the different antibodies (N20, SMP14, 2A10) with 
the mdm2 protein epitopes is demonstrated by↑. 
(B) Comparison of the major mdm2 isoforms p85/90MDM2 (contains all mdm2 epitopes), 
p74/76MDM2 (lacking of N-terminal epitope between aa 19 to aa 50) and p54/57MDM2 (deletion 
of C-terminal epitope). Adapted from Eymin, Gazzeri et al. 2002. 
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Brieflly, mdm2 is an oncoprotein targeting the degradation of p53 by acting as an E3 
ubiquitin ligase (Oliner, Kinzler et al. 1992; Bueso-Ramos, Yang et al. 1993; 
Kubbutat, Jones et al. 1997; Fuchs, Adler et al. 1998; Ito, Lai et al. 2001). It was 
revealed that the mdm2 gene was amplified in 33% of human sarcomas and 50% of 
human leukaemias (Oliner, Kinzler et al. 1992; Bueso-Ramos, Yang et al. 1993). As 
already described before, mdm2 plays an important role in the regulation of p53 
(Marechal, Elenbaas et al. 1997) and loss of mdm2 leads to early embryonic lethality 
because of p53 de-regulation (de Rozieres, Maya et al. 2000). In response, mdm2 is 
also overproduced through transcriptional activation by p53. Hence, mdm2 acts as a 
negative feedback regulator for p53 (Oliner, Pietenpol et al. 1993; Wang, Michael et 
al. 2002; Bond, Hu et al. 2005). One of the consequences of mdm2 binding to p53 is 
inhibition of action as a transcription factor for many p53 dependent genes (Haupt, 
Maya et al. 1997; Kubbutat, Jones et al. 1997; Wadgaonkar and Collins 1999) by 
targeting p53 for degradation through the ubiquitin-dependent proteosome pathway 
(Rovinski, Munroe et al. 1987; Hershko and Ciechanover 1998). Ubiquitin is a 
protein that consists of 67 amino acids and it binds to p53 at its N- terminal domain 
(Blaydes, Gire et al. 1997). There are several lines of evidence which revealed that 
mdm2 is the master regulator of p53 cDNAs which have a deletion mutation in the 
N- terminal domain of p53, yielding long half lives for p53 (Rovinski, Munroe et al. 
1987). Moreover, it was shown that the level of p53 increases in cells treated with 
peptides that inhibit the formation of the mdm2-p53 complex (Blaydes, Gire et al. 
1997; Kubbutat, Jones et al. 1997; Teoh, Urashima et al. 1997; Wasylyk, Salvi et al. 
1999). Cells, which were treated with antisense constructs for blocking the 
expression of mdm2, produce high levels of p53 (Haupt, Maya et al. 1997) while 
cells, characterized by overproduction of mdm2, have a low level of p53 expression 
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(Haupt, Maya et al. 1997; Li, Brooks et al. 2003). The latter evidence demonstrates 
that cells which have the ability to produce an mdm2 gene with a mutation disrupt the 
formation of the p53-mdm2 complex (Michael and Oren 2003).  
 
1.5.2 Regulation of p53 activity by mdm2 
It was reported that p53 faces two alternative fates, depending on mdm2 levels in the 
cell (Glickman and Ciechanover 2002):  
1. In case of high levels of mdm2, p53 undergoes polyubiquitination and degradation 
within the cell nucleus.  
2. Low levels of mdm2 drive p53 monoubiquitination and exportation from the 
nucleus. Therefore p53 protein is subject to polyubiquitination by the enzyme E4, 
followed by degradation in the cytoplasm via the 26S proteosome causing 
deubiquitination and transfer of p53 back into the nucleus for degradation by mdm2 
together with nuclear E4 like proteins (e.g. p300) (Grossman, Deato et al. 2003). P53 
which is exported to the cytoplasm could enter mitochondria and enhance the release 
of cytochrome c mediating apoptosis, (Figure 12). 
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Figure 12 
The relationship between p53 and mdm2 
P53 undergoes polyubiquitination (1), and degradation within the cell nucleus while (2) low 
levels of mdm2 drive p53 protein (3) monoubiquitination and (4) exportation from the 
nucleus into the cytosol, where p53 is subject to either (5) polyubiquitination by the enzyme 
E4 followed by (6) degradation on the 26S proteosome causing deubiquitination. P53 can be 
either (7) transferred back into the nucleus to be degraded by mdm2 together with nuclear E4 
like proteins (e.g. p300), or (8) exported to enter mitochondria and enhance the release of 
cytochrome c mediating apoptosis. Adapted from Shmueli and Oren 2007. 
 
 
 
Another pivotal p53 regulator via mdm2 protein is the E3 ubiquitin ligase which 
binds to p53 in the N-terminal domain promoting the covalent conjugation of 
ubiquitin residues leading to reorganisation by the 26S proteosome and ultimately to 
degradation of p53 (Michael and Oren 2003). Freedman and colleagues revealed that 
ubiquitin, which promotes p53 degradation by proteosomes, consists of multiple 
ubiquitin residues bound together covalently (Freedman, Wu et al. 1999). Inhibition 
of the mdm2 interaction with p53 in response to stress leads to the rapid stabilization 
 58 
of p53 activating the p53 response (Ashcroft and Vousden 1999). Mdm2 function is 
also required for the efficient export of p53 from the nucleus to the cytoplasm 
(Giaccia and Kastan 1998). P53 is regulated primarily by its stability (Meek 1999). 
The most important signal for p53 stabilization and activation is DNA damage, 
which induces phosphorylation for the protein. This phosphorylation at ser15 affects 
its affinity for mdm2 and its subsequent degradation (Shieh, Ikeda et al. 1997; Lin 
and Lowe 2001; Shmueli and Oren 2007). Moreover, p53 stability, in response to 
oncogene signalling by increased levels of P14ARF (a tumour suppressor protein), 
can form a complex with mdm2, inhibiting its ability to degrade p53 (Braithwaite, 
Sturzbecher et al. 1987). 
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1.6 Protein nitration 
 
Nitration is a chemical process where a phenol ring of L-tyrosine in proteins is 
subjected to nucleophilic attack by a nitrating agent such as NO2. Protein nitration is 
considered now as post-translational modification (Mannick and Schonhoff 2004). 
1.6.1 Formation and function of nitric oxide (NO) 
In 1987, nitric oxide (NO) accounted for the bioactivity of endothelium–derived 
relaxing factor (EDRF) (Braithwaite, Sturzbecher et al. 1987). This led to widespread 
research on the physiological and pathological roles of this molecule. NO has 
important roles in vasodilatation, neurotransmission, inhibition of platelet 
aggregation and immune defence, and acts as an intracellular messenger for many 
cells (Ignarro, Buga et al. 1987). NO is characterized by a short half-life (3-30s), it is 
a colourless gas, soluble in water, and also highly soluble in organic solvents 
(Braithwaite, Sturzbecher et al. 1987; Nathan and Xie 1994). NO has an acidophilic 
nature giving it the ability to diffuse across cell membranes (Nathan and Xie 1994). 
NO is synthesised from the terminal guanido nitrogen atom of L-arginine by 
NADPH – dependent enzymes called NO synthases (NOS). There are three main 
isoforms of NOS. These are, neuronal (n) NOS, inducible (i) NOS and endothelial 
(e) NOS. nNOS and eNOS are expressed in neurones and endothelial cells, 
respectively. They can, however, be expressed by many other cells. Activation of the 
two isoforms depends on calcium ions and calmodulin resulting in production of NO 
at low concentrations (nmol) (Fukumura, Kashiwagi et al. 2006). iNOS requires 
induction by bacterial products or inflammation-associated cytokines produced in 
many cell types (eg macrophages) (Radi, Peluffo et al. 2001). The activation of the 
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enzyme iNOS leads to the production of high NO concentrations (10-6 M), without 
the presence of calcium ions for activation. There are several activities attributed to 
NO. The physiological effect is represented in binding to its guanylyl cyclase (GC) 
coupled receptors, leading in turn to conformational changes affecting GC activity 
and production of cGMP from GTP followed by modification in cell functions such 
as platelet disaggregation, synaptic plasticity and smooth muscle relaxation 
(Mannick and Schonhoff 2004). NO has the ability to modify proteins by a direct 
chemical reaction through S-nitrosylation which is the binding of NO to the thiolate 
group of a cysteine residues. This process modulates many protein functions 
(Stamler, Lamas et al. 2001). Another action for NO and its related species is found 
in oxidation and nitration of L-tyrosine in proteins (Mannick and Schonhoff 2004). 
NO-induced apoptosis is characterized by biochemical and morphological changes 
such as DNA and nuclear fragmentation, cell shrinkage, membrane blebbing and 
apoptotic body formation (Albina, Cui et al. 1993). The anti-tumor activity of NO is 
characterised by the inhibition of tumour cell proliferation, differentiation and 
metastatic spread. NO was shown to induce the expression of DNA-dependent 
protein kinase (DNA-PKcs), which are considered as pivotal enzymes in DNA repair 
(Xu, Liu et al. 2000). In the meantime, it was shown that the sensitivity of tumour 
cells to ionising radiation is determined by DNA-PK expression which confers 
protection against oxidative and nitrosative stress (Vaganay-Juery, Muller et al. 
2000). 
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1.6.2 Formation of peroxynitrite  
Peroxynitrite (PN) anion (ONOO¯), is generated by the rapid reaction of NO with 
O2
˙¯ (Burney, Caulfield et al. 1999). The rate of ONOO¯ formation depends on the 
concentration of O2
˙¯ and NO. Peroxynitrite attacks a wide range of biological 
molecules including lipids (Rodenas, Carbonell et al. 2000), DNA (Berlett, Friguet et 
al. 1996) and proteins (Radi 2004). The major result from the reaction of PN with 
proteins is the formation of meta nitro tyrosine. Thus, this product can be used as a 
marker for PN activity. It was shown that PN affects protein function, for example it 
can deactivate enzymes such as tyrosine hydroxylase (Messmer, Ankarcrona et al. 
1994; Blanchard-Fillion, Souza et al. 2001) and prostacyclin synthetase (Szabo 
2003). PN has been observed in many inflammatory conditions and it is a cytotoxic 
mediator. It is more active than O2
˙¯, H2O2 and NO alone (Messmer and Brune 1996). 
 
1.6.3 The interaction between p53 and NO 
It has been established that NO has effects on both cellular p53 levels and activity. 
Hence, there is a close relationship between both NO and p53 especially, since p53 is 
upregulated, when exposed to NO producing compounds or enzymes which might be 
due to DNA damage mediated by NO (Messmer, Ankarcrona et al. 1994; Forrester, 
Ambs et al. 1996; Calmels, Hainaut et al. 1997). P53 mediates transcriptional trans-
repression of iNOS mRNA expression by a negative feed back loop (Calmels, 
Hainaut et al. 1997; Elias 2005) while mutant p53 does not perform this function. 
Also the exposure of p53 to a high level of NO leads to impairment of its DNA 
binding activity under in vitro conditions (Calmels, Hainaut et al. 1997). It was 
shown that, NO affects the expression and activity of oncogenes, which are 
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responsible for cell cycle and apoptosis (Messmer, Ankarcrona et al. 1994; Forrester, 
Ambs et al. 1996; Sandau, Pfeilschifter et al. 1997). These regulatory effects of 
oncogenes are specific for proper cell growth and differentiation. Both single (ss) and 
double (ds) DNA strand breaks caused by reactive nitrogen species (RNS) (Burney, 
Caulfield et al. 1999) have been reported (Merchant, Loney et al. 1996) but ss breaks 
are more common. It was demonstrated that DNA damage mostly occurs during 
replication and transcription where the tumor suppressor gene p53 has the key role in 
repairing DNA (Moochhala and Rajnakova 1999). P53 blocks the cell cycle during 
G1/S transition upon activation by radiation, DNA-damaging drugs, 
hyperproliferation, and hypoxia (Cadwell and Zambetti 2001) by expressing p21, a 
potent inhibitor of cyclin-dependent kinases (CDK). If DNA repairing mechanisms 
fail to correct genomic damage, apoptosis is initiated in the respective cells (Prives 
and Hall 1999). P53-induced apoptotic protein includes BAX (Miyashita, Krajewski 
et al. 1994; Miyashita 1997). At the same time wild-type p53 suppresses cellular 
survival factors such as BCL-2 (Miyashita, Harigai et al. 1994). Surprisingly, it was 
demonstrated that the most common mutations inactivating p53 are single amino acid 
substitutions, but preferable these mutations are favoured by sustained p53 
expression due to genomic damage indirectly mediated by NO (Wink, Kasprzak et 
al. 1991). 
 
 
 
 
 
 
 
 
 
 
 63 
 
1.7 The Human Epidermis 
 
1.7.1 General structure of the epidermis 
The skin represents the largest organ in the body. This organ is covering 
approximately 1.8m2. It acts as biological barrier by separating internal homeostasis 
from the external environment. Moreover, it prevents the loss of water, is involved in 
excretion, regulates the temperature of the body, absorbs UV light and acts as an 
antimicrobial defence system (Holbrook and Wolff 1993). 
The skin is divided into several layers, the epidermis and dermis.These layers are 
separated by the basement membrane. Interestingly, upper epidermis and dermis 
these two layers are not completely functionally separated, since they are 
participating together in numerous functions (Figure 13).  
 
1.7.2 The epidermis 
The epidermis is characterized by being the outer most superficial layer of the skin. It 
is derived from the ectoderm and has the ability to be regenerated in approximately 
30 days (Holbrook and Wolff 1993; Jensen, Lowell et al. 1999). Keratinocytes 
provide more than 90% of the cell populations. In addition there are dendritic 
melanocytes located on the basement membrane originating from the neural crest. 
Melanocytes play a crucial role in skin pigmentation. Moreover, there are other cells 
such as Langerhans cells and Merkel cells which are also dendritic cells. Stem cells 
have been found in the epidermis as well as along the basal lamina border (Lavker 
and Sun 1982; Christophers and Braver 1987). 
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Figure 13. 
Different cell types and layers of the human epidermis 
Adapted from (Christophers and Braver 1987) 
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1.7.2.1 Keratinocytes 
Keratinocytes originate from the ectoderm and they play a vital role in the barrier 
properties of the epidermis, in repair and regeneration. Keratinocytes are present in 
different layers of the epidermis forming the stratum basale, stratum spinosum, 
stratum granulosum and the stratum corneum, the most superficial layer of the 
epidermis. This physiological turnover process takes approximately 30 days 
(Holbrook and Wolff 1993). The basal layer is characterized by active cell division. 
The basal keratinocyte is different from the other cells by possessing a columnar 
shape, containing a large nucleus and pigmented melanosomes transferred from 
surrounding melanocytes. The next layer in the epidermis is termed stratum 
spinosum referring to the presence of desmosomes which look like spines under the 
electron microscope. This layer occupies 3-4 layers in the epidermis with polyhedral 
shaped keratinocytes consisting of a rounded nucleus. The upper layer of the stratum 
spinosum contains large cells with a flattened nucleus. Moreover, these cells contain 
lipid rich organelles which are termed as lamellar granules. The important function 
of these lamellar granules is secreting their contents into the intracellular space, 
providing the stratum corneum with its characteristic barrier function properties 
(Feingold, Man et al. 1990; Elias and Feingold 1992; Holbrook and Wolff 1993; 
Feingold 2007; Sevilla, Nachat et al. 2007). Below the stratum corneum is the 
stratum granulosum. Here the cells have a flattened shape due to degradation 
including the loss of the nucleus and all cellular contents except the keratin filaments 
which mark the transition from the granular cell to the differentiated cornified cell 
within the stratum corneum (Holbrook and Wolff 1993). Undifferentiated 
keratinocytes induce melanocyte proliferation and melanogenesis, but also the 
differentiated keratinocytes stimulate melanogenesis utilising the symbiotic 
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relationship in the epidermal melanin unit (EMU) (Abdel-Naser 1999). This 
important role of keratinocytes is performed by releasing numerous factors such as 
pro-opiomelanocortin (POMC) derived peptides including α-melanocyte stimulating 
hormone (α-MSH), β-endorphin and ACTH/ACTH fragments which can stimulate 
the melanocyte in a paracrine fashion (Yaar and Gilchrest 1991; Kauser, Thody et al. 
2004). Moreover, it was demonstrated that POMC-derived peptides and others 
including acetylcholine, catecholamines, nerve growth factor (NGF) and endothelin 1 
are produced in an autocrine manner by the melanocyte itself (Cramer 1991; 
Imokawa, Yada et al. 1992; Imokawa, Yada et al. 1996; Gillbro, Marles et al. 2004; 
Kurzen and Schallreuter 2004; Hirobe 2005; Schallreuter, Kothari et al. 2008). By 
binding to their receptors located on melanocyte membrane, proliferation, 
differentiation, dendritogenesis and melanin synthesis of melanocytes can proceed 
(Sangiovanni 1819). 
 
1.7.2.2 Melanocytes 
Melanocytes are dendritic cells derived from melanoblasts which initially originated 
from the neural crest (Cramer 1991). Cutaneous melanocytes are sitting in the basal 
layer an average of 1000-2000 melanocytes/cm2. Each melanocyte is accompanied 
by approximately 36-40 keratinocytes and this is described as the ‘epidermal-
melanin unit (Fitzpatrick and Breathnach 1963; Fitzpatrick, Miyamoto et al. 1967). 
The first description of pigment forming cells goes back to 1819 by Sangiovanni in 
1819 who detected chromatophores in squid (Sangiovanni 1819). The first 
description of MC was in the human epidermis by Henle (Henle 1837). This close 
localization of both melanocytes and keratinocytes mediates symbiotic relationship 
between both cell types (Fitzpatrick and Breathnach 1963; Hadley and Quevedo 
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1966). For instance it was shown that keratinocytes can provide the noradrenergic 
melanocyte with adrenaline, while melanocytes transfer melanosomes to surrounding 
keratinocytes (Schallreuter, Wood et al. 1992; Holbrook and Wolff 1993; Spencer, 
Vestey et al. 1993). 
 
1.7.2.3 Langerhans cells and Merkel cells 
In addition to melanocytes and keratinocytes there are two other dendritic cells 
present. Langerhans cells originate from bone marrow and they present 2 to 8 % of 
the total epidermal cell population. The second cell type are Merkel cells. 
Langerhans cells are antigen presenting cells (Holbrook and Wolff 1993), while the 
function of the Merkel cells is still not completely clear. 
 
1.7.3 Dermis 
The dermis and subcutis represent the biggest percentage of the human skin. The 
dermis contains the fibrous and filamentous connective tissue. The main function of 
the dermis resides in providing the skin with the strength, elasticity and protection 
from mechanical injury. Moreover, the dermis provides the epidermis with nutrients 
and has receptors of sensory stimuli. The dermis is divided into two layers according 
to the differences in connective tissue structure, papillary and reticular regions. In the 
dermis collagen which is formed by mesenchymally derived cell is the major 
constituent and occupies 90%. The fibroblasts present in the dermis play a vital 
function in producing elastin providing skin with support and strength. Some other 
cells are located in the dermis such as macrophages, adipocytes, mast cells, 
lymphocytes and plasma cells along with appendages such as sweat glands, hair 
follicles and sebaceous glands (Holbrook and Wolff 1993). 
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1.8 The presence of nitric oxide in the skin 
 
Endothelial NO is produced in the dermal vasculature by endothelial nitric oxide 
synthase (eNOS) and acts as a regulator for blood flow (Warren 1994; Feron 1999). 
The presence of inducible nitric oxide synthase (iNOS) has been shown in 
keratinocytes (Arany, Brysk et al. 1996), Langerhans cells (Qureshi, Hosoi et al. 
1996), dermal fibroblasts (Wang, Ghahary et al. 1996), melanocytes (Rocha and 
Guillo 2001) and melanoma cells (Tsatmali, Manning et al. 1999) after stimulation 
with inflammatory cytokines and lipopolysaccharide (LPS). Keratinocytes contain 
both constitutive NOS (eNOS or NOS3 and nNOS or NOS1) which are activated by 
ultraviolet B (UVB) (Deliconstantinos, Villiotou et al. 1995; Villiotou and 
Deliconstantinos 1995). Figure 14 shows the location of the different NOS in the 
human epidermis.  
 
Figure 14 
The formation of NO in the human epidermis  
The expression of NOS isoforms in the skin. Adapted from Cals-Grierson and Ormerod 
2004. 
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1.9 The formation of peroxynitrite in the skin 
 
Nitrotyrosine is considered as a footprint for PN production (Beckman and Koppenol 
1996; Crow and Ischiropoulos 1996). Nitrotyrosine has been detected in vivo by 
Western blotting or by ELISA in skin homogeneates during many conditions 
including chronic UVB exposure in rat skin treated with PN (Hattori, Nishigori et al. 
1996) and moderate temperature burns (Rawlingson, Greenacre et al. 2000). NO and 
PN are produced in keratinocytes after ultraviolet B irradiation (Deliconstantinos, 
Villiotou et al. 1996; Deliconstantinos, Villiotou et al. 1996). After application of 
NO releasing cream to the skin, nitrotyrosine was formed and detected mainly in the 
epidermis revealing that exogenous NO may react with the skin O2
˙¯ to produce PN 
(Ormerod, Copeland et al. 1999). 
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1.10 Oxidative stress 
 
Reactive oxygen species (ROS) are produced during many biological processes via 
biochemical reactions. ROS are neutralized by antioxidants but in some cases there is 
an imbalance between ROS and antioxidants leading to oxidative stress (Sies and 
Cadenas 1985). Important ROS molecules are hydrogen peroxide (H2O2), superoxide 
anion (O2
˙¯) and hydroxyl radicals (OH˙) (Poli, Leonarduzzi et al. 2004). These 
molecules are produced by many mechanisms in cells for instance exposure to X-ray, 
during drug metabolism and by cell metabolism where many redox reactions 
generate ROS (Schallreuter, Moore et al. 1999; Schallreuter, Moore et al. 2001; 
Schallreuter, Elwary et al. 2004; Schallreuter 2005; Schallreuter, Gibbons et al. 2006; 
Schallreuter, Gibbons et al. 2007). OH˙ is the most reactive ROS due to its fast 
reactivity with DNA nucleotides leading in turn to DNA damage and oxidation of 
amino acids, finally causing protein malfunction and inhibition of enzyme activity. 
OH˙ is produced from H2O2 in the presence of transition metals such as iron, copper 
etc. via the Fenton reaction or the Haber Weiss reaction (Haber and Weiss 1932; 
Goldstein and Czapski 1986) without involving transition metals. 
H2O2+ Fe
+2             OH˙+ OH¯+ Fe3+  Fenton Reaction 
H2O2+ O2
˙¯ 
  OH˙+ OH¯+ O2   Haber-Weiss Reaction 
Nowdays it is clear that ROS are always present in the cell at low concentrations. It 
has been demonstrated that many signals are regulated by ROS (Halliwell and 
Gutteridge 1995; Vertuani, Angusti et al. 2004). However, ROS become dangerous 
to the cells with increasing levels due to post-translational consequences including 
oxidation and nitration. NO is a reactive nitrogen species and it has been involved in 
multiple pathological disorders including hypoxia and inflammation (Beckman and 
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Koppenol 1996). At the same time NO regulates various physiological processes, 
such as vascular and neurological functions (Fukumura, Kashiwagi et al. 2006). In 
the presence of both NO and O2
˙¯ in the cell, they yield the production of PN 
(ONOO¯). PN is a strong oxidizing agent, which has the ability to modify proteins 
via tyrosine nitration as well as oxidation (Cobbs, Brenman et al. 1995; Cobbs, 
Samanta et al. 2001).  
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1.11 Vitiligo-a model disease for oxidative stress 
 
1.11.1 What is vitiligo? 
Vitiligo is a disease affecting the entire epidermis where melanocytes lose their 
functionality, but both, keratinocytes and Langerhans cells, are also affected (Le 
Poole, van den Wijngaard et al. 1993; Ortonne and Bose 1993; Tobin, Swanson et al. 
2000). The word vitiligo originates from vitula (latin) = calf and vitium (latin) = 
mistake. Vitiligo is characterised by white spots which can occur at any part of the 
skin and mucosa in different sizes. Based on the clinical picture vitiligo can be 
subdivided in different subgroups, vitiligo vulgaris, acrofacial vitiligo, segmental 
vitiligo and focal vitiligo (Schallreuter 2005; Schallreuter, Bahadoran et al. 2008). 
However, the reason for vitiligo is still unknown, but it can be said that it is a 
combination of many factors. Vitiligo affects 0.5-1% of the world population with no 
gender bias and age of onset starting from early childhood to old age (Ortonne and 
Bose 1993). By utilising WOOD’s light (UVA 351nm), vitiligo can be early 
diagnosed due to fluorescence in the depigmented area based on the presence of 
oxidised pteridines (Schallreuter, Wood et al. 1994). Many mechanisms have been 
proposed for the aetiology of vitiligo. The main theory currently is still the 
autoimmune theory followed by the neural and the oxidative stress theory (Westerhof 
and d'Ischia 2007; Schallreuter, Bahadoran et al. 2008).  
 
1.11.2. Evidence for H2O2 in the mM range in the epidermis of patients  
The amount of H2O2 produced was measured in the depigmented epidermis by in 
vivo FT-Raman spectroscopy where its peak was characterised at 875cm-1 with levels 
in the mM range (Schallreuter, Moore et al. 1999). Nowadays multiple sources 
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within the epidermis have been identified which can contribute to the generation of 
this ROS (Schallreuter, Bahadoran et al. 2008). Figure 15 summarise the current 
findings. These high concentration of H2O2 levels generated within the epidermis 
have many effects on the epidermal structure including DNA damage and oxidation 
of proteins and peptides (Spencer, Gibbons et al. 2007; Shalbaf, Gibbons et al. 2008; 
Schallreuter et al. 2008).  
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Figure 15. 
Production of H2O2 in the human epidermis 
H2O2 is produced by many ways such as UVA/UVB (Schallreuter and Wood 2001), photo-
oxidation of pterin (Rokos, Beazley et al. 2002). H2O2 can also be produced by some 
enzymes, tyrosinase (Wood, Chavan et al. 2004), monoamine oxidase A (Barzu and 
Dansoreanu 1980; Maker, Weiss et al. 1981), xanthine oxidase (Olson, Ballow et al. 1974; 
Kellogg and Fridovich 1975), NADPH oxidase (Rossi, Della Bianca et al. 1985), tyrosine 
hydroxylases (Adams, Klaidman et al. 1997; Haavik, Almas et al. 1997) and the nitric oxide 
synthases as well (Parks and Granger 1986; Schallreuter, Wood et al. 1996). Moreover, it 
was shown that some factors are associated with the production of H2O2 such as transforming 
growth factor-β (TGF-β) (Shibanuma, Kuroki et al. 1991; Thannickal, Hassoun et al. 1993), 
platelet derived growth factor (PDGF) (Sundaresan, Yu et al. 1995), epidermal growth factor 
(EGF) (Bae, Kang et al. 1997) and TNFα (Hoffman and Weinberg 1987). In addition to the 
previous sources there are aromatic steroids such as oestrogen (Schallreuter, Chiuchiarelli et 
al. 2006) and progesterones (Martinoli, Zocchi et al. 1984). Pheomelanin has the ability to 
produce H2O2 in the fair skin due to its photolabile characters (Slominski, Tobin et al. 2004).  
 
 
1.11.3 Detection of low epidermal catalase levels  
Catalase enzyme plays an important role against ROS because it catalyses the 
reaction from H2O2 to O2 and H2O (Aronoff 1965). Catalase mRNA expression is 
unaltered in vitiligo as shown in epidermal suction blister tissue from lesional and 
non lesional epidermis of patients (Schallreuter, Moore et al. 1999). By contrast 
protein levels of catalase are significantly reduced in both lesional and non lesional 
skin (Schallreuter, Wood et al. 1991). Low catalase levels can be based on 
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degradation of its porphyrin active site by high concentration of H2O2 (Aronoff 
1965) but also to oxidation of target amino acids in the enzyme active site and in the 
telomerisation domain (Gibbons, Wood et al. 2006; Maresca, Flori et al. 2006; Wood 
and Schallreuter 2006). Therefore a large variation in the loss of activity of catalase 
was detected in vitiligo ranging from 20-80% (Schallreuter, Wood et al. 1991). It 
was demonstrated that patients with vitiligo exhibit various types of polymorphisms 
in the catalase gene (Casp, She et al. 2002; Agrawal, Shajil et al. 2004; Gavalas, 
Akhtar et al. 2006; Park, Ha et al. 2006; Wood, Gibbons et al. 2008). In the 
epidermis of patients with vitiligo it has been established that activity of GTPCHI, 
the rate limiting enzyme for 6BH4 synthesis is increased 3-5 fold (Schallreuter, 
Wood et al. 1994). This scenario leads to an increase in 6BH4 production and 
increased 6BH4 levels have indeed been shown (Schallreuter, Wood et al. 1994). It is 
the oxidation of 6BH4 and other pterins via H2O2 that leads to the characteristic 
blue/green fluorescence under WOOD’s light (351nm) seen in vitiligo (Schallreuter, 
Wood et al. 1994). Moreover, it should be noted that the oxidation product of 6BH4, 
6-biopterin, is cytotoxic to melanocytes in vitro affecting both cell morphology and 
viability (Schallreuter, Büttner et al. 1994). Moreover, the final step of 6BH4 
recycling via DHPR is also affected due to the oxidation of methionine residues 
leading to an altered NADH binding and a deactivated enzyme (Schallreuter, Moore 
et al. 2001; Hasse, Gibbons et al. 2004).  
 
1.11.4 Constant up-regulation of epidermal wild type p53 in patients with 
vitiligo 
Earlier our and other groups demonstrated that patients with vitiligo exhibit high 
protein expression of wild type functioning p53 in their epidermis. Protein levels 
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were not affected by removal/reduction of epidermal H2O2 via pseudocatalase PC-
KUS. Therefore, it was  suggested that H2O2 levels were still high enough even after 
reduction with pseudocatalase PC-KUS to induce transcription of p53 (Vile 1997; 
Schallreuter, Behrens-Williams et al. 2003). In this context it is interesting that H2O2 
causes stabilization of p53 protein due to phosphorylation at ser 9, ser 15, ser 20 
leading in turn to inhibition of mdm2 binding to p53 (Xie, Wang et al. 2001). It was 
demonstrated that ROS-mediated DNA damage induces the protein kinase ATM 
which phosphorylates p53 on ser 395 (Akman, O'Connor et al. 2000). P53 is 
considered to be the major effector of the genotoxic stress-signalling pathways 
induced by ATM (Caspari 2000). Recently it was revealed that p53 induces 
cutaneous pigmentation after UV irradiation by mediating the transcriptional 
activation of POMC, while in the absence of p53 the tanning response was inhibited 
(Cui, Widlund et al. 2007). Here it is of interest that POMC cleavage and the derived 
peptides are also targets for H2O2-mediated oxidation (Spencer, Chavan et al. 2005; 
Spencer, Gibbons et al. 2007). Moreover, it was demonstrated that p53 can play an 
important role in starting melanogenesis by mediating the transcription of HNF-1α 
which in turn controls MITF and tyrosinase (Schallreuter, Wazir et al. 2004). 
Interestingly, those results were confirmed after exposure of the skin to UV (Yang, 
Zhang et al. 2006). Moreover, it was shown that O2
˙¯ that originates from released 
oligonucleotides can produce H2O2
 which in turn activates p53 (Atoyan, Sharov et al. 
2007). 
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2.0 AIM 
 
Nowadays there is accumulating evidence that the entire epidermis of patients with 
vitiligo exhibits oxidative stress based on mM (10-3M) concentrations of H2O2 
(Schallreuter, Moore et al. 1999; Schallreuter, Bahadoran et al. 2008). Moreover, 
Schallreuter and others showed the presence of up-regulated wild type p53 during 
apoptosis could not be detected in patients with vitiligo (Tobin, Swanson et al. 2000; 
van den Wijngaard, Aten et al. 2000; Schallreuter, Behrens-Williams et al. 2003). In 
addition, it was shown that NO affects both cellular p53 levels and activity, where 
p53 protein is up-regulated after exposure to NO leading in turn to DNA damage 
(Messmer, Ankarcrona et al. 1994; Forrester, Ambs et al. 1996; Messmer and Brune 
1996; Calmels, Hainaut et al. 1997). To the best of our knowledge, the effect of both 
ROS and RNS in the human epidermis of patients with vitiligo has not been 
investigated so far. Therefore, many aims were of interst in this thesis.  
1-What is the reason behind constant up-regulation of p53 in vitiligo?  
2-How could ROS and RNA affect p53-DNA binding capacity? 
3-Given the presence of severe oxidative stress in the epidermis of patients with 
vitiligo, oxidative DNA damage was highly expected. Therefore, we wanted to know 
which role p53 could play in this scenario. 
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3.0 MATERIALS AND METHODS 
 
3.1 Cell culture 
 
3.1.1 Epidermal melanocytes and keratinocytes  
In order to establish epidermal melanocytes and keratinocytes cell cultures, a piece of 
skin was obtained from routine cosmetic enhancement. The fat layer was removed 
and the skin was washed in phosphate buffered saline (PBS) (Sigma, Dorset, UK). 
To facilitate the separation of the epidermis from dermis, some incisions were made 
in the upper layer. Thereafter the skin sample was incubated overnight in the fridge 
(4°C) in dispase (Roche Applied Science, Roche Diagnostics Corporation, 
Indianapolis, USA). On the next day the epidermis was separated from the dermis by 
peeling. Followed by a wash in 5% penicillin/streptomycin (Life Technologies, 
Paisley, UK) and 5% fungisone (Life Technologies, Paisley, UK) the sample was 
placed into sterile PBS. In order to isolate both melanocytes and keratinocytes from 
the epidermis, a cell suspension from the whole epidermis was made by incubating 
the isolated epidermis for 10 minutes at 37°C in 1 x trypsin/EDTA (Life 
Technologies, Paisley, UK). Thereafter, the medium154 containing keratinocytes 
specific growth factors, 0.1mM calcium chloride (Cascade Biologics, Mansfield, 
Nottinghamshire, UK) and 1% P/S was added to stop the reaction because long 
incubation with trypsin can damage the cells. The resulted suspension was 
centrifuged at 500 x g for 10 minutes at RT. The supernatant was discarded and the 
cell pellet containing both melanocytes and keratinocytes was resuspended in 10 ml 
of medium154 containing 1% P/S and transferred into 75cm2 culture flasks 
(Scientific Laboratory Supplies, Nottingham, UK). For the nutritional requirements 
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of melanocytes and keratinocytes, the medium was changed regularly every two 
days. 
 
3.1.2 Isolation of melanocytes and keratinocytes in cell cultures  
The culture obtained is called “co-culture” because it contains both melanocytes and 
keratinocytes. To separate melanocytes from keratinocytes, the selective 
trypsinisation needs to take place. Melanocytes detach from the flask in 
approximately 1-2 minutes when 1 x trypsin/EDTA (Life Technologies, Paisley, UK) 
solution is added, whereas keratinocytes take at least 5 minutes. Detached 
melanocytes, were transferred into 75cm2 culture flasks (Scientific Laboratory 
Supplies, Nottingham, UK) containing 10 ml of medium 254 supplemented with 
melanocyte specific growth factors and 1% P/S (Cascade Biologics, Mansfield, 
Nottinghamshire, UK). Keratinocytes were cultured in 10 ml of medium 154 
(Cascade Biologics, Mansfield Nottinghamshire, UK) in a 75cm2 culture flask. 
 
3.1.3 Maintenance of cell cultures 
The last step is allowing cells to attach and proliferate until 70-80% confluence is 
reached. For this reason cells were kept at 37oC, 5% CO2 and 95% humidity. Usually 
it takes 7-10 days to reach this level of confluence. During this period the medium is 
changed every 2 days. To increase the amount of cells, they were trypsinised and 
split into 75cm2 flasks. Cells were cultured until reaching passage 3. Keratinocytes 
cell cultures were obtained as undifferentiated and differentiated cells. 
Differentiation was obtained by elevation of calcium chloride concentration to 2 
mM. 
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3.1.4 Preparation of epidermal melanocyte and keratinocyte cell extracts 
Both melanocyte and keratinocyte cell extracts were obtained by scraping the cells of 
the surface of the T75 flask into 10 ml of 1 x PBS. The cell suspension was 
centrifuged at 14,000 x g and resuspended in 200 µl of 0.05 M Tris pH 7.4 (Sigma, 
UK) followed by grounding with a pestle and mortar. The supernatant was aliquoted 
and stored at -80°C until further use. 
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3.2 Preparation of cell extracts from epidermal suction blister tissue 
 
200 µl of 10 mM Tris buffer (pH 7.5) (Sigma, Dorset, UK) were added to the 
epidermal sheet. To get a good grinding, a very small amount of sand was added to 
the frozen skin. Another 200 µl of 10 mM Tris buffer (pH 7.5) was added under 
continuous grinding until no piece of epidermis could be seen. The liquid including 
sand was transferred to an Eppendorf tube and centrifuged at 14,000 x g for 10 
minutes at RT in a bench top MSE MicroCentaur centrifuge (Sanyo, UK). The 
supernatant was removed carefully and aliquoted into separate Eppendorf tubes. 
 
3.2.1 Protein determination 
Total protein concentrations were determined by using the Bradford assay following 
the manufacture’s protocol (BioRad Laboratories LTD., Hemel Hempstead, Herts, 
UK). 
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3.3 Immunohistological Methods 
 
3.3.1 Cryosection preparation 
Before cutting of the skin biopsy, slides holding the skin sections have to be coated 
with poly-L-lysine (Sigma, Poole, Dorset, UK) to allow the cryosections to adhere to 
the glass slide. The coating process was done by washing the slides in distilled water 
for 15 minutes, and then immersed in 70% alcohol for about 10 minutes, followed by 
coating for 10 minutes with 10% poly-L-lysine and finally air drying. A 3 mm punch 
biopsy was taken under local anaesthesia from the inner proximal arm as full 
thickness skin from consented volunteers, transferred into optimal cutting 
temperature compound (OCT) (Sakura, RA Lamb, Eastbourne, UK) for about 5 
minutes to allow the skin to be frozen in liquid N2. 3-5 µm sections of this skin were 
cut using a Leica CM3050 S cryostat (Leica Microsystems, Milton Keynes, UK) and 
placed onto the poly-L-lysine coated slides. The slides were saved at -80°C for future 
work. 
 
3.3.2 Preparation of chamber slides with cell cultures 
To do in vitro immuno fluorescence studies, cells (melanocytes and keratinocytes) 
were cultured in chamber slides (Nalge Nunc International, Naperville, IL, USA). 
100 µl cells (approximately 1 x 104 cells) and 300 µl medium were added to each 
chamber. After a few days each chamber was approximately 70-80% confluent. The 
medium was removed and cells were washed 3-4 times in sterile 1 x PBS, pH 7.4 
followed by fixation in cold methanol (-20°C) for 10 minutes, then the slides were 
stored at -20°C until future work. 
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3.3.3 In situ immuno fluorescence labelling 
Frozen slides were allowed to defrost at RT for 10 minutes followed by dehydration 
in 1 x PBS for 5 minutes. Fixation was performed by immersing slides for 6 minutes 
in ice cold- methanol. Except for mdm2 protein expression the slides were fixed in 
ice cold- acetone. Then slides were washed in 1 x PBS for 5 minutes, followed by 
blocking with normal donkey serum (10% NDS, Jackson Immunoresearch 
Laboratories, Cambridgeshire, UK) for 90 minutes at RT. Slides were washed in 1 x 
PBS for 5 minutes, followed by overnight incubation at 4°C with the primary 
antibodies, diluted in 10% NDS. In our experiment we used the following antibodies.  
 
 
Thereafter, slides were washed twice in 1 x PBS for 5 min followed by another wash 
once in Tween-20 (0.05%) for 5 minutes and then once again in 1 x PBS for 5 
Abcam, UK, CambridgeRabbit polyclonal antibodyOvernight, 4°C1:50PCNA
Abcam, UK, CambridgeRabbit monoclonal antibodyOvernight, 4°C1:50ATM
Santa Cruz Biotechnology. 
UK
Mouse monoclonal antibody Overnight, 4°C1:25p21 
Upstate, UK Polyclonal rabbit anti-humanOvernight, 4°C1:25Anti-nitrotyrosine
Abcam, Cambridge, UK Polyclonal rabbit anti-human Overnight, 4°C1:50Inducible nitric 
oxide synthase
(iNOS) 
Santa Cruz Biotechnology, 
Inc. Santa Cruz, CA, USA 
Mouse monoclonal antibodyOvernight, 4°C1:20p76MDM2 
(SMP14) 
Abcam, Cambridge, UK Mouse monoclonal IgG2a Overnight, 4°C1:20 p90MDM2  
Oncogene Research 
products, UK 
Monoclonal mouse IgG2 Overnight, 4°CNeatp53 (Ab-6)
CompanySourceIncubation 
time/t
DilutionAntibody
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minutes. After that, slides were incubated for 1 hour at RT with a fluorescent 
secondary antibody in a dilution of 1:100 in 1% NDS for 1 hour (donkey anti-rabbit, 
rat, mouse or sheep depending on the primary antibody that was used) (Jackson 
Immuno Research Laboratories, Cambridgeshire, UK). Slides were washed twice in 
1 x PBS for 5 minutes, then once in Tween-20 for 5 minutes followed by a final 
wash in 1 x PBS for 5 minutes. Finally, slides were dried and mounted using 
Vectashield Mounting Medium containing 4, 6-diamino-2-phenylindole (DAPI) 
(Vector Laboratories, CA, USA) and covered with a coverslip. Viewing the pictures 
was carried out by using a Leica DMIRB/E fluorescence microscope (Wetzlar, 
Germany). Images were captured using a Nikon Eclipse 80i microscope with a DS-
U101 Nikon camera coupled to a Nikon ACT-2U capture programme (Nikon, 
Europe). In situ double immunofluorescence was performed in cryosections in order 
to detect two specific antibodies within one section. After incubation of the sections 
with secondary antibody it was blocked again as described before, followed by 
incubation with the second primary antibody after that the previous procedures were 
followed. Paint Shop Pro™ 7 was used to merge the two used different 
fluorochromes, tetramethyl rhodamine isothiocyanate (TRITC) and flluorescein 
isothiocyanate (FITC) (Jackson Immuno Research Laboratories, Cambridgeshire, 
UK). 
Control staining was carried out by removing the primary antibody from the staining 
procedure and substitution of 1% NDS / PBS. 
 
3.3.4 In vitro immuno fluorescence labeling 
The staining procedures were carried out as described under in situ immuno-
reactivity studies. The same antibodies with the same dilutions were utilised. 
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However, washing times were decreased because prolonged washing could damage 
the cells. 
3.3.5 Quantification of fluorescence intensity and statistical analysis 
To quantify the fluorescence, ImageJ version 1.37 was utilised (supplied online by 
NIH at http://rsb.info.nih.gov/ij/index.html). The region to be quantified was 
highlighted and a mean intensity obtained. This was repeated for the rest of the 
layers. The procedure was repeated three times for the region and the mean value 
was obtained and plotted. Statistical analysis was performed by Graph pad prism 
version 4 and 1-way ANOVA with Bonferroni analysis. The mean of the calculated 
values were plotted in the figures. 
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3.4 SDS-PAGE of protein samples 
 
Electrophoresis analysis of protein samples was performed by using SDS-
polyacrylamide gel consisting of a 10% w/v resolving gel (3.8 ml of distilled water, 
3.4 ml of 30% acrylamide mix, 2.6 ml of 1.5 M Tris pH (8.8), 0.1 ml of 10% SDS, 
0.1 ml of 10% ammonium persulphate, 0.004 ml of TEMED) (Sigma, Dorset, UK) 
and 5% w/v stacking gel (4.2 ml of distilled water, 1 ml of 30% acrylamide mix, 0.76 
ml of 1.5 M tris pH (8.8), 0.06 ml of 10% SDS, 0.06 ml of 10% ammonium 
persulphate, 0.006 ml of TEMED) (Sigma, Dorset, UK). Samples were transferred 
from -20°C and thawed at RT and loaded together with a protein ladder (#7720, Cell 
Signalling, UK). The gel was run at 90 volts for about 2 hours in Tris-Glycine buffer 
(25 mM Tris, 250 mM glycine, 0.1% w/v SDS) at pH 8.3. Afterwards the gel was 
immersed in Coomassie blue staining solution for about 5 min (50% v/v methanol, 
10% v/v acetic acid and 0.2% w/v Coomassie Brilliant Blue R-250) (Sigma, Dorset, 
UK). In order to visualise any proteins, the gel was destained in solution Ι (50% v/v 
methanol, 10% v/v acetic acid in distilled water) for about 5 minutes, and finally 
immersed in the destaining solution Π (7.5% v/v methanol, 10% v/v acetic acid in 
distilled water) for 5 minutes to remove the excess dye. 
 
3.4.1 Western blotting 
In order to perform Western blotting, the protein samples were first resolved in SDS 
PAGE gel electrophoresis as described before. The gel was placed against a PVDF 
membrane (Millipore, MA, USA) sandwiched with filter paper solidly supported. 
The electro blotting chamber was filled with transfer buffer (39 mM glycine, 48 mM 
Tris base, 0.037% w/v SDS and 20% v/v methanol) (Sigma, Dorset, UK). The 
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transfer was run at 20 volts for about 2hours. Afterwards the PVDF membrane was 
immersed in a blocking solution consisting of 5% w/v non-fat dry milk powder in 1 x 
PBS, 0.2% v/v Tween 20 and shaken for 1 hour at room temperature to block non 
specific binding sites. Then the membrane was washed 4 times for 1 hour in 1 x PBS 
and 0.2% v/v Tween 20 under continuously shaking. The membrane was incubated 
for 1 hour with the following corresponding antibodies to detect proteins.  
 
 
All the previous antibodies were diluted in 5% w/v non fat dry milk powder in 1 x 
PBS, 0.2% v/v Tween 20. This was followed by 4 washing steps within 1 hour in 1 x 
PBS under continuous shaking. The membrane was transferred into a plastic dish 
containing either a rabbit anti-mouse IgG antibody (Dakocytomation, Glostrup, 
Denmark, 1:1000) or anti-rabbit antibody HRP (Cell signalling, UK, 1:10000) in 5% 
w/v non fat dry milk powder in 1 x PBS, 0.2% v/v Tween 20 depending on the host 
Abcam, UKRabbit polyclonal antibody1 hour/RT1:1000PCNA
Abcam, UKRabbit monoclonal antibody1 hour/RT1:500ATM
Santa Cruz Biotechnology. 
UK
Mouse monoclonal antibody 1 hour/RT1:500 p21 
Upstate, UK Polyclonal rabbit anti-human1 hour/RT1:1000Anti-nitrotyrosine
Abcam, Cambridge, UK Polyclonal rabbit anti-human 1 hour/RT1:1000Inducible nitric 
oxide synthase
(iNOS) 
Santa Cruz Biotechnology, 
Inc. Santa Cruz, CA, U.S.A 
Mouse monoclonal antibody1 hour/RT1:1000 p76MDM2 
(SMP14) 
Novacastra, UKMonoclonal mouse IgG2 1 hour/RT1:1000p53 (DO-1)
CompanySourceIncubation 
time/t
DilutionAntibody
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of the primary antibody and incubated for 1 hour at RT, followed by wash in 1 x 
PBS. Positive immunoreactivity was detected by the enhanced chemiluminescence’s 
method (ECL). To do so, the membrane was immersed for 2 minutes in equal 
volumes of solution Ι (1 ml of 250 mM luminol in DMSO, 0.44 ml of 90 mM p-
coumaric acid in DMSO, 10 ml of 1 M Tris-HCl pH 8.5 in a final volume of 100 ml) 
(Sigma, UK) and solution Π (64 µl of 30% v/v H2O2, 10 ml of Tris-HCl pH 8.5 in a 
final volume of 100 ml) (Sigma, UK). Positively stained protein bands send a 
luminescent signal that was visualised on a sheet of X-ray film (Sigma, Dorset, UK). 
 
3.4.2 Statistical analysis for Western blot 
The bands were evaluated by utilizing Image J version 1.37 (supplied online by NIH 
at http://rsb.info.nih.gov/ij/index.html). Each band was highlighted and the intensity 
was calculated. Statistical analysis was performed by Graph pad prism version 4 and 
1-way ANOVA with Bonferroni analysis. The mean of the calculated values were 
plotted in the figures. 
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3.5 Dot Blotting 
 
Dot blot is a technique which mimics Western blot. This technique is used for 
identification, detection, and analysing of the required proteins. The mechanism of 
this method is to spot the protein samples directly onto the membrane instead of 
performing separation by electrophoresis. 
 
3.5.1 Dot blotting of resolubilised p53 protein from E.Coli  
Blot analysis was utilised to follow the effect of H2O2 on p53 protein. Oxidation of 
p53 (0.2 mg/ml) was performed with different concentrations of H2O2 (30%, Fluka, 
UK).  
P53 protein was incubated with different concentrations of H2O2 (1, 5, 10, 50, 100 
mM) for 1 hour at RT. Then, dry paper towel was placed on the surface. Next four 
filter papers previously immersed in 0.05% Tween 20 in TBS were put on top of 
these paper towels followed by a PVDF membrane (Millipore, MA, USA) prior 
soaked in methanol for 20-30 sec, followed by washing with distilled H2O and 
finally transferred to 0.05% Tween 20 in TBS for 2-3 minutes. Protein samples were 
spotted directly onto the PVDF membrane and left to air dry (5-10 minutes). The 
blocking procedure was carried out by incubating the membrane with 5% w/v non-
fat dry milk powder in 1 x PBS, 0.2% v/v Tween 20 for 2 hours at RT under shaking 
conditions. The next procedures included washing and exposing to primary and 
secondary antibodies until the developing process was carried out in the same way as 
Western blotting described in detail before. 
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3.6 Microbiological medium: Lauria-Bertani (LB) 
 
This media consisted of 10 g of bacto-tryptone (Oxoid, Basingstoke, Hampshire, 
England), 5 g of bacto-yeast extract, 10 g of NaCl and was adjusted to pH 7.0 using 5 
M NaOH, and then made up to a volume of 1 litre using distilled water. The medium 
was autoclaved at 120°C for 20 minutes. LB agar medium was prepared by adding 
15 g of agar to 1 litre of LB medium before autoclaving. Where stated, LB medium 
was supplemented with ampicillin to a final concentration of 10 µg/ml. 
 
3.6.1 Purification of plasmid DNA  
Plasmid DNA was purified utilising the alkaline lysis method of Birnboim and Doly 
(1979) and Ish-Horowiz and Burke (1981) by using plasmid DNA isolation kits 
(Qiagen, England). 1.5 ml of overnight culture was placed into an Eppendorf tube 
and then centrifuged at 14,000 x g for 1 minute at RT in a bench top MSE 
MicroCentaur centrifuge (Sanyo, UK). The supernatant was discarded and the cell 
pellets were resuspended in 250 µl of buffer P1 (100 µg/ml RNase, 50 mM Tris-HCl, 
10 mM EDTA, pH 8.0). After 5 minutes 250 µl of P2 lysis solution (200 mM NaOH, 
1% w/v SDS) was added and mixed by gentle inversion for a further 5 minutes to 
lyse the cells. Then 350 µl of neutralisation buffer N3 (5.6 M KAc, pH 4.8) was 
added to obtain a cloudy precipitate of denatured chromosomal DNA and proteins. 
After spinning the tube in a microcentrifuge for 10 minutes at 14,000 x g the 
supernatant was transferred to a separate QIAprep spin column and centrifuged at 
14,000 x g for 30-60 sec at RT again in a microcentrifuge. The QIAprep spin column 
was washed with 0.75 ml buffer PE (1.0 M NaCl, 50 mM. MOPS, 15% v/v ethanol, 
pH 7.0) and centrifuged for 30-60 sec. The flow-through was discarded and the spin 
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column again was centrifuged at 14,000 x g for 1 minute to remove residual washing 
buffer. Then the QIAprep column was transferred to a sterile Eppendorf tube and 50 
µl of elution buffer EB (10 mM Tris-HCl, pH 8.5) was added to the centre of 
QIAprep column to elute the plasmid DNA. After leaving the column to stand for 1 
minute, plasmid DNA was recovered from the column by centrifuging at 14,000 x g 
for 1 minute in a microcentrifuge at RT. Plasmid DNA was stored at -20°C until 
further use. 
 
3.6.2 Transformation of a BL 21/DE3 strain with pT7.7 Hup53 plasmid DNA 
using CaCl2 
0.1 ml of a BL21/DE3 overnight culture was added to 10 ml of LB media in a 50 ml 
Falcon tube, and left to grow at 37°C while shaking at 180 rpm in a Gallenkamp 
orbital incubator. The OD650nm was measured until the growth reached mid-log phase 
(OD650nm 0.3-0.4) and then the culture was placed on ice for 10 minutes. 1.5 ml of 
culture was added to each of two 1.5 ml sterile Eppendorf tubes and centrifuged in an 
MSE MicroCentaur microcentrifuge at 14,000 x g for 1 minute at RT. The pellets 
were resuspended in 0.4 ml of ice-cold 0.1 M CaCl2 solution (Sigma, UK) and left 
for 15 minutes before centrifugation at 14,000 x g for 1 minute. After discarding the 
supernatant the pellets were resuspended in 0.2 ml of ice-cold 0.1 M CaCl2 solution 
and the competent cells aliquoted into two sterile Eppendorf tubes. 5 µl of plasmid 
pT7.7 Hup53 DNA (~0.1 µg) was added to one tube, while to the other (control) 5 µl 
of sterile distilled water was added. Both tubes were placed on ice for 20 minutes. 
Plasmid DNA uptake was promoted by transferring the tubes to a water bath at 45°C 
for 90 sec, and then transferred directly on ice for 5 minutes, to complete the heat 
shock step. 0.6 ml of LB medium was then added to each tube and was incubated and 
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shaking for 1 hour at 180 rpm. After 1 hour, the two sterile Eppendorf tubes were 
centrifuged in a microcentrifuge at 14,000 x g for 1 minute at RT. The pellets in the 
two sterile Eppendorf tubes were resuspended in 0.2 ml of LB broth, before being 
plated out onto dried LB agar plates supplemented with 10 µg/ml ampicillin followed 
by incubation at 37°C overnight. 
 
3.6.3 Pilot experiment for determination of the optimal p53 expression time 
from the BL21/DE3 strain containing pT7.7 Hup53 construct (Midgley et al., 
1992) 
Two 50 ml Falcon tubes containing 10 ml of LB broth were supplemented with 100 
µl of a BL21/DE3 pT7.7 HuP53 overnight culture and 100 µl of ampicillin (10 
µg/ml). Another two 50 ml Falcon tubes containing 10 ml LB broth were also 
supplemented with 100 µl of BL21/DE3 overnight culture. All four cultures were 
grown in Falcon tubes at 37°C with shaking at 180 rpm in a Gallenkamp orbital 
incubator, until reaching the early log phase (OD650nm 0.15-0.2). After 90 minutes, an 
aliquote of 800 µl was taken to measure the OD650nm. Isopropylthiogalactopyranoside 
(IPTG) at a final concentration of 1 mM was added once the OD650nm reached 0.15-
0.2, which indicates the early log phase. The remaining cultures without IPTG 
supplement served as negative controls. The transferred 800 µl of the cultures was 
centrifuged in MSE MicroCentaur microcentrifuge at 14,000 x g for 1 minute at RT. 
Then the supernatant was discarded and the pellets were resuspended in 30 µl of 2 x 
SDS gel–loading dye (100 mM Tris-HCl pH 6.8, 10% w/v bromophenol blue, 20% 
v/v glycerol) and 6 µl of 100 mM DDT (Sigma, Dorset, UK) and boiled for 5 
minutes. These and later samples were then stored at -20°C for further use. The 
culture was left to grow for 4 hours and after each hour the OD650nm was measured by 
 93 
removing 800 µl of the cultures from each tube, which were then processed for SDS-
PAGE gel analysis. 
 
3.6.4 Large scale expression and resolubilisation of human p53 protein  
20 ml of overnight culture of BL21/DE3 pT7.7 HuP53 and 200 µl of ampicillin (10 
µg/ml) was added to 2 litres of LB broth. The culture was kept in the Gallenkamp 
orbital incubator at 37°C and 180 rpm until the OD650nm reached 0.15-0.2 (early log 
phase). At this stage IPTG was added to a final concentration of 1mM and the culture 
was left to grow for 4 hours (optimum condition). 4 hours later the culture was 
transferred in clear tubes and centrifuged (Beckmann, AvantiTM J-25) at 16,000 x g 
for 20 minutes at 4°C using the large rotor (JLA, 10,500). The resulting pellets were 
resuspended in 20 ml cold 50 mM Tris-HCl (pH 8.0) and for preservation purposes 
0.66 ml per gram cells of buffer (10% w/v sucrose, 50 mM Tris-HCl pH 8.0) was 
added prior to storage at -80°C. When required cells were thawed at 25°C and 15 µl 
of 10 mg/ml lysozyme and 20 µl of 5 M NaCl per ml of cells were added. Cells were 
kept for 45 minutes on ice and continuously mixed to allow complete cell lysis. 
Because the solution of lysed cells became very viscous, it was warmed in a water 
bath at 37°C for 1 minute, incubated again in ice water and sonicated three times at 
maximum amplitude for 30 sec. Insoluble particles were removed by centrifugation 
of the lysates at 5,200 x g at 4°C for 20 minutes using a small rotor (JA) of the 
Beckmann, AvantiTM J-25. The supernatant was kept at -80°C after adding glycerol 
(10% v/v) for preservation. This supernatant contains soluble p53 protein (2%) 
important for future work. The pellets were resuspended twice in 5 ml of buffer (50 
mM Tris-HCl pH 8.0, 2 mM EDTA, 10 mM NaCl, 1 mM PMSF, 0.5% v/v Triton-
X100) to wash the protein, then centrifuged again at 5,200 x g at 4°C for 20 minutes 
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using a small rotor (JA) of Beckmann AvantiTM J-25. The pellets were solubilised in 
5 ml of 5 M guanidine hydrochloride, 50 mM Tris-HCl pH 8.0, 0.005% v/v Tween 
80 by mixing on a rotating wheel at 4°C overnight in the cold room and then 
centrifuged at 5,200 x g at 4°C for 20 minutes using a small rotor (JA) to remove 
insoluble material. The supernatant was transferred into a fresh tube and diluted to a 
final concentration of 1M guanidine hydrochloride (40 ml of a mixture of 50 mM 
Tris- HCl pH 8.0, 0.005% v/v Tween 80, 2 mM reduced glutathione and 0.02 mM 
oxidized glutathione) (Sigma, Dorset, UK) and placed on a rotating wheel at 4°C 
overnight. Afterwards the protein was dialysed for at least 6 hours at 4°C using 2 
litres of the following buffers  
a) 50 mM HEPES pH 8.0, 300 mM NaCl, 0.005 % v/v Tween 80 
b) 50 mM HEPES pH 8.0, 250 mM NaCl, 0.005 % v/v Tween 80 
c) 50 mM HEPES pH 8.0, 200 mM NaCl, 0.005 % v/v Tween 80 
d) 50 mM HEPES pH 8.0, 150 mM NaCl, 0.005 % v/v Tween 80 
The resolubilised protein was centrifuged at 5,200g for 20 minutes at 4°C in the 
Beckmann, AvantiTM J-25 using the JA rotor. A sample was transferred, 100 µl from 
the supernatant which is the resolubilised protein, and added the same volume of 2 x 
loading dye supplemented with 1/10 volume of 100 mM DDT, then testing the purity 
by SDS-PAGE gel analysis. For the remaining volume of the dialysed protein, 10% 
v/v glycerol was added for preservation purposes and stored at -80°C for further use. 
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3.7 Nitration of p53 protein by peroxynitrite  
 
An aliquoted of 0.2 ml of p53 protein (0.2 mg/ml) was transferred into two glass test 
tubes, for nitration with 0.1 mM PN (174 mM) (Batch no # B62483, Cal Biochem, 
UK) and with 0.5 mM PN (174 mM). One additional test tube with each 0.2 ml of 
BSA protein (0.2 mg/ml) was included as a positive control (nitration with 0.5 mM 
PN). All of the three glass tubes were placed in a 37°C shaking water bath for 30 
minutes. After this initial incubation the nitration process was started by adding 0.1 
µl and 0.57 µl of PN to the appropriate glass tubes at final concentration of 0.1 mM 
and 0.5 mM of PN, respectively. While adding PN, a pinch stirrer was used to allow 
maximum reaction of PN with both p53 and BSA proteins. Then 10 x SDS loading 
dye was added to the p53 and BSA protein samples and the samples were transferred 
into a water bath (100°C) for 4 minutes. Immediately the samples were loaded into a 
10% w/v SDS-PAGE gel and gel electrophoresis was started (80 volts for about 2 
hours). Western blotting followed for detection of nitro tyrosine (Upstate, Lake 
Placid, U.K) at a concentration of 1:1000 for 1 hour at RT. Rabbit anti-mouse IgG 
HRP (Dacocytomation, Glostrup, Denmark) was used as a secondary antibody for 1 
hour at RT (dilution 1:1000). 
 
3.7.1 Dose response for nitration of p53 by peroxynitrite  
To test the nitration in a concentration dependent manner, 0.1ml p53 protein was 
used, starting in six different glass test tubes. Then p53 protein in each glass tube was 
diluted with 50 mM HEPES, 50 mM NaCl and 0.005% v/v tween 80 to a final 
volume of 500 µl. These tubes were classified into, nitrated p53 with PN at final 
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concentrations 20 µM, 40 µM, 60 µM, 80, µM and 100 µM. Nitrated BSA (0.05 mM 
PN) served as a positive control. All samples were analysed by Western blotting. 
 
3.7.2 Time response for nitration of p53 by peroxynitrite  
The main purpose of this experiment was to find out, how long it takes for PN to act 
with proteins. In order to approach this question 0.1ml p53 was nitrated with 0.1mM 
PN over time (1 sec, 5 sec, 15 sec, 30 sec, 60 sec and 90 sec). Previously nitrated p53 
(0.1mM PN) was used as a positive control. P53 protein was diluted with 50 mM 
HEPES, 50 mM NaCl and 0.005% v/v tween 80 to a final volume of 500 µl as 
performed in the previous section. This experiment was completed by Western 
blotting. 
 
3.7. 3 Immunoprecipitation of the mutant p53 of HT-29 cells by using protein G 
agarose 
To an aliquoted of 1 ml of HT-29 frozen cell suspension containing mutant p53 (kept 
in -80°C, suspended in 1 ml PBS) 50 µl of 1 x protease inhibitor (Roche Diagnostics 
GmbH, Mannheim, Germany), 10 µl of 10% v/v Igepal and 10 µl of 0.5 M EDTA 
were added. Incubation for 45 minutes on ice was followed with occasional mixing. 
Then the suspension was centrifuged for 15 minutes at 14,000 x g at 4°C. 20 µl of 
the supernatant was transferred to a fresh tube and 20 µl of 2 x loading dye and 4 µl 
DDT (100 mM) was added. Prior to loading the samples into a gel, they were boiled 
in a water bath for 4 minutes. 15 µl of these samples served as an internal control. 
Additionally p53 (resolubilized from E. coli, strain and BL21/DE3 pT7.7Hup53 that 
were kept in -80°C) was diluted by 1:30 using 1 x loading dye and 6 µl 100 mM 
DDT was added followed by heating for 4 minutes before loading into the gel. 
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Preclearing stage 
A 30 µl of protein G agarose (Sigma, Dorset, UK) was added to the protease 
inhibitor, 10% v/v Igepal and 0.5 M EDTA and kept in ice for 20 minutes to ensure 
that same condition. After mixing the solution was centrifuged at 14,000 x g for 1 
minute in a micro centrifuge. A 700 µl of supernatant was mixed with protein G 
agarose and kept on ice for 45 minutes. Then it was centrifuged at 14,000 x g for 3 
minutes in a microcentrifuge and the pellets (protein G agarose) were transferred into 
fresh tubes followed by washing twice with 20 µl 1 x PBS, 20 µl HSB (high salt 
buffer, 0.5 M NaCl, 5 mM EDTA and 50 mM Tris-HCl, pH 8.0). After a final 
centrifugation step (14,000 x g for 3 minutes) 15 µl was loaded into the gel to probe 
whether protein G agarose bound to p53 protein. 15 µl of the supernatant was loaded 
into the gel to test for unbound p53 protein. 
 
Clearing stage  
After removing protein G agarose by centrifugation, 700 µl of supernatant was 
supplemented with 4 µl of antibody DO-1 and kept on ice for 1 hour under 
occasionally mixing. Thereafter, 40 µl of protein G agarose was added to the 
antibody labelled supernatant and incubated on a mixing rotor in a cold room (4°C) 
for 90 minutes. This step was followed by centrifugation at 14,000 x g for 3 minutes 
in a microcentrifuge. 50 µl of the supernatant was added to 50 µl 2 x loaded dye, 8 µl 
100 mM DDT and boiled for 4 minutes in the water bath. Then 15 µl was loaded 
onto the gel in order to test whether there was still p53 protein in the supernatant. 
The pellets were washed twice with HSB, then centrifuged at 14,000 x g for 3 
minutes and 15 µl of the resulting supernatant was loaded onto the SDS-PAGE gel. 
This was an important step to ensure whether p53 protein was still present after 
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washing. Also 15 µl of the pellets (p53 protein, DO-1 and protein G agarose) was 
loaded into the gel to determine whether DO-1 labelled protein G agarose contained 
p53 protein. 
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3.8 Detection of mutant type p53 from HT-29 cells 
 
3.8.1 Identification of immunoprecipitated mutant p53 protein from HT-29 cells  
Serial volumes from the sample were made by loading 2 µl, 4 µl, 6 µl, 15 µl and 20 
µl onto the gel to demonstrate different concentrations of the immunoprecipitated 
mutant type p53 (HT-29 cell). The SDS-PAGE gel was run as described previously 
and prepared for Western blotting. 
 
3.8.2 Immunoprecipitation of the nitrated mutant p53 protein of HT-29 cells 
using protein G agarose 
HT-29 cells were cultured in three T75 culture flasks and after 6 days these four 
large flasks were trypsinized with 6 ml. After trypsinization, 4 ml RPM1, 1640 
media (Invitrogen, Paisley, UK) were used to wash all cells off. The complete cell 
suspension was transferred into separate 1.5 ml Eppendorf tubes and centrifuged at 
7,000 x g for 10 minutes. The supernatant was discarded and the pellets were washed 
twice with PBS, previously kept in a water bath at 37°C. Thereafter, the pellets 
obtained from each T75 culture flasks were resuspended in 1 ml of PBS. Finally 
there were 4 ml of cell lysates, nitrated cell lysates with 0.5 mM PN and cell lysates 
treated with decomposed 0.5 mM. 1ml of cell lysate was not nitrated to be used as a 
negative control. All cell lysates (HT-29 cells) were subjected to 
immunoprecipitation using protein G agarose as described in detail. SDS-PAGE gel 
and Western blotting were prepared as described previously. Stripping procedures 
were carried out to incubate the membrane in the washing solution (5% w/v milk, 
0.4% tween 20, 1x PBS) supplemented with 2% v/v SDS and 5% v/v 2 β-
mercaptoethanol for 45 minutes at 80°C followed by a wash for 30 minutes and 
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exposed to the primary anti-nitro tyrosine antibody (1:1000) for 1 hour at RT. 
Thereafter, the membrane was washed for 30 minutes and incubated with the 
secondary rabbit anti mouse IgG HRP antibody (1:1000) for 1 hour at RT followed 
by a final wash with the same washing solution for 30 minutes and the result was 
visualised with ECL solution. 
 
3.8.3 Dose response for nitrated mutant p53 protein  
Separate aliquots (5 ml each) were obtained from HT-29 cells as described above. 
The nitration process for HT-29 cells was performed by treating 4 ml of the cell 
lysate with 10 µM PN, 50 µM PN, 100 µM PN and 250 µM PN. To test the effect of 
decomposed PN on the cell lysate, 1ml of the lysate was treated with decomposed 
0.5 mM PN as described earlier. All lysates (HT-29 cells) underwent the 
immunoprecipitation process using protein G agarose as described in detail, followed 
by Western blotting and stripping procedures as described earlier. 
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3.9 Electromobility Shift Assay (EMSA) 
 
3.9.1 Designing, radiollabeling and purification of the labelled oligonucleotides 
duplex 
Oligonucleotides containing the 20-mer consensus DNA binding site of p53 (the 
forward) and their complementary sequences (the reverse) were ordered from Sigma 
Genosys. 
5’ -AGACATGCCTAGACATGCCT-3’ (Forward) 
5’ –AGGCATGTCTAGGCATGTCT-3’ (Reverse) 
Both forward and reverse oligonucleotides were diluted to a concentration of 1 µg/µl 
with nuclease free water (Promega Corporation, Southampton, UK). The diluted 
oligonucleotides were mixed together in a 1:1 ratio and left at RT for 5 minutes, in 
order to form the oligonucleotide duplex. The end labelled process was carried out 
by adding 10 pmol of 5’-ends of oligonucleotides and 4 µl of [32P] γ-ATP (stock: 
9.25 MBq/50 µl, Perkin Elmer, UK) into the tube that contained ready-to-go T4 
polynucleotide kinase (Amersham Pharmacia, Biotechnology, UK) and distilled 
water giving a final volume of 50 µl. Thereafter, the reaction mixture was incubated 
in a water bath for 38 minutes at 37°C and the reaction was stopped by adding 5 ml 
of 250 mM EDTA. 
Radiolabelled oligonucleotides as well as unincorporated [32P]γATP were separated 
by using spin columns (MicroSpinTM G-25 columns, Active Motif, Belgium) by 
following the manufacture’s protocol. To confirm the purity of the end-labelled 
oligonucleotide duplex, 4% non-denaturing polyacrylamide gel (32.22 ml H2O, 5.33 
ml of 30% acrylamide, 40 µl TEMED, 400 µl of 10% APS, 2 ml of 10 x TBE) 
(Sigma Diagnostics Inc., St. Louis, USA) was prepared and placed into a protein ΙΙΧI 
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vertical electrophoresis cell (Bioradcorporation, Hertfordshire, UK). The reaction 
mixture (2 µl of radiolabelled oligonucleotides, 4 µl of distilled water and 4 µl of 6 x 
blue / orange loading dye (Promega corporation, Southampton, UK) was loaded and 
the autoclaved 10 x TBE buffer (pH8.3) was used as running buffer (108 g Tris base, 
55 g boric acid, 9.3 g disodium EDTA and distilled water to a final volume of 1000 
ml). 
The gel was electrophoresed at 150 V until the dye front reached a third of the way 
from the top. Gels were dried by a dryer (Drygel Sr. Slab gel dryer, Hoeffer 
Scientific Instruments, SanFrancisco, USA) for about 1.5 hour at 80˚C. Finally the 
band for endlabelled oligonucleotide duplex was detected by exposing the dry gel to 
Kodak X-Omat film for 24 hours followed by standard ECL technique. 
 
3.9.2 Effect of H2O2 and peroxynitrite (PN) on p53-DNA binding capacity  
The effect of H2O2 and PN on p53-DNA binding was investigated separately in two 
experiments. The combined effect of PN / H2O2 on p53-DNA-binding was shown in 
one single experiment. 250 ng/µl of active wild type p53 protein (expressed in insect 
cells using baculovirus expression system, 500 ng/µl, Active Motif, Belgium) was 
treated with different H2O2-concentration (100 µΜ, 200 µΜ, 300 µΜ, 500 µΜ, 800 
µΜ, 1 mM) for 2 minutes and then the excess H2O2 was removed by adding 5 ml of 
5 mg/ml catalase (Sigma, Dorset, Poole, UK). The treated p53 was transferred into a 
new Eppendorf tube containing 4 µl of the purified radiolabelled oligonucleotide 
duplex and p53-DNA binding buffer (Hupp, Meek et al. 1992) to complete the 
reaction volume to 20 µl. Native active p53 protein and 4 µl of the purified 
radiolabelled oligonucleotide were used as a positive control. Resolubilised p53 
(expressed in E. Coli) and 4 µl of the purified radiolabelled oligonucleotide was used 
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as a negative control. All samples were incubated at 0°C on ice for 36 minutes. The 
reaction products were loaded onto pre-cooled 3% polyacrylamide native gel (33.56 
ml H2O, 4 ml of 30% acrylamide, 40 µl TEMED, 400 µl of 10% APS, 2 ml of 10 x 
TBE) (Sigma Diagnostics Inc., St. Louis, USA) in 0.5XTBE running buffer followed 
by electrophoresis at 196 V until the dye marker reached half way down the gel. 
Thereafter the gel was dried and the bands were visualised on a Kodak X-Omat film. 
In order to investigate the effect of PN on p53, peroxynitrite (174 mM Calbiochem, 
Darmstadt, Germany) diluted in 0.1 M NaOH (Oberprieler 2007) was used as 
described for H2O2. To study the effect of the combination of PN/H2O2 on DNA-
binding, p53 was first treated with H2O2 as described above followed by treatment 
with PN. 
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3.10 Molecular structural computer modelling of the native and 
oxidized/nitrated p53-DNA binding domain 
 
In order to provide a better insight into the effect of H2O2, PN and the combination of 
both on p53-DNA binding the molecular modelling program “HyperChem” 
(Hypercube, Inc, Gainesville, FL, USA), Deep View analysis was used to compare 
and investigate the changes that could happen after oxidation and nitration to p53-
DNA binding capacity. The crystal structure of human p53 was obtained from the 
Protein Data Bank (http://www.rcsb.org/pdb/hoe/home.do.) accession number 1TUP. 
This work was carried out in collaboration with Dr N. Gibbons, University of 
Bradford. 
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4.0 RESULTS 
 
4.1 The presence of p53 in the human epidermis 
 
4.1.1 Up-regulation of p53 protein in association with low catalase expression in 
patients with vitiligo 
It was previously demonstrated that p53 expression is up-regulated in vitiligo 
(Schallreuter, Behrens-Williams et al. 2003). Moreover, this up-regulated p53 is a 
wild type and functioning protein (Schallreuter, Behrens-Williams et al. 2003). The 
current study was planned to test whether p53 protein expression in vitiligo was 
correlating with H2O2-mediated oxidative stress levels. Since catalase is considered 
as a biomarker for oxidative stress (Schallreuter, Bahadoran et al. 2008), these levels 
formed the base as internal standard for assessment of H2O2 stress in all patients 
(n=10) and controls (n=4). In order to minmize variabelity, skin samples from the 
same patients were used throughout all investigations.  
The in situ results show high p53 protein expression throughout the epidermis of 
vitiligo lesional (f) and vitiligo non lesional skin (j) compared to healthy controls (b). 
In addition we show that p53 is over expressed in the nucleus of vitiligo lesional (h) 
and vitiligo non lesional skin (l) compared to controls (d) (Figure 16A). 
Image analysis of p53 protein expression in the whole epidermis revealed that 
protein expression is significantly increased in both vitiligo lesional (∗∗∗ p<0.001, 
mean ± SD) and vitiligo non lesional (∗∗ p<0.01, mean ± SD) epidermis compared to 
healthy controls (Figure 16B/C). There is no significant difference between lesional 
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and non lesional skin (p>0.05). This observation confirmed earlier results 
(Schallreuter et al 2003, van den Wijngaard et al 2000). 
In order to correlate the expression of p53 levels to individual H2O2-mediated 
oxidative stress in trhe same samples, epidermal catalase levels were evaluated as 
well. Catalase is significantly lower in vitiligo lesional and non lesional epidermis 
(∗∗∗ p<0.001, mean ± SD), when compared to healthy controls. This result is in 
agreement with H2O2-mediated stress in vitiligo as documented earlier (Schallreuter 
et al 2008). 
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Figure 16  
Increased epidermal p53 expression in patients with vitiligo in association with low 
catalase levels 
(A) Immuno fluorescence staining (FITC labelling) shows over expression of p53 protein in 
vitiligo lesional (n=10) (f) and non lesional skin (n=10) (j) compared to healthy controls 
(n=4) (b); skin phototype III (Fitzpatrick classification). Low levels of catalase in vitiligo 
lesional (e) and non lesional skin (i) compared to healthy controls (a). The nucleus of 
epidermal cells of vitiligo lesional (h) and non lesional (l) exhibits a high expression level of 
p53 protein compared to controls (d). c, g and k presents DAPI for healthy control, vitiligo 
lesional and non lesional respectively. Magnification x 400, scale bar 100 µm. 
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(B) Image analysis of catalase. Values are the mean ± SD (∗∗∗ p<0.001). 
(C) Image analysis of p53 protein. Values are the mean ± SD (∗∗∗ p<0.001). 
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4.1.2 Confirmation of over expression of p53 in vitiligo by Western blot 
In order to further support the in situ findings on up-regulation of p53 in patients 
with vitiligo compared to healthy controls, Western blotting was carried out in 
epidermal suction blister tissue from 4 patients (Figure 17A). The results support the 
in situ results of p53 protein over expression in these cell extracts (lanes 3-9) 
compared to normal healthy control (lane 2). 
Moreover, epidermal p53 is up-regulated in lesional and non-lesional skin of patients 
with vitiligo in the presence of epidermal H2O2 levels in the mM range as evidenced 
by the corresponding low catalase levels of the patients examined.  
One important take home message emerges from this study. Up-regulated p53 is not 
only present in the lesional epidermis. This result corresponds to almost all results 
which have been collected over many years (Schallreuter et al 2008) pointing to a 
general mechanism involved in this disease.  
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Figure 17 
Epidermal suction blister tissues exhibit up-regulated p53 protein in vitiligo  
(A) Western blot showing an increase in p53 protein expression in patients with vitiligo 
(lanes 3-9) compared to healthy controls (lane 2). The numbers on top of Western blot 
identify patient’s numbers (4). Lane 1 is a protein ladder; GADPH was used as a loading 
control. 
(B) Densitometry analysis of the bands reveals significantly higher levels of p53 protein after 
re-probing the blots with GADPH antibody (blots are ±SD). (∗∗∗ p<0.001). 
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4.1.3 H2O2 does not affect the epitope of the p53 antibody  
In order to exclude a possible effect of H2O2 on p53, we performed dot blot analysis 
using purified p53 (0.2 µg) from E. Coli in the presence of H2O2-oxidised protein. 
P53 was exposed to various H2O2 concentrations ranging from 1 to 100 x10
-3M for 1 
hour at RT prior to analysis. The results (Figure 18) show that the epitope binding 
site for the antibody is not affected by H2O2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 
P53 protein epitope is not affected by H2O2 
Dot blot proves that H2O2 does not affect immune-reactivity of the p53 protein epitope of the 
primary antibody used (DO-1, 1:15000) 
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4.1.4 Increased in vitro expression of p53 protein in vitiliginous melanocytes 
Since melanocytes are the target cells in vitiligo we wanted to know whether p53 
protein levels are also increased under in vitro conditions. Our immuno-reactivity 
results revealed that p53 protein is highly expressed in the nucleus of vitiliginous 
melanocytes (Figure 19f) whereas p53 is only expressed in the cytoplasm in healthy 
control cells (Figure 19c). This result indicates that p53 is even up-regulated under 
in vitro conditions.  
Together with the in situ and the Western blot data, it is tempting to invoke a very 
central role for p53 as master conductor in vitiligo. 
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Figure 19 
Strong cytosolic and nuclear p53 expression in vitiligo melanocytes  
In vitiligo melanocytes (d) p53 protein is present throughout the cytosol and the nucleus 
compared to healthy control melanocytes where p53 expression is weaker and is more 
distributed in a granular pattern (a). (b) and (e) represent DAPI for control and vitiligo 
melanocyte respectively. Overlay with DAPI indicates strong nuclear expression in vitiligo 
(f).Magnification x 400, scale bar 100 µm. 
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4.2 Detection of two mdm2 isoforms in vitiligo 
 
4.2.1 Normal expression of p90
MDM2
 in patients  
Given that p53 is up-regulated in vitiligo, we next looked into the degradation 
pathway of this protein. P90MDM2 plays a crucial role in regulation of p53 in the cell 
because it is important for the nuclear signal transduction pathway. Therefore, we 
employed again in situ and in vitro immuno-reactivity staining in the corresponding 
skin samples. The in situ results show epidermal p90MDM2 expression in normal 
healthy controls (a), vitiligo lesional (d) and non lesional (g) skin. Moreover, we 
found that p90MDM2 expression is more pronounced in the nucleus (Figure 20A). 
Image analysis shows no statistically significant difference between patients and 
controls (p>0.05, mean ± SD) (Figure 20B). This result is not influenced by the 
presence of high epidermal H2O2 levels as analysed in comparison to the 
corresponding catalase levels in the same samples (data not shown). Based on these 
results we can conclude that P90MDM2 expression is not affected by H2O2 in vitiligo. 
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Figure 20 
Expression of p90 
MDM2
 is not altered in patients with vitiligo compared to healthy 
controls 
(A) Immuno-reactivity staining shows no significant difference in p90MDM2 expression in 
vitiligo lesional (n =10) (d), vitiligo non lesional (n=10) (g) compared to healthy controls 
(n=4) (a); skin phototype III (Fitzpatrick classification). The expression of p90MDM2 is also 
found in the nucleus as shown by overlay with DAPI. Magnification x 400, scale bar 100 
µm. 
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(B) Image analysis Average fluorescence intensity reveals that there is no significant 
increase in p90MDM2 expression (p>0.05).  
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4.2.2 In vitro expression of p90
MDM2
 in vitiliginous melanocytes compared to 
controls 
In order to follow p90MDM2 expression under in vitro conditions, immuno 
fluorescence staining for both vitiligo and healthy control melanocytes was 
processed. Again, p90MDM2 expression is the same in vitiligo melanocytes and 
normal melanocytes (Figure 21a and d respectively). Moreover, the protein is 
strongly expressed in the nucleus (Figure 21c and f respectively). The current 
observations would favour that p90MDM2 promotes degradation of p53 in the nucleus 
through an E3 ubiquitin ligase mechanism. 
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Figure 21 
p90
MDM2
 immuno-reativity shows the same expression level in vitiligo and control 
melanocytes 
Normal melanocyte (a) and vitiligo melanocyte (d). Both normal melanocyte (c) and vitiligo 
melanocyte (f) induce this protein in their nucleus as shown by the overlay with DAPI. 
Magnification x 400, scale bar 100 µm. 
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4.2.3 Increased p76
MDM2
 level in patients with vitiligo compared to healthy 
controls 
The mdm2 protein is a nuclear protein that regulates p53 function with its capacity to 
suppress the transcriptional activity of the p53 protein. We confirmed that p53 is not 
degraded but it is over expressed and functional in patients with vitiligo (Schallreuter 
et al 2003). Therefore, the next aim was to seek an explanation for why mdm2 
protein does not degrade p53. It has been shown that p76MDM2 has the ability to 
antagonize p90MDM2 action i.e. degradation of p53. Hence, it was tempting to 
investigate the pattern of p76MDM2 expression in a large series of patients with 
vitiligo by using in situ immuno fluorescence technique with a specific antibody for 
p76MDM2 (SMP14, Santa Cruz Biotechnology, Inc. Santa Cruz, CA, U.S.A). This 
staining was carried out again in comparison with the corresponding catalase levels 
in the same samples to assess the levels of oxidative stress (data not shown). 
We found the presence of up-regulated epidermal p76MDM2 in patients with vitiligo 
compared to healthy controls (Figure 22A/B). This isoform was also found in the 
nucleus. 
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Figure 22 
Patients with vitiligo reveal induced epidermal p76
MDM2
 levels  
(A) In situ immuno fluorescence of p76MDM2 (FITC-labelled) reveals high protein expression 
of p76MDM2 in vitiligo lesional skin (d), non lesional skin (g) compared to control skin (a). (f) 
and (i) are overlays of vitiligo lesional and non lesional respectively with DAPI showing the 
presence of p76MDM2 in the nucleus which is absent in healthy controls (c). Magnification x 
400, scale bar 100µm,  
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(B) Image analysis of p76
MDM2
 in vitiligo N.B. significant increase in the expression of 
p76MDM2 throughout vitiligo (n=10) skin compared to healthy controls (n=4) (*** p<0.001, 
mean ± SD, ** p<0.01, mean ± SD, ns = not significant). N.B. There is no difference 
between lesional and non lesional skin. 
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4.2.4 Epidermal cell extracts from patients with vitiligo reveal significantly 
higher p76
MDM2 
protein levels 
In order to further validate the immuno fluorescence data, Western blot analysis was 
performed in epidermal suction blister cell extracts from 3 patients with vitiligo and 
3 healthy controls using the same p76MDM2 antibody. p76MDM2 was significantly 
stronger expressed in extracts from patients with vitiligo compared to healthy 
controls (Figure 23). These results suggest that p76MDM2 antagonizes p90MDM2 
leading in turn to stability and consequently to up-regulation of p53. Importantly, the 
up-regulation is present in lesional and non- lesional tissues. 
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Figure 23 
Over expressed p76
MDM2
 protein in vitiligo  
(A) Western blot with SMP14 antibody Over expression of p76MDM2 in 3 patients with 
vitiligo compared to healthy controls. Lane 1 protein ladder, lanes 2-4 healthy controls and 
lanes 5-10 patients with vitiligo. GADPH was used as a loading control.  
 
(B) Image analysis Evaluation of the bands was performed in relation to loaded protein 
(GADPH). The result demonstrates that p76MDM2 is up-regulated in vitiligo compared to 
controls (∗∗∗ p<0.001). 
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4.3 Immuno-reactivity expression of iNOS and nitrated tyrosine in 
the human epidermis  
 
4.3.1 Increased epidermal iNOS expression in patients with vitiligo as an 
indicator for the presence of NO 
On one hand, it has been shown that NO can stabilize p53 (Forrester et al 1996, 
Messmer et al 1994 &1996). On the other hand it was shown that nitration affects 
p53-DNA binding (Calmes et al 1997, Cobbs et al 2001). Since patients with vitiligo 
have high levels of H2O2 in their epidermal compartments, it was tempting to explore 
the possibility of p53 oxidation/nitration. Therefore, we investigated the level of 
iNOS in the epidermis of patients and controls. In order to demonstrate the 
expression level of this enzyme, immuno fluorescence and Western blotting studies 
were used. Our in situ immuno fluorescence results show stronger expression levels 
throughout all patients with vitiligo lesional (d) and vitiligo non lesional skin (g) 
(Figure 24A) in comparison to healthy controls (a). Catalase was again used as 
internal control to monitor oxidative stress (data not shown). Statistical analysis for 
all patients used in this study, revealed significant higher levels of iNOS in both 
vitiligo lesional (** p<0.01, mean ± SD) and non lesional skin (* p<0.05, mean ± 
SD) compared to controls (Figure 24B). There is no significant difference between 
vitiligo lesional and vitiligo non lesional skin in the expression level of iNOS 
(p>0.05, mean ± SD).  
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Figure 24 
Increased in situ iNOS expression in patients with vitiligo  
(A) In situ immuno fluorescence staining of iNOS (FITC-labelled) demonstrates high 
expression level of iNOS in vitiligo lesional (d), non lesional (g) compared to control (a). (f) 
and (i) overlay of vitiligo lesional and non lesional respectively with DAPI shows 
localization of iNOS in the nucleus compared to healthy control (c). (b), (e) and (h) represent 
DAPI for controls, lesional and non lesional skin respectively. Magnification x 400, scale bar 
100µm.  
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(B) Image analysis showing a significant increase in the expression of iNOS in vitiligo 
lesional (** p<0.01) and non lesional skin (* p<0.05) compared to healthy controls.  
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4.3.2 More evidence for up-regulation of iNOS in vitiligo 
The increased expression of iNOS in the epidermis of patients with vitiligo was 
confirmed by Western blotting in cell extracts from 5 patients with vitiligo and 2 
controls. The results show that iNOS exhibits a high expression level in vitiligo 
(lanes 4-13) when compared to control (Lanes 2 and 3) (Figure 25). 
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Figure 25 
Induction of epidermal iNOS in patients with vitiligo  
(A) As seen on the Western blot, iNOS levels are significantly different between 5 patients 
with vitiligo (lanes 4-13) and 2 controls (lanes 2 and 3). Lane 1 represents protein ladder. 
GADPH served as loading control. 
(B) Densitometric measurements were performed to iNOS levels in correlation with loaded 
protein (GADPH). iNOS is significantly over expressed in vitiligo lesional compared to 
control (plots are mean ± SD). (∗∗∗ p<0.001). 
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4.3 3 Vitiliginous melanocytes express iNOS under in vitro conditions  
Our in situ previous data showed up-regulation of iNOS in the skin of patients with 
vitiligo. Moreover, this result was confirmed by Western blot. To explore whether 
this was also the case under in vitro conditions in vitiliginous melanocytes, we used 
again immuno fluorescence labelling. The result in Figure 26 displays expression of 
iNOS, which is much more pronounced in the nucleus of melanocytes from patients 
(Figure 26d), compared to control cells (Figure 26a). Importantly, expression of 
iNOS is also present in the nucleus of vitiliginous melanocytes (Figure 26f) and 
control (Figure 26c). Taken together, increased iNOS expression in vitiligo suggests 
increased NO production which in turn reacts with O2
˙¯ to produce ONOO¯. 
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Figure 26 
In vitro immuno-reactivity reveals up regulated iNOS in vitiligo melanocytes  
Melanocytes from patients with vitiligo are characterized by the presence of up-regulated 
nuclear iNOS (d and f respectively) when compared to healthy control cells (a and c 
respectively). (b) and (e) represent DAPI for control and vitiligo melanocytes respectively. 
Magnification x 400, scale bar 100µm 
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4.3.4 Up-regulated iNOS correlates with high expression of nitrated tyrosine 
residues in vitiligo  
As said before, the observed increased levels of epidermal iNOS protein expression 
could contribute to a marked generation for NO in vitiligo. In this context it is 
important to mention that O2
˙¯ reacts with NO to give peroxynitrite (ONOO¯). The 
main footprint for the presence of ONOO¯ is nitrated tyrosine formed by the nitration 
of L-tyrosine in proteins. To define the formation of ONOO¯ in vitiligo, we 
monitored the rate of formation of nitro-tyrosine by using again immuno 
fluorescence staining with a specific antibody against nitrated tyrosine residues. As 
done in all other studies full skin biopsies from normal healthy control, (n=4) vitiligo 
lesional, (n=10) and vitiligo non lesional skin, (n=10) skin phototype III (Fitzpatrick 
classification) were used. The results show a pronounced in situ expression of 
nitrated tyrosine throughout the epidermis of patients with vitiligo lesional, non 
lesional skin compared to healthy controls (Figure 27A). Quantification analysis of 
nitrated tyrosine expression reveals statistically significant increased nitrated tyrosine 
in the entire epidermis of vitiligo lesional skin (*** p<0.001, mean ± SD) vitiligo non 
lesional skin (*** p<0.001, mean ± SD) compared to controls (Figure 27B). 
However, again there is no significant difference in the expression level of nitrated 
tyrosine in both epidermal vitiligo lesional and non lesional (p>0.05, mean ± SD). 
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Figure 27 
Significantly higher epidermal nitro tyrosine levels in vitiligo  
(A) Immuno-reactivity staining (FITC labelling green) shows strong expression of nitrated 
tyrosine in vitiligo lesional (n=10) (d), vitiligo non lesional skin (n=10) (g), compared to 
healthy controls (n=4) (a), skin phototype III (Fitzpatrick classification) at magnification x 
400. (b), (e) and (h) represent DAPI for healthy control, vitiligo lesional and vitiligo non 
lesional respectively. Nitrated tyrosine is not present in the nucleus. Scale bar 100µm. 
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(B) Image analysis Average fluorescence intensity shows significantly increased levels of 
nitrated tyrosine in both vitiligo lesional and non lesional skin compared to healthy controls. 
However, there is no significant difference between vitiligo lesional and non lesional skin. 
(∗∗∗ p<0.001). 
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4.3.5 Increased in vitro expression of nitrated tyrosine in vitiliginous 
melanocytes 
Epidermal melanocyte cell cultures established from patients with vitiligo and 
controls cells as mentioned in methods were used for immuno fluorescence staining. 
The result is consistent with the in situ data. Nitrated tyrosine residues are over 
expressed in vitiliginous melanocytes compared to control (Figure 28d and a 
respectively). Moreover, the overlay with DAPI showed localization of nitro-tyrosine 
in the nucleus of vitiliginous melanocytes (Figure 28f). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
 
Figure 28 
Vitiliginous melanocytes exhibit high levels of nitro tyrosine in the cytosol and in the 
nucleus 
In vitro immuno fluorescence for vitiliginous and control melanocytes (d and a) respectively. 
DAPI for control and vitiliginous melanocytes is presented (b) and (e) respectively. The 
overlay shows nuclear localization of nitro-tyrosine in melanocytes from patients with 
vitiligo (f) compared to control melanocytes (c). Magnification x 400, scale bar 100µm.  
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4.4 Detection of nitrated p53 in vitiligo 
 
4.4.1 In situ immuno-reactivity reveals signaficantly increased nitrated p53 
expression in vitiligo skin 
In situ and in vitro immuno fluorescence as well as Western blot revealed iNOS 
expression which in turn produces NO. In the presence of O2
˙¯
, ONOO¯ is formed 
causing nitration of L-tyrosine yielding nitrated tyrosine. The levels of nitrated 
tyrosine are significantly higher and lesional and non lesional skin of the patients 
compared to controls (Figure 29A). Given that, p53 is up-regulated in vitiligo, we 
postulated that p53 nitration is taking place. In order to substantiate this assumption, 
we utilized, immuno fluorescence and Western blot. The results in Figure 29A 
revealed the presence of nitrated p53 in vitiligo lesional and non lesional skin as 
identified by a strong yellow colour after overlay of p53 and nitro-tyrosine 
expression (f and i respectively). Quantitative image analysis (Figure 29B) yielded a 
significantly higher expression in vitiligo lesional and non lesional skin compared to 
controls (*** p<0.001, mean ± SD). Notably, there was no significant difference 
between vitiligo lesional and non lesional skin. 
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Figure 29. 
Increased in situ expression of nitrated p53 in vitiligo  
(A) Immuno fluorescence reactivity of TRITC-labelled p53 and FITC-labelled nitrate 
tyrosine (NTYR). (e and h) represent nitrated tyrosine in vitiligo lesional, (n=10) and non 
lesional skin, (n=10). Overlay of p53 and nitrated tyrosine identifies the presence of 
cytosolic nitrated p53 through our epidermis, spearing nuclei in (f) and (i), vitiligo lesional 
and non lesional skin respectively when compared to controls (c) (skin phototype III, 
Fitzpatrick classification). Magnification x 400, scale bar 100µm. 
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(B) Image analysis of nitrated p53 content. Nitrated p53 levels are significantly increased 
in vitiligo lesional (n=10) (*** p<0.001), non lesional (n=10) (*** p<0.001) compared to 
healthy controls (n=4). N.B. There is no difference between lesional and non lesional skin. 
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4.4.2 Western blot supports in situ immuno-reactivity of high nitrated p53  
To further substantiate the presence of nitrated p53 in vitiligo, we explored epidermal 
suction blister cell extracts from patients with vitiligo by Western blot analysis for 
detection of native p53 and nitrated tyrosine. The tyrosine residue was nitrated by 
peroxynitrite. The results in Figure 30 (lanes 3-10) prove ability of peroxynitrite to 
induce nitration for p53 in vitiligo compared to the control (lane 2). The results 
proved that p53 is nitrated in vitiligo. The results reveal the presence of increased 
p53 expression in epidermal vitiligo cell extract in association with increased nitrated 
tyrosine levels. The levels are significantly higher in all samples from patients 
compared to healthy controls. Together with the in situ results we can conclude that 
epidermal p53 is nitrated in vitiligo  
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Figure 30 
Accumulation of nitrated p53 in vitiligo 
(A) Western blot analysis of total cell extracts from patients with vitiligo (n=4) (lanes 3-10) 
and healthy control (n=1) (lane 2). The results show strong p53 expression and association 
with strong N-tyrosine expression in vitiligo (lanes 3-10) compared to control (lane 2). Lane 
1 represents protein ladder. GADPH was used as loading control. 
(B) Image analysis of native p53 expression. 
(C) Image analysis of nitrated p53 expression. Results show the significantly over expression 
of nitrated p53 in vitiligo compared to control. (Plots are mean ±SD). (∗∗∗ p<0.001). 
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4.5 Expression of human p53 protein in E. Coli 
At this point it was important to investigate our findings from the patients in more 
details. For this purpose we needed purified human p53 protein. E. Coli is the most 
important organism to be used to express p53, due to its long history of laboratory 
culture and ease of manipulation. Moreover, it is considered a very versatile host for 
the production of recombinant proteins. 
4.5.1 Pilot experiment for determination of the optimal time for p53 protein 
expression from the BL21/DE3 containing the pT7.7 Hup53 construct 
A preliminary time course experiment was performed to establish the optimum time 
for p53 expression in the T7 expression system as described previously in the 
Materials and Methods. In Figure 31A bands corresponding to p53 were neither 
observed in lane 2 (induced BL21/DE3 pT7.7Hup53), nor lane 3 (non induced 
BL21/DE3 pT7.7Hup53) as these samples were at time zero, they were also not 
observed in lanes 4, 5, 8 and 9 because these samples represented controls where the 
strain did not contain the p53 gene. After 1 hour of induction by IPTG, a band of 
approximately 53 kDa was observed in lane 6, but it was not present in the non-
induced control, lane 7. A p53 band was recognized in lane 2, (BL21/DE3 
pT7.7Hup53), in lane 6 (BL21/DE3 pT7.7Hup53) (Figure 31B) and in lane 2 
(BL21/DE3 pT7.7Hup53) (Figure 31C). This band increased with intensity over 
time due to induction by IPTG after 2 hours and 3 hours respectively (Figure 31B) 
and 4 hours (Figure 31C).  
We also observed some induction in non induced cells as shown in lane 3 
(BL21/DE3 pT7.7Hup53) and lane 7 (BL21/DE3 pT7.7Hup53) of Figure 31B and in 
 142 
lane 3 (BL21/DE3 pT7.7Hup53) of Figure 31C. A band possibly corresponding to 
p53 protein was obtained. The intensity of this band increased over time. The reason 
for the possible expression of p53 protein in these non-induced cells is likely due to 
leaky expression of the lac promoter that promotes the transcription of T7 RNA 
polymerase gene even during non-induced IPTG conditions (Dubendoff and Studier, 
1991). 
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Figure 31 
4 hours are the optimum period for the expression of p53 from E. Coli 
(A) SDS-PAGE gel showing expression of p53 from E.Coli at time 0. There is no 
corresponding band for p53 in both lane 2 (induced, BL21/DE3 pT7.7Hup53) and lane 3 
(non induced, BL21/DE3 pT7.7Hup53). Lane 4 and 5 represent induced and non induced 
BL21/DE3 respectively which do not contain p53 gene and act as negative controls. Lane 6 
shows the expression of p53 protein by E. Coli after 1 hour induction by 1 mM IPTG when 
compared to lane 7 which represents non induced BL21/DE3 pT7.7Hup53. While lane 8 and 
9 are negative controls strain (induced BL21/DE3 and non induced BL21/DE3) respectively. 
Lane 1 is the prestained protein marker. The dot indicates the position of p53 protein in SDS-
PAGE gel. 
(B) Lane 2 and 6 represent induced BL21/DE3 pT7.7Hup53 showing the expression of p53 
protein by E. Coli after 2 and 3 hours induction by 1 mM IPTG respectively when compared 
to lane 3 and 7 which represent non induced BL21/DE3 pT7.7Hup53 during the same 
induction periods respectively. Lanes 4 and 5 represent negative controls strains (induced 
BL21/DE3 and non induced BL21/DE3) respectively after 2 hours induction. Lane 8 and 9 
are the same negative controls strain but after 3 hours induction. Lane 1 is the prestained 
protein marker. The dot indicates the position of p53 protein in SDS-PAGE gel. 
(C) Lane 2 (induced BL21/DE3 pT7.7Hup53) demonstrates the maximum expression of p53 
from E. Coli after 4 hours induction. Lane 3 represents non induced BL21/DE3 pT7.7Hup53. 
While lane 4 and 5 are negative controls strain (induced BL21/DE3 and non induced 
BL21/DE3) respectively which do not contain p53 gene. Lane 1 is the prestained protein 
marker. The dot marks the position of p53 protein in SDS-PAGE gel. 
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4.5.2 Measurement of the optical density for all the E. Coli strains used for p53 
expression 
In order to investigate the growth rate in all strains used for p53 expression, the 
optical density of OD650nm of the induced strains and non-induced was measured 
prior to sample preparation for SDS-PAGE gel (Figure 32). The retarded growth in 
the BL21/DE3 pT7.7Hup53 was not observed in the host BL21/DE3 strain as 
expected (Studier et al., 1990), reflecting the effect of over expression from the 
powerful T7 promoter. 
It was observed from the SDS-PAGE gel that the BL21/DE3 pT7.7Hup53 strain after 
induction exhibited a weaker protein stain profile than the non-induced strain 
reflecting the retardation of growth as shown (Figure 32). 
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Figure 32 
Growth curves for the strains used for p53 expression 
Upon addition of IPTG the growth of all bacterial strains started after 90 minutes 
(BL21/DE3 pT7.7Hup53 and BL21/DE3). In the absence of IPTG no growth was detected. 
The induction with 1 mM IPTG was performed every 60 min over 4 hours.  
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4.5.3 Confirmation of p53 expression from E. Coli by Western blotting  
Following the pilot expression of human p53, Western blots were carried out for 
further confirmation. Aspecific antibody for p53 (NCL-p53-DO-1, Novacastra, UK) 
was used. The results demonstrate in lanes 2 and 4 of Figures 33A and B a strong 
band, corresponding to p53 protein, and this band revealed an increase in intensity 
with the time of induction, 1, 2, 3 and 4 hours respectively by 1 mM IPTG. It is 
noticeable that the induced samples in lanes 2 and 4 of Figures 33A and B showed a 
smear protein below the full molecular size of p53 protein. This result may be due to 
the extensive sonication used to prepare the samples for SDS-PAGE analysis. 
Moreover, a weak band for p53 protein in non-induced cells was detected in lanes 3 
and 5 of Figures 33A and B. This band was most likely due to the known leaky 
activity of lac promoter (Dubendoff and Studier, 1991). 
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Figure 33 
Human p53 protein expression from E. Coli strain (BL21/DE3 pT7.7 Hup53) after 
induction with 1 mM IPTG over time (1, 2, 3 & 4 hours)  
(A) Western blot analyses the detection of p53 protein after induction with 1 mM IPTG by 1 
and 2 hours using E. Coli strain, BL21/DE3 pT7.7 Hup53, Lane 2 and 4 respectively. Lanes 
3 and 5 represent non induced BL21/DE3 pT7.7 Hup53. Protein ladder is represented in lane 
1. 
(B) Increased intensity of p53 protein expression after induction by 3 and 4 hours (lanes 2 
and 4). Lanes 3 and 5 (non induced BL21/DE3 pT7.7 Hup53) exhibit p53 protein expression 
due the leaky activity of lac promoter. Lane 1 is protein ladder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53kDa
53kDa
1 and 2 hours 
after induction
3 and 4 hours 
after induction
1            2                           3                     4                            5
A
B
 148 
4.5.4 Large scale expression of human p53 from BL21/DE3 pT7.7 Hup53 
 
After determination of the optimum time (4 hours) for p53 expression from E. Coli 
strain BL21/DE3 pT7.7 Hup53. A large scale of p53 expression was carried out by 
scaling up to 2 litres. The results revealed increased expression of p53 protein in a 
time dependent manner after induction with 1 mM IPTG. There is no expression for 
p53 protein before induction as shown in lane 2 (Figure 34). 
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Figure 34 
p53 protein expression from E. Coli BL21/DE3 pT7.7 Hup53, before and after 
induction with 1 mM IPTG 
SDS-PAGE gel showing the expression of p53 protein throughout the induction time, 1, 2, 3 
and 4 hours (lanes 3, 4, 5 and 6 respectively) marked by dot. There is no expression for p53 
before induction, lane 2. Lane 1, prestained protein marker. 
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4.6 Nitration of the resolubilised human p53 protein by 
 peroxynitrite 
 
Our data showed that p53 undergoes nitration in vitiligo. In order to substantiate 
these findings, we utilized resolubilised purified p53 from E. Coli. 
 
4.6.1 Peroxynitrite nitrates the resolubilised p53 protein 
A pilot experiment for nitration of resolubilised p53 protein was performed by 
treating the protein with different concentrations of PN (0.1 mM and 0.5 mM) using 
nitrated BSA (0.5 mM of PN) as a positive control. The results of the nitration 
experiment show a strong band which is in agreement with nitrated BSA protein 
(Figure 35A). This result proves PN acting as a nitrating agent for tyrosine residues 
in p53 protein confirming earlier data in the literature (Berlett, Friguet et al. 1996). 
 
4.6.2 Dose response for nitration of p53 by peroxynitrite  
To gain further insight into the process of nitration on p53 protein, we investigated 
the effect of different PN concentrations (20 µM, 40 µM, 60 µM, 80 µM and 100 
µM) on the resolubilised p53 protein. Nitrated BSA (50 µM of PN) was used as a 
positive control. Our result revealed that nitration of p53 is a dose dependent (Figure 
35B). 
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4.6.3 Nitration of p53 by peroxynitrite is time dependent 
Next we investigated the effect of time on nitration of p53. In this experiment the 
following time intervals (1 sec, 5 sec, 15 sec, 30 sec, 60 sec and 90 sec) were used to 
follow nitration of p53 protein in the presence of 0.1 mM PN. The results showed an 
increase in the formation of nitrated p53 protein up to 30 sec (Figure 35C), while 
time > 30 sec had no additional effect. Nitrated p53 (0.1 mM PN) was used as a 
positive control (Figure 35C). From this result we can conclude that nitration of 
tyrosine residues is a fast event, taking place in seconds.  
Taken together, our in vitro results using purified human p53 confirmed nitration of 
p53 as shown by Berlett and colleagues in 1996. We show that this process is fast 
and dependent on the presence of PN concentration. 
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Figure 35 
Nitration of the resolubilised p53 by PN is dose and time dependent 
(A) The resolubilised p53 was nitrated with concentrations of 100 and 500 x10-6M of PN. 
Nitrated BSA protein was used as a positive control. 
(B) Nitration of p53 is concentration dependent of PN, (20-100 µM). Nitrated BSA (50 µM) 
served as a positive control. 
(C) Nitration of p53 by PN is time dependent. NB gradual increases up to 30 sec. Exposure 
>30 seconds had no additional effect. Positive control, nitrated p53 (0.1 mM PN). 
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4.7 Nitration of immunoprecipitated p53 protein from 
HT-29 cells 
 
To further explore the effect of ONOO¯ on p53 protein, we immunoprecipitated p53 
protein from HT-29 cells by using protein G agarose beads and antibodies specific 
for p53 as mentioned earlier in materials and methods (section, 3.8). The HT-29 cell 
line obtained from human colon carcinoma and was chosen for this study because it 
contains a mutant p53 protein. Here it was of interest whether PN had the ability to 
nitrate mutant p53.  
 
4.7.1 Immunoprecipitation of p53 protein from HT-29 cells 
In order to prove nitration of mutant protein, we prepared a large amount of mutant 
p53 protein from HT-29 cells. Protein G agarose was used for immunoprecipitation 
because it has a high affinity for IgG, e.g. DO-1. Figure 36A shows a condensed 
band in the position of immunoprecipitated mutant p53 protein in lane 10. To further 
confirm immunoprecipitation of p53 protein, a positive control has been used 
(resolubilised p53 protein from E. coli strain, BL21/DE3 pT7.7Hup53, lane 2). Lane 
3 represents HT-29 cell extract serving as a control for estimating the amount of 
mutant type p53 protein in proportional to the resolubilised p53 protein (lane 2). 
Lanes 4, 5, and 6 represent controls for protein G agarose including protein G 
agarose only, protein G agarose+HT-29 cell extracts after washing with HSB and 
protein G agarose+TH-29 cell extract after washing with HSB for the second time 
respectively. This step done to show that protein G agarose can not bind to mutant 
type of p53 protein after incubation together in the absence of the antibody (DO-1). 
Lanes 7 and 8 represent the loading of clearing supernatant and the washing solution 
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of the immunocomplex (protein G agarose+DO-1+mutant type of p53 protein) with 
HSB respectively. These two lanes show a band corresponding to mutant type p53 
protein. This result was acceptable because the DO-1 antibody cannot bind to all 
mutant type p53 protein molecules. This is also the case for protein G which cannot 
bind to the entire immunocomplex. In lane 9 there is not any band for mutant p53 
protein because it represents the washing solution of the immunocomplex with HSB 
for the second time. This result confirms that there was no non-specific binding. To 
provide more confirmation the same sample as in lane 10 (Figure 36A) was 
subjected to further analysis by Western blot. This data (Figure 36B) revealed that 
mutant p53 protein was clearly detected by the immunoprecipitation obtained with 
protein G agarose and DO-1 antibody (Figure 36A). The data in Figure 36B show 
detection of different amounts of mutant p53 protein from HT-29 cells. Lanes 2, 3, 4, 
5, and 6 represent bands for mutant p53 protein bands corresponding in a 
concentration dependent manner (2 µl, 4 µl, 6 µl, 15 µl and 20 µl of p53 protein).  
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Figure 36 
Immunoprecipitation of mutated p53 protein  
(A) SDS-PAGE showing the successful immunoprecipitation for p53 protein from HT-29 
cells. Lane 1 is the prestained protein marker. Lanes 2 and 3 are representing positive control 
and total cell extract from HT-29 cells respectively. Lanes 4, 5 and 6 are serving as protein G 
agarose only, protein G agarose+HT-29 cell extract after washing with HSB and protein G 
agarose+TH-29 cell extract after washing with HSB for the second time respectively. The 
loading of supernatant, the washing solution of the immunocomplex (protein G agarose+DO-
1+mutant type of p53 protein) with HSB and the washing solution of the immunocomplex 
with HSB for the second time are shown in lanes 7, 8.and 9 respectively. The dot indicates 
the position of the immunoprecipitated p53 in lane 10. On the other hand the light and heavy 
chain for the DO-1 antibody is located above and below the p53 band. 
(B) Western blot shows the detection of immunoprecipitated p53 (lanes 2-6) from HT-29 
cells using CM-1 antibody (1:1000) after performing titration with different amounts of p53 
(2 µl, 4 µl, 6 µl, 15 µl and 20 µl). Lane 1 serves as protein ladder. 
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4.7.2 Immunoprecipitation of the nitrated mutant p53 protein from HT-29 cells 
The nitration process for mutant p53 protein (HT-29 cells) was followed by using the 
DO-7 labelled immunocomplex after nitration with 0.5 mM PN (protein G 
agarose+CM-1+ mutant p53 protein) to demonstrate that the immunoprecipitated 
protein was indeed mutant p53 protein. After stripping by using anti-nitro tyrosine 
antibody only one band was detected (Figure 37B). From these results we can 
conclude that mutant p53 from HT-29 cells is still subjected to nitration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37 
Detection of nitrated mutant p53 protein from HT-29 cells 
(A) Western blot shows the detection of the immunoprecepitated p53 from HT-29 cells by 
using DO-1 antibody. Lane 2 represent pellets (HT-29 cells non nitrated+protein G 
agarose+CM-1), lane 3 pellets (HT-29 cells +protein G agarose + CM-1) nitrated with 0.5 
mM PN and lane 4 pellets (HT-29 cells +protein G agarose + CM-1) decomposed 0.5 mM 
PN respectively. 
(B) Stripping showing the identification of the immunoprecipitation of nitrated mutant p53 
protein (HT-29 cells) lane 3. The primary antibody is anti-nitro tyrosine (1:1000) and the 
secondary antibody is rabbit anti mouse IgG HRP (1:1000). The dot indicates the position of 
nitrated p53 protein. Lane 1 is serving as protein ladder. 
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4.7.3 Dose response for nitration of mutant p53 protein  
This experiment has been performed to investigate the effect of different 
concentrations of PN (10 µM, 50 µM, 100 µΜ and 250 µM), as well as the effect of 
the decomposed 0.5 mM PN on p53. The stripping data show that treatment of 
mutant p53 protein with different concentration of PN exhibits a dose response. 
There is a gradual increase in nitration of p53 protein proportional to the 
concentration of PN as shown in lanes 2, 3, 4 and 5 of Figure 38A. There was no 
effect for decomposed PN as shown in lane 6. Western blotting (Figure 38B) 
demonstrates nearly equal amounts of p53 protein in all wells after stripping 
supporting the result that mutant p53 can be nitrated.  
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Figure 38 
Nitration of mutant p53 protein is dose dependent 
(A) Western blot shows the dose response for the nitrated immunoprecepitated p53 from HT-
29 cells by using anti-nitro tyrosine (1:1000) antibody, specific for nitrated p53 protein at 
different concentration of PN (10 µM, 50 µM, 100 µΜ and 250 µM), lane 2, 3, 4 and 5 
respectively. Lane 6 represents the decomposed PN.  
(B) After stripping showing the identification of the same mutant p53 protein levels (HT-29 
cells) lane 2-6. The primary antibody was DO-1 (1:1000). Lane 1 represents protein ladder. 
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4.7.4 Effect of both nitration and oxidation on p53-DNA binding 
The presence of high epidermal H2O2 levels in association with up-regulated nitrated 
p53 in the epidermis of patients with vitiligo calls into questions whether oxidation / 
nitration affect DNA-binding capacity. In order to get a better insight into this 
process we performed EMSA. The results revealed that after nitration of p53 protein 
its binding capacity to DNA oligonucleotide sequence is completely abrogated in the 
presence of >300 µΜ ONOO ¯ (Figure 39A). When p53 protein was subjected to 
oxidation by H2O2 using different concentrations (100 – 800x 10
-6 M and 10-3 M) 
p53-DNA binding was improved (Figure 39B). Importantly , after p53 protein was 
incubated for the maximum of 1 minute with combined H2O2 and ONOO 
¯ (1:1), the 
DNA binding capacity was further enhanced (Figure 39C). 
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Figure 39 
The effect of peroxynitrite-mediated nitration and H2O2-mediated oxidation and the 
contribution of both on DNA binding capacity of p53 
(A) PN mediated nitration abrogates p53-DNA binding in a dose dependent manner (lanes 6-
8) (500, 800 x 10-6 M and 10-3 M respectively). Low concentrations of PN, has no effect 
on DNA-binding (lanes 3-5) (100, 200, 300 x 10-6 M respectively). Lane 1 negative 
control, lane 2 native p53 (positive control).  
(B) H2O2-mediated oxidation Increase p53-DNA binding capacity (lanes 3-8) (100, 200, 
300, 500, 800 x 10-6 M and 10-3 M respectively). Lane 1 negative control, lane 2 native 
p53 (positive control),  
(C) P53-DNA binding was improved as a result of combined effect of H2O2 and PN (lanes 8 
and 9) (10-3 M) when compared to H2O2 effect only (lanes 6 and 7) (10
-3 M). However lanes 
4 and 5(10-3 M) represent the abrogation of p53-DNA binding due to the effect of PN. Lanes 
1 and 3 positive controls, lane 2 negative control. 
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4.7.5 Computer simulation supports enhanced DNA binding of p53 due to 
combination of H2O2-mediated oxidation plus nitration  
In the native structure of p53 there are seven amino acids (lys 120, ser 241, arg 248, 
arg 273, ala 276, cys 277 and arg 280) in the DNA binding site which bind 6 
nucleotides (Cho et al 1994) (Figure 40A). Nitration converts 8 tyrosine residues to 
3-nitrotyrosine in the DNA binding domain of p53 (tyr 103, tyr 106, tyr 126, tyr 163, 
tyr 206, tyr 220, tyr 234, tyr 236) leading to severe changes in the secondary and 
tertiary structure. From the 7 residues involved in DNA binding (lys 120, ser 241, arg 
248, arg 273, ala 276, cys 277 and arg 280) arg 248 and cys 277 are lost yielding a 
reduced nucleotide binding capacity (Figure 40B). This result is consistent with our 
gel shift assay. 
After applying oxidation by H2O2 the nucleotide, binding enhances due to the 
participation of 13 amino acids instead of 7. From the original complex lys 120, arg 
248, arg 273, cys 277 and arg 280 are retained, whereas H-bonds from ser241 and ala 
276 are lost. However, there are now 8 new amino acids (val 122, lys 139, his 179, 
ser 240, arg 249, pro 250, val 274, arg 283) H-bonding to DNA. This result supports 
a pronounced increase in DNA binding (Figure 40C). Combined oxidation and 
nitration of met, trp and tyr residues results in a number of structural changes but 
most of the original amino acids remain, including those most crucial to p53-DNA 
binding. New H-bonding interactions are formed from 10 new amino acids, 
increasing the number of amino acids interacting to 15. However, the model expects 
the binding of 10 nucleotides in the oxidised complex (Figure 40D). This work has 
been contributed by Dr NCJ Gibbons from our group. 
 
 162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 
Computer modelling of p53 in the presence and absence of H2O2 and ONOO
¯¯ 
after 
H2O2-mediated oxidation and after nitration / oxidation 
(A) Native p53-DNA complex 
DNA binding to p53 involves seven amino acids forming the basis for interaction to the 
DNA backbone and the major and minor grooves via H-bonds to 6 nucleotides. 
(B) Effect of PN mediated nitration on DNA binding of p53  
Nitration of tyrosine residues in p53 does not affect the overall number of residues 
interacting with DNA. However, two residues are lost and substituted by new amino acids, 
including one of the crucial arg residues, arg248. This result supports the DNA binding data.  
(C) H2O2-mediated-oxidation of the p53 -DNA binding site enhances nucleotide binding 
capacity 
Oxidation of met and trp residues results in changes in the structure of p53 in association 
with the loss of some original amino acids. However, key amino acid residues remain H-
bonded to DNA but there are new H-bondings from 8 new amino acids increasing the 
number of amino acids interacting with DNA to 13 in association with the binding of 10 
nucleotides. This result is in support with the data obtained with oxidised p53 as shown by 
EMSA. 
(D) Oxidation / nitration enhances DNA binding of p53 
Oxidation of met, trp and tyr residues results in a number of structural changes. However, 
once again, most of the original amino acids remain, including those most crucial to the 
binding of p53 to DNA. In addition new H-bonding interactions are formed from 10 new 
amino acids, increasing the number of amino acids interacting to 15. The number of 
nucleotides bound is the same as with the oxidised complex.  
Colour key–nucleotides, yellow–guanosine, blue–thymine, green–cytosine (no adenine 
nucleotides involved. Original amino acids–burgundy, new amino acids–brown. (With kind 
permission from Dr NCJ Gibbons) 
native p53 p53+ONOO-
p53+H2O2 p53+H2O2+ONOO
-
A B
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4.8 Activation of p53 protein in vitiligo 
 
 
Under normal physiological conditions p53 is regulated by mdm2. In response to 
genotoxic stress, such as DNA damage, p53 is hyperphosphorylated and acetylated at 
multiple sites within or near the mdm2 binding domain (Giaccia and Kastan 1998; 
Chehab, Malikzay et al. 1999). It was shown by several groups (Hirao, Kong et al. 
2000; Shieh, Ahn et al. 2000) that DNA damage causes activation of ATM kinase 
promoting phosphorylation and acetylation of p53 which in turn leads to its 
stabilization by preventing mdm2 from binding to p53 (Shieh, Ikeda et al. 1997); 
(Unger, Juven-Gershon et al. 1999). 
 
4.8.1 Evidence for phosphorylation of p53 in vitiligo 
Phosphorylation is an important step for stabilization and activation of p53 in order 
to perform its function as a transcription factor (reviewed in Giaccia and Kastan 
1998; Appella and Anderson 2000). In this context it was shown that this process is 
induced by many stress factors including DNA damage affecting mainly 30 amino 
acids residues at both the amino terminus and the carboxyl terminus (Appella and 
Anderson 2001). Cellular stress activates the expression of a protein kinase family 
including ATM and ATR which mediate phosphorylation of ser 15, ser 9 and ser 37 
on p53 (Canman, Lim et al. 1998; Tibbetts, Brumbaugh et al. 1999). 
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4.8.1.1 Epidermal ATM is significantly increased in vitiligo 
To follow ATM protein expression, epidermal suction blister cell extracts were 
analyzed by Western blot (Figure 41). The results revealed that ATM expression is 
significantly higher in cell extracts from patients with vitiligo (lane 3-12) while in 
healthy controls ATM is barely detectable (lane 2). These results suggest that the 
increased p53 protein in vitiligo is phosphorylated / activated by ATM due to the 
presence of DNA damage as pended down by the presence of 8xoG levels in the 
epidermis and plasma of patients with vitiligo (Shalbaf 2009).  
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Figure 41 
Epidermal cell extracts from vitiligo reveal induced ATM protein expression  
(A) Western blot analysis shows an increase of ATM protein expression in all 5 patients with 
vitiligo tested (lanes 3-12) while ATM is absent in healthy control (lane 2), lane 1 protein 
ladder. GADPH was used as a loading control. 
(B) Densitometry analysis of the band related to GADPH. ATM protein expression is 
significantly higher in vitiligo lesional compared to control (plots are mean ± SD). (∗∗∗ 
p<0.001). 
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4.8.1.2 Expression of ATM in vitiligo melanocytes 
Briefly, ataxia telangiectasia mutated (ATM) is a serine/threonine-specific protein 
kinase. The protein is named based on the disorder Ataxia telangiectasia caused by 
mutations of ATM. This protein is recruited and activated by DNA damage. It 
phosphorylates several proteins that initiate activation of DNA damage checkpoints, 
leading in turn to cell cycle arrest, DNA repair or apoptosis. One of these targets is 
p53.  
In this thesis we showed the presence of nitrated p53 in patients with vitiligo together 
with up-regulated p53. In this contest it is noteworthy that earlier data from our 
group demonstrated up-regulated functional p53 (Schallreuter et al 2003). However, 
phosphorylation and acetylation of p53 in vitiligo have not been documented so far. 
Since both phosphorylation / acetylation are important steps in activation of p53 we 
tested ATM protein expression in vitiligo in vitro melanocytes and in suction blister 
from patients with vitiligo and controls. The result revealed a stronger expression of 
ATM under in vitro conditions in vitiliginous melanocytes compared to control cells 
(Figure 42d and a). Overlay with DAPI indicate nuclear localization of ATM which 
seems to be stronger in vitiligo cells (Figure 42f and c).  
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Figure 42 
Enhanced ATM expression in vitiliginous melanocytes 
Increased ATM expression in vitiliginous melanocytes (d) compared to control cells 
(a). (b) and (e) DAPI. ATM is also present in the nucleus (f). The expression seemed 
stronger in this organelle compared to cytosol (c). Magnification x 400, scale bar 
100µm 
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4.8.1.3 Phosphorylation of ser 9 and ser 15 in p53 protein  
Next we followed phosphorylation of vitiliginous p53 since it was shown (Canman, 
Lim et al. 1998; Tibbetts, Brumbaugh et al. 1999) that phosphorylation of ser 9 and 
ser 15 are due to activity of ATM (Canman, Lim et al. 1998; Tibbetts, Brumbaugh et 
al. 1999). Western blot analysis of epidermal cell extracts from patients with vitiligo 
(n=6) and healthy controls (n=2) were revealed phosphorylated ser 9 and ser 15.  
Based on these results we can conclude that up-regulated epidermal ATM is 
functional yielding activation / stabilization of p53 via phosphorylation of ser 9 and 
ser 15 of the protein. 
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Figure 43 
Presence of phosphorylated ser 9 and ser 15 in p53 protein in vitiligo cell extracts  
(A) Western blot analysis shows phosphorylation of ser 9 and ser 15 of p53 protein in 6 
patients with vitiligo (lanes 3-14). Lane 2 represents cell extract from healthy control. N.B. 
there is no band detectable. Lane 1 a protein ladder. GADPH is a loading control. 
(B and C) Densitometry analysis for phosphorylated ser 9 and ser 15 respectively in 
correlation to GADPH. Results show the significantly increase of the phosphorylated ser 9 
and ser 15 in vitiligo compared to control. (Plots are mean ±SD). (∗∗∗ p<0.001). 
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4.8.2 Evidence for acetylation of p53 protein in vitiligo 
Acetylation is one of the posttranslational modifications for many proteins. PCAF, a 
histone acetyltransferase (HAT), acetylates lys-370, lys-371, ys-372, lys-373 lys-381, 
lys-382 of p53 at its C-terminal leading to activation of p53 DNA binding activity 
(Kouzarides 2000; Sterner and Berger 2000). Acetylation of p53 is also a result of 
exposing the cell to cellular stress, including DNA damage (Sakaguchi, Watanabe et 
al. 1998); (Liu, Jin et al. 1999; Pearson, Carbone et al. 2000; Gottifredi and Prives 
2001; Ito, Shinkai et al. 2001).  
 
4.8.2.1 Acetylation of lys 373 and lys 382 in p53 protein by PCAF 
Consequently we decided to follow this step in more detail by investigating PCAF 
expression in vitiligo. To do so Western blot analysis was utilised for epidermal 
suction blister cell extracts from patients with vitiligo (n=6) lesional and non lesional 
skin and healthy controls (n=2). The results revealed a significant higher expression of 
PCAF protein in patients (lane 3-14) compared to control (lane 2) (Figure 44). This 
results suggested that acetylation of p53 could be intact. Western blot analysis was 
employed to follow selected modification sites on p53 induced by PCAF. The results 
prove that acetylation of lys 373 and lys 382 in the sequence of p53 protein in vitiligo 
cell extracts is indeed present (lanes 3-14) meanwhile this residues are absent in 
control skin. These data imply that acetylation in vitiliginous p53 is not hampered 
(lane 2). Our earlier data together with these novel data prove the presence of an up-
regulated functional / activated p53 in vitiligo (Schallreuter et al 2003).  
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Figure 44 
Evidence for acetylation of p53 protein by PCAF in vitiligo 
(A) Western blot analysis reveals the over expression of PCAF in vitiligo (lanes 3-14) when 
compared to control (lane 2). 6 patients have been used in this experiment. Moreover, PCAF 
protein mediates acetylatoin of lys 373 and lys 382 in the endogenous p53 protein in vitiligo 
(lanes 3-14) when compared to control (lane 2) While lane 1 represents a protein ladder. 
GADPH is a loading control. 
(B and C) Densitometry analysis of the PCAF protein and acetylated lysine residues 
respectively in correlation to GADPH. The results demonstrate a significantly higher 
expression of the PCAF and acetylated lysine residues in vitiligo compared to control. (Plots 
are mean ±SD). (∗∗∗ p<0.001). 
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Within this thesis it is demonstrated, for the first time, that up-regulated p53 in vitiligo 
corresponds with increased phosphorylation in association with increased ATM 
expression and with increased acetylation in association with increased PCAF 
expression. These results support our earlier finding on wild type functioning p53 in 
vitiligo (Schallreuter et al 2003). Moreover, we have shown that the DNA-binding 
capacity of p53 in vitiligo is enhanced due to contribution of nitration / H2O2 mediated 
oxidation. In addition, we have shown the presence of increased epidermal p76MDM2 
levels, which could provide an explanation for the constant up-regulation of epidermal 
p53 in this disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 173 
4.9 More evidence for functioning of p53 in vitiligo 
 
After showing active p53 in vitiligo we addressed protein functionality. Considering 
that p53 is a multifunctional protein mediating transcription for proteins involved in 
cell cycle arrest as well as DNA repair and apoptosis (Lane 1992; Harris 1993; 
Prives 1994) we chose to follow p21 and PCNA expression under those conditions as 
found in vitiligo.  
 
4.9.1 Cell cycle arrest is mediated by p53 protein 
After activation of p53 the protein mediates induction of p21 which in turn can 
initiate cell cycle arrest at the G1 phase (Kuerbitz, Plunkett et al. 1992; el-Deiry, 
Tokino et al. 1993) and G2 phase (Lin and Lowe 2001) in order to stop the 
replication of the damaged DNA (Hartwell 1992; Hartwell and Kastan 1994). It was 
reported that if p53 failed to recover DNA damage during cell cycle arrest, it still has 
the capacity to mediate apoptosis and inhibit replication of the damaged DNA 
(Hermeking and Eick 1994; Lin and Lowe 2001); (Yonish-Rouach, Resnitzky et al. 
1991). 
 
4.9.1.1 Up-regulation of p21 in epidermal cell extracts further support 
functioning p53 in vitiligo  
Expression of p21 in the epidermis of patients with vitiligo was confirmed by 
Western blotting in epidermal suction blister cell extracts from patients lesional and 
non lesional skin (n=5) and controls (n=3). The results prove the presence of up-
regulated p21 expression (Figure 45). Taken together, this result provides further 
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support for a functional up-regulated p53 in vitiligo. Notably, evaluation of the bands 
indicates variable p21 levels between patients (Figure 45b).  
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Figure 45 
Increased induction of p21 in patients with vitiligo 
(A) Western blot demonstrates p21 levels which are significantly different between patients 
with vitiligo(5) (lanes 5-14) and controls (3) (lanes 2-4). Lane 1, protein ladder. This 
Western blot was performed along with GADPH, which served as loading control. 
(B) Densitometry analysis of the bands in correlation to GADPH proves the presence of high 
p21 levels in vitiligo which are not detectable in control skin (plots are mean ± SD). (∗∗∗ 
p<0.001). 
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4.9.1.2 Increased in vitro expression of p21 protein in epidermal vitiliginous melanocytes 
Even under in vitro conditions we observed enhanced p21 protein expression 
compared to control cells (Figure 46). Moreover, p21 was present in the nucleus of 
vitiliginuos cells (Figure 46f). 
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Figure 46 
Pronounced p21 expression in vitiligo melanocytes  
p21 protein is over expressed in vitiligo melanocytes (d) compared to healthy control 
melanocytes (a). Overlay of images for control and vitiligo melanocytes with DAPI reveal a 
high nuclear expression for p21 in vitiligo melanocytes (f) which is absent in control cells 
(c). Magnification x 400, scale bar 100 µm. 
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4.9.2.1 Induced PCNA expression in epidermal suction blister cell extracts from 
patients with vitiligo 
Next we examined PCNA expression in the presence of up-regulated p53 in our 
patients.  
Again we used Western blot. The results revealed strongly induced over expression 
of PCNA in all patients lesional and non lesional skin (n=5) whereas PCNA 
expression was not detectable in healthy control skin (Figure 47). 
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Figure 47 
Induction of PCNA in patients with vitiligo. 
(A) Western blot analysis reveal high PCNA levels in vitiligo cell extracts (lanes 3-12) 
which is absent in control skin (lane 2). Lane 1 protein ladder. GADPH was identified to 
serve as a loading control. Numbers on top of the Western reflect how many patients were 
used in this investigation. 
(B) Densitometry analysis of PCNA bands in correlation to GADPH. PCNA is significantly 
induced in vitiligo (∗∗∗ p<0.001) (Plots are mean ± SD). 
 
 
 
 
 
 
 
 
 
 
 
PCNA
1     2      3      4       5        6      7       8       9   10     11    12     
GADPH
A
B
les nl les nl les nl les nl les nl
21 3 4 5
Control Lesional Non lesional
ns
0
10
20
30
40
50
60
70
80
90
100
110
%
 o
f 
P
C
N
A
 p
r
o
te
in
 e
x
p
r
es
si
o
n
(n=2) (n=5)(n=5)
%
 o
f 
P
C
N
A
 p
r
o
te
in
 e
x
p
r
es
si
o
n
%
 o
f 
P
C
N
A
 p
r
o
te
in
 e
x
p
r
es
si
o
n
%
 o
f 
P
C
N
A
 p
r
o
te
in
 e
x
p
r
es
si
o
n
 180 
These results indicate that up-regulated PCNA could serve as an effective DNA 
clamp to promote DNA replication together with DNA polymerase δ controlling, in 
turn, DNA replication via long patch BER. However, PCNA can also interact 
directly with APE1 mediating short patch BER (Dianova et al. 2001). P21 is a 
cycline dependent kinase inhibitor 1, disrupting / blocking DNA replication by 
binding to PCNA.  
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4.9.2.2 In vitro up-regulation of PCNA protein in epidermal vitiliginous melanocytes 
Immuno fluorescence labelling of PCNA indicates that even under in vitro 
conditions this protein is induced in vitiliginous melanocytes, while it is barely 
detectable in control cells (Figure 48d). PCNA is also highly expressed in the 
nucleus (Figure 48f) compared to control melanocytes (Figure 48c). 
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Figure 48 
In vitro over expression of PCNA in vitiligo melanocytes  
Immuno fluorescence shows increased levels for PCNA protein in vitiligo melanocytes (d) 
compared to control melanocytes (a). The overlay with DAPI shows nuclear localization for 
PCNA in vitiligo melanocytes (f). Magnification x 400, scale bar 100 µm. 
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4.9.3 No place for increased apoptosis in vitiligo 
As said already, earlier results on apoptosis in vitiligo are conflicting (Boissy and 
Nordlund 1997; Kemp, Waterman et al. 2001; Huang, Nordlund et al. 2002; Ruiz-
Arguelles, Brito et al. 2007; Schallreuter, Gibbons et al. 2007; Song, Xu et al. 2008) 
The results of this thesis together with the data of Shalbaf point to the presence of 
DNA damage in vitiligo as evidenced by increased 8-oxoG levels in the epidermis 
and in the plasma of these patients (Shalbaf 2009). Our data within the thesis favour 
a leading role for p53 in the scenario of DNA repair in this disease. However, it was 
decided to use the same sample material for analysis of BCL-2 because this protein 
has the ability to inhibit several proapoptotic factors.  
Our results identified by Western blot analysis significantly higher expression of 
BCL-2 in cell extracts of vitiligo (n=5) (lanes 5-14) compared to controls (n=2) 
(lanes 2 and 3) (∗∗∗ p<0.001). (Figure 49) 
 
Together with earlier reports and with the recent data from Shalbaf, who showed 
absence of caspase 3 and cytochrome c, it is tempting to conclude that in the 
epidermis of patients with vitiligo is no evidence for increased apoptosis. 
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Figure 49 
Over expression of epidermal BCL-2 in vitiligo 
(A) Western blot shows over expression of BCL-2 in 5 samples of cell extracts of patient’s 
lesional and no lesional skin (n=5) (lanes 5-14) compared to controls (n=2) (lanes 2 and 3) 
Lane 4 positive control, lane 1 protein ladder. GADPH served as a loading control. 
(B) Densitometry analysis in correlation to corresponding GADPH. Data are shown as mean 
± SD. BCL-2 expression is significantly higher in patients with vitiligo (∗∗∗ p<0.001).  
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5.0 DISCUSSION 
 
To date there is convincing evidence that the entire epidermis of patients with vitiligo 
exhibits oxidative stress based on mM (10-3M) concentrations of H2O2 (Schallreuter, 
Moore et al. 1999; Schallreuter, Bahadoran et al. 2008). The first clue in this puzzle 
originated from low epidermal catalase levels in these patients (Schallreuter, Wood 
et al. 1991). Over the last decade much work has been concentrating to elucidate the 
effect of H2O2-mediated oxidation in more detail (Schallreuter, Bahadoran et al. 
2008). Nowadays there is accumulating evidence that this H2O2 mediated stress 
affects many proteins and peptides in their function due to oxidation of target amino 
acid residues in their structure including L-methionine, L-tryptophan, L-cysteine and 
seleno cysteine (Rokos, Beazley et al. 2002; Gillbro, Marles et al. 2004; Hasse, 
Kothari et al. 2005; Schallreuter, Chavan et al. 2005; Spencer, Chavan et al. 2005; 
Chavan, Gillbro et al. 2006; Elwary, Chavan et al. 2006; Gibbons, Wood et al. 2006; 
Schallreuter, Bahadoran et al. 2008; Shalbaf, Gibbons et al. 2008; Wood, Decker et 
al. 2009). Importantly, epidermal H2O2 is transferred to the system, where it affects 
several enzymes including DHPR (Hasse, Gibbons et al. 2004). Moreover, low 
catalase levels have been shown in the epidermis as well as in blood cells (Maresca, 
Flori et al. 2006; Schallreuter, Bahadoran et al. 2008). Recent data from Shalbaf et al 
revealed that patients with vitiligo produce allantoin which is an excellent marker for 
H2O2-mediated oxidative stress (Shalbaf, Gibbons et al. 2008). In this context it is 
noteworthy that xanthin oxidase, the enzyme important in this pathway, is activated 
by  low H2O2-concentrations, while higher concentrations partially inhibit the 
enzyme producing in turn allantoin from uric acid (Shalbaf, Gibbons et al. 2008). 
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Signs for oxidative stress were documented in epidermal cells even under in vitro 
conditions (Medrano and Nordlund 1990; Tobin, Swanson et al. 2000). However, 
much earlier work by others documented cellular vacuolation in epidermal cells and 
the deposition of cellular debris (Moellmann, Klein-Angerer et al. 1982; Bhawan and 
Bhutani 1983). These findings were finally re-interrelated when it was shown that 
upon reduction of epidermal H2O2 by a pseudocatalase PC-KUS this vacuolation 
disappeared (Tobin, Swanson et al. 2000). One major finding deserved more 
research. These patients exhibit constant up regulated wild type functioning p53 
protein in their skin, while apoptosis could not be detected (Tobin, Swanson et al. 
2000; van den Wijngaard, Aten et al. 2000; Schallreuter, Behrens-Williams et al. 
2003). Importantly, p53 up regulation is not affected by H2O2-reduction as shown in 
this thesis (Figure 16). Taking into consideration that these patients have massive 
oxidative stress in association with depigmented, but otherwise unremarkable skin, 
several crucial questions are arising. In this context it is noteworthy that Shalbaf 
showed for the first time that the skin and the plasma have increased levels of 8-oxo 
guanine (8-oxoG) which in turn are an excellent footprint for DNA damage (Shalbaf 
2009). In this context it is noteworthy that all DNA bases are particularly susceptible 
to ROS mediated oxidation (Neeley and Essigmann 2006) but the low redox 
potential of guanine makes this base especially vulnerable leading to several guanine 
oxidation products. 8-oxoG is the most investigated species and it is often utilised as 
biomarker for oxidative stress. Failure to remove 8-oxoG before replication leads to 
G-T transversion mutations (Neeley and Essigmann 2006). Hence, repair 
mechanisms (GO repair pathway via OGG1) need to be in place. 
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In this context it is noteworthy that patients with vitiligo have no increased risk for 
solar induced skin cancer or increased photo damage (Calanchini-Postizzi and Frenk 
1987; Westerhof and Schallreuter 1997; Schallreuter, Tobin et al. 2002). 
Consequently many questions came into our mind.  
• How do the patients combat and repair their DNA damage?  
• What could be the role of up regulated p53 in this scenario in vitiligo?  
• Why is p53 not degraded by p90MDM2?  
• What about phosphorylation and acetylation of p53?  
• What about down stream signalling via p21 and PCNA? What about 
apoptosis in vitiligo? 
• Is the presence of massive amounts of H2O2 and the presence of affecting 
p53?  
The tumour suppressor p53 is considered to be a major effector of the genotoxic 
stress-signalling pathways which are in part induced by the kinase ATM (Caspari 
2000). Here it is noteworthy that ROS mediated DNA damage is related to 
phosphorylation of p53 by ATM (Akman, O'Connor et al. 2000). 
Moreover, it was shown that NO affects both cellular p53 levels and activity. P53 
protein is up regulated after exposure to NO leading in turn to DNA damage 
(Messmer, Ankarcrona et al. 1994; Forrester, Ambs et al. 1996; Messmer and Brune 
1996; Calmels, Hainaut et al. 1997). As discussed earlier the deleterious effects of 
NO are related to the generation of ONOO- which is an extremely reactive species. 
The reaction of ONOO- with proteins leads to the formation of meta nitrotyrosine 
which in turn can be used as a biomarker for ONOO- activity (Beckman and 
Koppenol 1996; Crow and Ischiropoulos 1996).  
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Given that H2O2–stress is present in the skin of patients with vitiligo, we can now 
add for the first time that these patients have also high levels of ONOO- in their 
epidermis as evidenced by the presence of nitro tyrosine in this thesis (Figure 27). 
Consequently we were interested, whether p53 would be affected by H2O2 and / or 
ONOO-. To explore this avenue in more detail, immunofluorescence staining 
techniques, Western blotting, dot blot analysis, immuno precipitation and 
electromobility shift assay (EMSA) were utilised. Purification of wild type p53 
allowed us to follow kinetics on tyrosine residues in detail.  
To confirm up regulated epidermal p53 vitiligo with more improved methodology, 
we first re-investigated the expression of p53 in this disease (van den Wijngaard, 
Aten et al. 2000; Schallreuter, Behrens-Williams et al. 2003). In order to follow the 
effect of H2O2 on the protein, we utilised the corresponding catalase expression in 
the same specimen because expression levels of catalase are excellent biomarkers for 
H2O2 concentrations (Schallreuter, Moore et al. 1999; Schallreuter, Bahadoran et al. 
2008). 
The results confirmed indeed the original data by in situ immuno fluorescence and in 
epidermal suction blister cell extracts from the patients by Western blot (Figure 16 
and 17) (Schallreuter, Behrens-Williams et al. 2003). However, in this thesis we 
show both the presence of p53 in the cytosol and in the nucleus. To our surprise we 
also found up regulated p53 in melanocytes established from patients with vitiligo 
compared to control cells (Figure 19). This discovery unfolds that even under in 
vitro conditions the cells retain this phenomenon. Based on these data it was 
tempting to invoke stabilisation of p53. This assumption is in agreement with 
published data that H2O2 and other ROS cause stabilization of p53 protein (Akman, 
O'Connor et al. 2000; Xie, Wang et al. 2001). Validity of our data is supported by the 
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fact that the antibody binding site on p53 is not affected by H2O2 directly as shown 
by via dot blot analysis (Figure 18). We can conclude that up regulated epidermal 
p53 is a fact in vitiligo.  
Our next question of interest was, why is p53 not degraded in this disease? 
 
5.1 The presence of p76
MDM2
 - the cuase behind up-regulated p53 in vitiligo? 
As already mentioned earlier in this thesis, mdm2 acts as an E3 ubiquitin ligase 
playing an important role in the regulation of p53 by targeting the degradation of this 
protein (Bueso-Ramos, Yang et al. 1993; Kubbutat, Jones et al. 1997; Fuchs, Adler et 
al. 1998; Hershko and Ciechanover 1998). Hence, it was a logical step to follow 
p90MDM2 expression in the skin of our patients. Both in situ and in vitro immuno 
reactivity revealed the same amount of p90MDM2 expression in patients and controls 
(Figures 20A and B, Figure 21). Hence, the question remained, why was p53 not 
degraded in vitiligo? Since mdm2 gene generates many mdm2 protein products, we 
decided to follow this route, especially since some isoforms bind to the N-terminal 
domain of p53 protein while others lack this function. The most frequent isoform is 
p85/90MDM2 which contains the entire structure for the main mdm2, p74/76MDM2 and 
p54/57MDM2 (Olson, Marechal et al. 1993; Gudas, Nguyen et al. 1995). Importantly 
p74/76MDM2 isoform can not bind to p53 protein because it lacks the N-terminal 
domain of the full length protein (Olson, Marechal et al. 1993; Haines, Landers et al. 
1994). Moreover, p74/76MDM2 can antagonise the function of p85/90MDM2 to target 
p53 protein degradation (Perry, Mendrysa et al. 2000). By contrast the p54/57MDM2 
isoform still has the capacity to bind to p53 protein although the C-terminal domain 
is lacking (Olson, Marechal et al. 1993). Taken together, the expression level of 
p76MDM2 emerged as a promising candidate to shed some light on the up regulated 
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p53 in vitiligo. The in situ immuno-reactivity results in lesional and non-lesional skin 
as well as Western blot analysis of epidermal suction blister cell extracts showed 
indeed high epidermal expression of p76MDM2 protein in all patients while healthy 
controls have hardly any of this isoform (Figure 22A and B, Figure 23). This 
observation is completely novel. It certainly provides an answer for why p53 protein 
is not degraded in vitiligo. Our assumption is backed up by the function of p76MDM2. 
It antagonises the binding capacity of p90MDM2 to p53 protein (Perry, Mendrysa et al. 
2000) while p76MDM2 itself can not bind to p53 (Perry, Mendrysa et al. 2000).  
To sum up, it is tempting to conclude that p76MDM2 inhibits p90MDM2 in vitiligo from 
binding to p53 and therefore p53 is not degraded explaining in turn up regulated p53 
in this disease.  
 
5.2 Patients with vitiligo produce NO via iNOS in their epidermis 
Earlier it has been documented that NO affects both cellular p53 levels and activity 
(Messmer, Ankarcrona et al. 1994; Forrester, Ambs et al. 1996; Messmer and Brune 
1996; Calmels, Hainaut et al. 1997). Moreover, iNOS is able to produce 10-6 M 
amounts of NO (Nathan and Xie 1994). Since the co-factor for the enzyme (6R)-L-
erythro 5,6,7,8 tetrahydrobiopterin is produced in epidermal cells, the generation of 
NO was an interesting candidate in the scenario of vitiligo (Schallreuter, Wood et al. 
1994). In situ expression of iNOS demonstrated significantly higher levels 
throughout the entire epidermis in lesional and non lesional skin compared to control 
skin (Figure 24A and B). This result confirms earlier histochemical data by Nelson 
(Nelson 1996). Importantly, again iNOS expression is also high under in vitro 
conditions in vitiliginous melanocytes (Figure 26). Western blotting of epidermal 
cell extracts obtained from suction blister roofs confirmed up regulated iNOS in 
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vitiligo compared to healthy controls (Figure 25). These observations raised the 
question, whether epidermal NO could lead to formation of ONOO- in this disease. 
 
5.3 NO generates nitrated tyrosine in vitiligo -a footprint for peroxynitrite 
(ONOO
-
) 
In this context it has been well established that the ONOO‾ is generated by the rapid 
reaction of NO with O2
.- radical, where the rate of ONOO‾ formation depends on the 
concentration of O2
.- and NO (reviewed in (Radi, Peluffo et al. 2001).  
To answer the question of interest, immuno-reactivity for nitrated tyrosine was used 
as a footprint for ONOO‾ production (Beckman and Koppenol 1996; Crow and 
Ischiropoulos 1996). The results in Figure 27A and B revealed significantly higher 
levels of nitrated tyrosine in all vitiligo samples compared to healthy controls. 
Moreover, vitiliginous melanocytes expressed high levels of nitrated tyrosine, even 
under in vitro conditions suggesting NO production as a general event in vitiligo 
(Figure 28). 
 
5.4 Nitration of p53 takes place in vitiligo 
Due to the presence of many tyrosine residues in the sequence of p53 it is not 
surprising that nitration of the protein has been shown by several groups (Messmer, 
Ankarcrona et al. 1994; Forrester, Ambs et al. 1996; Messmer and Brune 1996; 
Calmels, Hainaut et al. 1997). 
However, to the best of our knowledge, the presence of nitro-tyrosine and nitrated 
epidermal p53 has never been shown in dermatology so far (Figure 29A). The in situ 
results in this thesis prove co-localisation of both p53 and nitro tyrosine in the 
cytosol as well as in the nucleus throughout the epidermis. The expression was 
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significantly higher in lesional and non-lesional vitiligo skin compared to controls. 
These results support that epidermal p53 is nitrated by ONOO- in vitiligo (Figure 
29B). The in situ result is further supported in Western blot analysis in epidermal cell 
extracts of all patients tested (Figure 30).  
 
5.5 More evidence for nitration of p53 by ONOO
-
 
In order to get a more detailed understanding on the role of ONOO¯ in vitiligo, p53 
was produced using the E. coli expression system. A T7 RNA polymerase was 
considered as a re-solublelised active promoter (Midgley, Fisher et al. 1992) 
allowing production of full length p53 from the E. coli strain (BL21/DE3) (Figure 
31, 32, 33 and 34). However, some protein degradation was observed, which could 
be due to the sonication procedure. At the same time there was also production of 
p53 protein in the non induced cells. This observation has been reported earlier and is 
most likely due to a leaky lac promoter (Studier, Rosenberg et al. 1990). Further 
experiments demonstrated concentration dependent nitration of p53 (Figure 35A 
and B). Since ONOO- is a secondary intermediate anion with a short biological half 
life, it was important to follow the time course of nitration to judge on the relevance 
in vivo (Thomas, Espey et al. 2002; Bian, Gao et al. 2003). In this thesis we show a 
time dependent nitration with an optimum at 30 sec using Western blot (Figure 
35C). These results indicate that ONOO- is already degraded if the time is >30sec. 
We also learned that nitration of p53 can occur on relative low levels of ONOO-. 
Moreover, we obtained an understanding, how long this effect can extend. Most 
important was the observation that p53 protein was nitrated by ONOO- and not by 
NO2 from decomposed ONOO
-.  
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5.6 Mutant p53 protein in HT-29 cells is also nitrated  
The nitration reaction was followed on the mutant p53 protein from HT-29 cells. 
These cells own a lot of mutant non functional cellular p53 protein (Figure 36A and 
B, Figure 37A and B). Mutant type p53 was nitrated according to the same protocol 
as wild type p53. The experiments revealed that the mutant was also nitrated in a 
dose dependent manner (Figure 38A and B). Nitration of p53 has been shown by 
others (Chazotte-Aubert, Hainaut et al. 2000; Cobbs, Samanta et al. 2001). We can 
confirm that nitration is a general mechanism in the regulation of p53, regardless 
whether it is the wild-type or a mutant protein.  
In summary, nitration of p53 in epidermal cells is a novel observation. Certainly the 
high levels of nitrated p53 present in vitiligo skin are adding a new player to the 
oxidative stress hypothesis in this disease. 
 
5.7 Enhanced DNA binding capacity of p53 in the presence of H2O2 and ONOO
- 
 
a source for DNA repair in vitiligo? 
The presence of H2O2 in vitiligo together with ONOO- enphasises a major role of 
oxidative stress in this disease (Schallreuter, Moore et al. 1999; Schallreuter, 
Bahadoran et al. 2008). In order to get a better understanding of possible implications 
on the mode of action via p53 under these conditions, we decided to mimic the 
situation under in vitro conditions. Utilising EMSA we learned that ONOO- 
abrogated p53-DNA binding capacity at high concentrations >300 µM of this RNS 
(Figure 39A). We could not confirm that nitration already abrogates p53-DNA 
binding at concentrations <300µM of ONOO- (Chazotte-Aubert, Hainaut et al. 2000; 
Cobbs, Samanta et al. 2001). Surprisingly, oxidation of p53 protein with different 
concentrations of H2O2 (range from 100 µM to 1 mM) revealed that the p53-DNA 
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binding capacity is not affected by H2O2-mediated oxidation (Figure 39B). 
Importantly, we discovered a much higher DNA-binding capacity of p53 after 
exposure to both ONOO- and H2O2 (Figure 39C).  
To our knowledge this observation has not been documented so far. This result also 
provides additional in vitro evidence in support of a functional active p53 in vitiligo 
as demonstrated earlier in epidermal suction blister cell extracts from patients 
(Schallreuter, Behrens-Williams et al. 2003). 
 
5.8 Computer simulation supports the in vitro finding 
To get some more insight into the mechanism as observed by the EMSA results, 
computer modelling was utilised to follow the effect of nitration and oxidation on the 
DNA-binding domain of p53. This work was carried out by Dr NCJ Gibbons from 
our group. 
In the native structure of p53 there are seven amino acids (lys 120, ser 241, arg 248, 
arg 273, ala 276, cys 277 and arg 280) in the DNA binding site which bind 6 
nucleotides (Cho, Gorina et al. 1994) (Figure 40A). Nitration converts 8 tyrosine to 
3-nitrotyrosine in the DNA binding domain of p53 (tyr 103, tyr 106, tyr 126, tyr 163, 
tyr 206, tyr 220, tyr 234, tyr 236) leading to severe changes in the secondary and 
tertiary structure. From the 7 residues involved in DNA binding (lys 120, ser 241, arg 
248, arg 273, ala276, cys 277 and arg 280) arg 248 and cys 277 are lost yielding a 
reduced nucleotide binding capacity (Figure 40B). This result is in agreement with 
our gel shift assay. 
After H2O2-mediated oxidation the nucleotide binding increases based on the 
participation of 13 amino acids instead of 7. From the original complex lys 120, arg 
248, arg 273, cys 277 and arg 280 are retained, whereas H-bonds from ser 241 and 
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ala 276 are lost. However, there are now 8 new amino acids (val 122, lys 139, his 
179, ser 240, arg 249, pro 250, val 274, arg 283) H-bonding to DNA. This result 
supports a marked increase in DNA binding (Figure 40C). Combined oxidation and 
nitration of met, trp and tyr residues results in a number of structural changes, but 
most of the original amino acids remain, including those most crucial to the binding 
of p53 to DNA. New H-bonding interactions are formed from 10 new amino acids, 
increasing the number of amino acids interacting to 15. The model predicts the 
binding of 10 nucleotides in the oxidised complex (Figure 40D). 
Taken together, our in vitro data from the EMSA experiments is supported by the 
results from computer simulation. 
 
5.9 Phosphorylation of epidermal p53 is not affected in vitiligo 
Phosphorylation is a crucial step for p53 stabilization to perform its function as a 
transcription factor (Giaccia and Kastan 1998; Appella and Anderson 2001; Ito, 
Shinkai et al. 2001). In this context it has been shown that phosphorylation of p53 
proteins is initiated by DNA damage. Activated ATM/ATR protein kinases are in 
charge for phosphorylation of 30 amino acids residues at both the amino- and the 
carboxyl terminus (Canman, Lim et al. 1998; Tibbetts, Brumbaugh et al. 1999; 
Appella and Anderson 2000). Our results identified up regulated expression of ATM 
in epidermal cell extracts from the patients (Figure 41). Again we found up 
regulated immuno-reactivity in vitiliginous melanocytes compared to control cells 
(Figure 42).  
Moreover, our investigation proved enzyme activity via phosphorylation of p53 at 
ser 9 and ser 15 in epidermal cell extracts from all patients with vitiligo by Western 
blotting (Figure 43).  
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Based on these results it is temping to conclude that p53 is phosphorylated by ATM 
in vitiligo leaving a stabilised p53 which is ready to exercise his further functionality 
on the transcription machinery. 
 
5.10 Epidermal up-regulated p53 is acetylated in patients with vitiligo 
Acetylation is one step of posttranslational modifications (Polevoda and Sherman 
2000). Therefore we decided to embark on this step by following acetylation of 
epidermal p53 in vitiligo by choosing histoneacetyl transferase PCAF. Our Western 
blot results revealed for the first time the presence of this enzyme in epidermal 
suction blister cell extracts from these patients (Figure 44). The function was proven 
by the presence of acetylated lysine residues at position 373 and 382 in p53 protein 
in epidermal cell extracts of all patients compared to control (Figure 44). The 
presence of acetylated p53 in vitiligo is supported by the work of several groups, 
who showed that increase in cellular stress leads in turn to increased acetylation of 
p53 protein (Barlev, Liu et al. 2001; Forsti, Luo et al. 2001; Vaziri, Dessain et al. 
2001; Knights, Catania et al. 2006; Kim, Chen et al. 2008; Zhao, Kruse et al. 2008). 
The up-regulated acetylated p53 is in agreement with work from Luo et al and 
Brooks et al who demonstrated that PCAF mediates the transcription and activation 
of p53 protein (Luo, Su et al. 2000; Brooks and Gu 2003). 
To sum up, both phosphorylation and acetylation of up regulated p53 are in place in 
vitiligo highlighting the important role for this protein in the pathogenesis of this 
disease (Schallreuter, Bahadoran et al. 2008). 
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5.11 Evidence for p53-mediated cell cycle arrest via p21/PCNA and induction of 
BER in vitiligo 
On the one hand we have an up regulated stabilised (phosphorylated) and acetylated 
p53 protein in vitiligo, on the other hand we have DNA damage  as  shown by the 
presence of significantly increased 8-oxoG levels in the epidermis but even in plasma 
in all patients tested (Shalbaf 2009).  
Therefore it was tempting to have a closer look at some further down stream events. 
Cell cycle arrest is the first action that p53 performs in a transcription dependent 
manner to stop replication of DNA damage. It is an important step because it stops 
the spread of DNA-damage. PCNA is a protein that is essential for DNA replication 
(Warbrick 2000; Maga and Hubscher 2003; Prosperi 2006), functioning  as an aid to 
DNA polymerase δ allowing efficient attachment and binding to DNA controlling in 
turn  both DNA synthesis and prevention of dissociation from DNA leading to 
interruption of DNA synthesis. PCNA acts as a DNA clamp. The PCNA trimer 
assembles on the replication fork of DNA, where it binds DNA polymerase δ and 
slides along with it to enhance DNA function. 
P21, known as cyclin-dependent kinase inhibitor 1, acts to disrupt the replication of 
DNA by binding to PCNA. The PCNA trimer stays intact and as result of p21 
binding does not disassemble. It is thought that p21 blocks key areas on the PCNA 
that are required to form the DNA replication complex rather than de-stabilising the 
PCNA trimer. P21 is a 164 amino acid monomer, of which the N-terminus alone 
confers the ability to bind to PCNA. A 21 amino acid peptide in the C-terminal 
region has been shown to be able to bind to and inhibit PCNA activity on its own 
(Pan, Reardon et al. 1995; Gibbs 1997)  
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Therefore, we selected both p21 and PCNA as major down stream events to get a 
better understanding of the scenario in vitiligo. We were able to show increased 
expression of p21 as well as PCNA under in vitro conditions by Western blot in 
epidermal suction blister cell extracts of all patients tested compared to control skin 
(Figure 45 and 47). To our surprise we were also able to detect increased expression 
of both p21 and PCNA in vitiliginous melanocytes compared to control cells (Figure 
46 and 48). These results imply cell cycle arrest in the G1 and G2 phase in vitiligo 
because p21 blocks PCNA replication activity. Our assumption is strengthened by 
up-regulated Gadd45 in the skin of the same patients (el-Deiry, Tokino et al. 1993; 
Taylor and Stark 2001; Xu, Kim et al. 2002; Shalbaf 2009). 
Importantly, both proteins p21 and Gadd45 have the ability to bind to PCNA and 
stop its DNA replication mechanism enhancing in turn the DNA repair function via 
base excision repair (BER) (Cahilly-Snyder, Yang-Feng et al. 1987; Flores-Rozas, 
Kelman et al. 1994; Warbrick 2000; Perucca, Cazzalini et al. 2006). In this context it 
has been shown by Shalbaf that the DNA glycosylase hOgg1, the enzyme which 
removes 8-oxoG, is present in vitiligo. However, at present it is unknown, whether 
this enzyme also removes the corresponding nucleoside 8-OH-dG (Nakano, 
Kawanishi et al. 2003). Moreover, Shalbaf also showed that DNA polymerase β and 
APE1 are up-regulated in vitiligo, indicating an efficient BER mechanism in this 
disease (Shalbaf 2009). 
 
5.12 Absence of increased apoptosis in vitiligo 
There is an ongoing debate in the scientific community over the presence/absence of 
increased apoptosis as major mechanism, why melanocytes in vitiligo decrease in 
numbers and die (Boissy and Nordlund 1997; Kemp, Waterman et al. 2001; Huang, 
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Nordlund et al. 2002; Ruiz-Arguelles, Brito et al. 2007; Schallreuter, Gibbons et al. 
2007; Song, Xu et al. 2008). As mentioned before the results are conflicting. Some 
groups could not detect any sign for programmed cell death, while others claim to 
find evidence (Tobin, Swanson et al. 2000; van den Wijngaard, Aten et al. 2000). In 
their ultra structural studies Tobin and colleagues could neither detect apoptosis on 
melanocytes and keratinocytes in situ in epidermal suction blister sheets nor in 
melanocytes cell cultures from lesional and non lesional skin despite the presence of 
vacuolation in situ and even under in vitro conditions (Tobin, Swanson et al. 2000). 
Shalbaf re- explored this avenue and he was unable to detect the presence of caspase 
3 and cytochrome c in these patients (Shalbaf 2009). This result further supports the 
absence of the apoptotic pathway. In this thesis we explored also the expression of 
the anti apoptotic protein BCL-2. The results revealed a highly over expressed 
protein in epidermal suction blister tissue from all patients tested compared to 
controls (Figure 49). 
Taking into consideration that p90 MDM2 activity is blocked in vitiligo by p76MDM2 as 
shown in this thesis, it seems that apoptosis can not be a major mechanism in vitiligo. 
Some more support for this concept stems from earlier work of Elwary and 
colleagues who showed that acetylcholine esterase protein expression and activity is 
very low in patients with vitiligo compared to healthy controls (Schallreuter, Elwary 
et al. 2004). Recently this enzyme has been stressed as an apoptosis regulator. Over 
expression of the enzyme inhibits cell proliferation and promotes apoptosis (Park, 
Kim et al. 2004; Jiang and Zhang 2008). Since epidermal acetylcholine esterase 
levels and activities are low in patients with vitiligo, these data also argue against 
increased apoptosis in vitiligo. 
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In conclusion, the results of this study favour enhanced DNA repair via short patch 
BER where p53 is the master regulator in the scenario. Since all findings reported 
herein were also present on the cellular level in melanocytes from patients, it seems 
overwhelming evidence that even under in vitro conditions a command for efficient 
DNA repair is in place. Unfortunately we only had one cell line of epidermal 
melanocytes from a patient with vitiligo. However, since all observations in situ and 
by Western blot were the same in the entire patient group, the data at least suggest 
that efficient DNA repair is in demand in vitiligo. The strength of the results in this 
thesis is also based on the number of patients included in the entire analysis. 
Moreover, all immuno-reactivity studies were carried out in the same patients. All 
Western blot results are based on the same epidermal suction blister cell extracts. 
The findings are in all patients the same although the expression varies slightly. The 
presence of H2O2-mediated stress in the mM range was guarded by the intra 
individual epidermal catalase expression. The data presented herein together with all 
the data available on oxidative stress in vitiligo provide conclusive evidence for 
efficient DNA repair machinery in vitiligo. Hence, these results could provide an 
explanation for the absence of an increased risk for sun induced skin cancer and 
photo damage in this patient group. 
The final view is summarised in Scheme 1. 
 
 
 
 
 
 
 201 
 
 
 
 
Scheme 1 
Up-regulated wild type p53 as the main conductor of ROS-mediated DNA 
damage/repair in vitiligo 
ROS–mediated DNA damage in vitiligo leads to increased 8-oxoG levels in the epidermis 
and in plasma of patients with vitiligo (Shalbaf 2009). Phosphorylation is a crucial step for 
p53 stabilization to perform its function as a transcription factor (Giaccia and Kastan 1998; 
Appella and Anderson 2001; Ito, Shinkai et al. 2001). In this context it has been shown that 
phosphorylation of p53 protein is initiated by DNA damage. Up-regulated wild type p53 is 
phosphorylated on ser 9 and ser 15, proving functionality of up-regulated ATM in this 
disease. Acetylation is one step of posttranslational modifications (Polevoda and Sherman 
2000). Up-regulated epidermal PCAF in vitiligo is functioning as shown by the presence of 
acetylated lysine residues at position 373 and 382, both steps support functioning stabilised 
p53 as shown earlier (Schallreuter, Behrens-Williams et al. 2003). Under normal conditions 
p53 is degraded by p90MDM2 (Oliner, Kinzler et al. 1992). The isomer p76MDM2 binds to 
p90MDM2, preventing binding of p90MDM2 to p53, stopping in turn degradation of p53 (Perry, 
Mendrysa et al. 2000). Our results revealed for the first time high epidermal p76MDM2 levels 
in vitiligo, whereas p90MDM2 expression is not affected in this compartment Functioning 
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stabilised p53 leads to transcription of p21, Gadd45α and PCNA. Both p21 and Gadd45α 
induce cell cycle arrest and both signals are up regulated in vitiligo (Shalbaf 2009). 
Oxidative DNA damage is repaired via BER, which is initiated by hOgg1 excising 8-oxoG 
(Michaels, Tchou et al. 1992; Boiteux 1993; Boiteux and Radicella 1999). Depending on the 
type of DNA damage, the repair pathways would involve either short or long-patch BER, 
although these pathways can switch between each other (Wilson and Thompson 1997; 
Dogliotti, Fortini et al. 2001; Fromme and Verdine 2004). PCNA binds to DNA polymerase 
δ and works as a processivity factor for this enzyme, which together with FEN1 is involved 
in long-patch BER (Matsumoto, Kim et al. 1994; Frosina, Fortini et al. 1996; Klungland and 
Lindahl 1997; Fromme and Verdine 2004). Notably, we were unable to detect epidermal 
DNA polymerase δ and FEN1 in our patients, but we found up-regulated epidermal APE1 
and DNA polymerase β levels (Shalbaf 2009). This result favours short patch BER in 
vitiligo. However, DNA polymerase β can function in both repair pathways (Dianov, Prasad 
et al. 1999; Prasad, Dianov et al. 2000). In this context it is of interest that PCNA can 
interact directly with APE1 (Dianova, Bohr et al. 2001). Moreover, hOgg1, APE1 and DNA 
polymerase β are directly regulated by p53 (Sengupta and Harris 2005). Therefore, it can be 
concluded that oxidative DNA damage in vitiligo can be repaired through short-patch BER 
in cooperation with a specified long-patch BER in the absence of FEN1 and DNA 
polymerase δ (Shalbaf 2009). Epidermal programmed cell death is ruled out because up-
regulated BCL-2 favours anti-apoptotic activity which is further supported by decreased 
levels of cytochrome c and caspase 3 (Shalbaf 2009). These new findings are further 
supported by unremarkable levels of the pro-apoptotic stimulus BAX and low acetylcholine 
esterase levels / activities in vitiligo as shown earlier (van den Wijngaard, Aten et al. 2000; 
Schallreuter, Elwary et al. 2004). Importantly, the DNA binding capacity of p53 is enhanced 
by H2O2 / ONOO
- oxidation as shown in this thesis. Taken together, patients with vitiligo can 
efficiently combat epidermal H2O2 / ONOO
- induced DNA damage via an up-
regulated/activated wild type functioning p53 with a more efficient DNA binding, where p53 
is the main conductor in the scenario. 
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6.0 FUTURE WORK 
 
 
 
The results demonstrated in this thesis have introduced a new mechanism in the 
repair of oxidative DNA damage. Future work in this area should investigate the 
following points: 
 
• More investigation for the role of PCNA in DNA repair 
 
• Our immunofluorescence results showed the presence of p53 in 
cytoplasm. More research needs to be carried out to explore the role of 
p53 in the cytoplasm and nucleus. 
 
• To have a closer look whether there is any correlation between 
acetylcholine esterase expression and p53 protein in vitiligo 
 
• These novel data could be applied to hair and tumour biology. 
 
• The role of p21 in UV-response needs to be studied in more detail. 
 
• Demonitration of the role of ubiquitin degradation process. 
 
• More clarification for the DNA damage and repair by utilising new 
assayes. 
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